

Greater Miami Valley EMS Council



2022 Standing Orders

Acknowledgement

Region 3 EMS Providers,

This Protocol and the supporting Training Manual has been produced as a result of countless hours of work by a diverse cross section of the regional EMS community. This group includes the members of the Standing Orders Committee and the Regional Physician's Advisory Board. In editing the protocol, the team considered changes in State of Ohio- EMS scope of practice changes, medication availability, patient management best practices and EMS care procedural improvements. Additionally, the input given by you, the providers operating under this protocol, was factored in. The overall goal of this document is to make it easier to provide quality care to your patients.

There are companion documents and additional resources that are available for you to either view online or download for further explanation on the Training and Testing process for 2022. The first of these is the "2022 Implementation Guide". It addresses the new philosophy, CEUs, and other important information regarding the testing. The other is the Ohio Public Safety "Scope of Practice" document. We hope to have additional supplemental material posted on the website at a later date.

The entire protocol, the training manual and testing processes would not have been possible without the strong foundation left by the many past chairpersons of the Continuing Education Committee and all of the other council members. Thank you to all who have volunteered to edit and critique these manuals.

I would also like to thank Dr. Randy Marriott and all of the many RPAB members for their work.

Sincerely,

John Russell Standing Orders Co-Chair



General Patient Management	1000 Series	
1001	Introduction to Treatment Protocols	
1002	Communication with Hospital or Medical Control	
1003	Non-initiation of Care	
1004	Do Not Resuscitate	
1005		
1006	Patient Abuse and Neglect	
1007	Basic Airway Maintenance	
1008	Advanced Airway Management	
1009	Advanced Airway Confirmation Devices	
1010		
1011	Tracheostomy and Laryngectomy Care	
1012	Intraossesous Infusion	
1013	Alternate Vascular Access	
1014	Pain Management	
Cardiac Protocol	2000 Series	
Cardiac Protocol	2000 Series	
2001		
	Cardiac Arrest – Asystole of PEA Cardiac Arrest – Renal Dialysis	
	Cardiac Arrest – V-Fib or Pulseless V-Tach	
	Suspected Cardiac Chest Pain	
2010	Bradycardia	
	Tachycardia	
	•	
Trauma Protocol	3000 Series	
	General Trauma Management	
	Glasgow Coma Score	
	Drowning	
3010	Extremity Injuries	

Table of Contents Page 1 of 4



3011	Eye Injuries	
3012	Frostbite	
3013		
3014	Heat Exposure	
3015	Hemorrhage Control	
3016		
3017	SALT Triage Systems	
3018	Spinal Motion Restriction	
3019	Trauma Transport Guidelines	
3020	Regional Hospital Notification System	
3021	Crisis Standard of Care in MCI	
Medical Protocol	4000 Series	
	Abdominal Pain	
	Allergic Reactions/Anaphylaxis	
	Asthma/Emphysema/COPD	
4004	Behavioral Emergencies	
4005	Childbirth	
4006	Childbirth with Complications	
-	Combative Patients/Emergency Sedation	
4008	Diabetic Emergencies - Hypoglycemia	
4009	Diabetic Emergencies - Refusal of Transport	
4010	Extrapyramidal Reactions	
4011	Obstetrical Emergencies	
4012		
4013	Respiratory Distress/Pulmonary Edema	
4014	Seizures	
4015	Sepsis	
4016	Shock	
4017	Stroke	
Pediatric Considerations	5000 Series	
	Apparent Life Threatening Event	
	Pediatric Assessment Triangle	
5004	Safe Harbor	
Special Operations Protocol	6000 Series	
Special Operations (Totaled)		
6001	General Management for Haz Mat	
	Antidote Resources	

Table of Contents Page 2 of 4

6003	Hazardous Drug Exposure
6005	
6006	Other Hazardous Materials
Administra	tion 7000 Series
7001	
	Drug Bag Program: Wasted Drug Procedure
· ·	
	Drug Bag Program: New Member Agency Policy
	Drug Bag Program: GMVEMSC Drug Bag Discrepancy Report
	Drug Bag Program: Report of Theft or Loss of Dangerous Drugs, Controlled Substances and Drug Documents
	Ambulance Restocking Policy
7012	Diversion of Emergency Patients
7013	Hospital Capabilities Chart
7014	
7015	
7015	illiectious disease Exposure i olicy
EMS Drug F	
EMS Drug F	
EMS Drug F	Formulary 8000 Series
80018	Formulary 8000 Series Adenosine
8001 8002 8003	Formulary 8000 Series Adenosine Albuterol
8001 8002 8003 8004	Formulary Adenosine Albuterol Amiodarone
8001	Adenosine Albuterol Amiodarone Aspirin
8001	Adenosine Albuterol Amiodarone Aspirin Atropine
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine
8001	Formulary Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Dopamine
8001	Formulary Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Doxycycline
8001	Adenosine Albuterol Aspirin Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Dopyamine Doxycycline Duodote
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Doxycycline Doxycycline Duodote Epinephrine
8001	Formulary Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Dopamine Doxycycline Duodote Epinephrine Etomidate
8001	Adenosine Albuterol Amiodarone Aspirin Atropine Calcium Chloride Calcium Gluconate Ciprofloxacin Dextrose 10% Diazepam Diphenhydramine Doxycycline Doxycycline Duodote Epinephrine

Table of Contents Page 3 of 4

19 Hydroxocobalamii
)20Ipratropiun
)21 Ketamino
)22Lactated Ringer
)24Lidocaine 2% Ge
025
)26
)27
D29
)30
931
Normal Saline
)33
134
935
936
937
)38
Sodium Nitrite
040
041
)42

Appendices

Table of Contents Page 4 of 4

1000 Series

General Protocol

1001

Subject: Introduction to Protocols

Effective: June 1, 2021

Last Modified:

Dec. 21, 2021

1001.1 Introduction to Treatment Protocols

- a. Each protocol has been approved by the Greater Miami Valley EMS Council and the Regional Physician Advisory Board for Region 3 (as defined by the State Board of Emergency Medical, Fire and Transportation Services (EMFTS).
- b. Each protocol bears an effective date making it current, and a last modified date marking it as the latest version.
- c. An addition to protocol would reflect a duplicate "Effective" and "Last Modified" date.
- d. When changes or revisions are made, only the "Last Modified" date will be changed.
- e. Each time changes or additions are made; they can be referred to by their specific line in the protocol. i.e. A change was made to "1001.1.e".

1001.2 Printing, Retention, and Display

- a. All GMVEMSC Treatment Protocols are intended for color printing, and hard copy retention.
- b. These protocols are also intended for electronic display in Adobe Portable Document Format (PDF).
 - i. The PDF version includes links to the different tabs throughout the document.
 - ii. The GMVEMSC logo on most pages is a hyperlink back to the table of contents.
- c. Distribution is provided by means of the GMVEMSC official website.

1001.3 Application

- a. This protocol is for use by those individuals operating in and under the authority of the Greater Miami Valley EMS Council (GMVEMSC) Drug Bag Exchange Program and certified by the State of Ohio as an EMS provider.
- b. The provider must pass both the skills check-off and Computer Based Testing (CBT) for the current year.
- c. The GMVEMSC Treatment Protocols apply to the following certification levels:
 - i. Emergency Medical Responder (EMR)
 - ii. Emergency Medical Technician (EMT)
 - iii. Advanced Emergency Medical Technician (AEMT)
 - iv. Paramedic (PM)

1001.4 Stipulations

- a. The protocol is to be used in the field only.
- b. Communicate with the receiving facility as soon as practical:
 - i. When transporting unstable patients
 - ii. Transporting to hospitals that request contact for all patients delivered to their facility.
- c. No procedures, techniques, or drugs will be used without the proper equipment or beyond the training or capabilities of the prehospital personnel.
- d. Nothing in this protocol may be used without specific pre-approval of the Medical Director for the local department or agency.
- e. The protocol is to be utilized as clinically indicated. Not every standing order in a treatment protocol must be carried out on every patient treated under that treatment protocol.
- f. Discretionary judgment is required and stepwise adherence to specific protocols may not be in the patient's best interest.

1001 – Introduction to Protocols Page 1 of 3

1001

Subject: Introduction to Protocols

Effective: June 1, 2021

Last Modified:

Dec. 21, 2021

g. At no time should treatment options exceed those authorized without direct consultation with the Medical Control Physician (MCP).

1001.5 Protocol Design

- a. The GMVEMSC protocols are organized around the General Patient Management Protocol which must be followed for all patients. This universally applicable protocol/flowchart allows the providers to integrate additional treatment protocols beyond general patient management as clinically necessary for specific patient care, emergency stabilization, and treatment.
 - i. As an example, while caring for a specific patient with chest pain, shortness of breath, and nausea the provider would:
 - 1. Follow the General Patient Management Protocol
 - 2. Integrate and follow the Chest Pain Protocol
 - 3. Integrate and follow the Respiratory Distress Protocol if indicated
 - 4. Integrate and follow the Cardiac Alert Protocol if indicated
 - 5. Integrate and follow the Abdominal Pain Protocol if indicated
 - 6. Refer to protocol for specific medication concentrations, dosages, and volumes.
 - 7. Complete the General Patient Management Protocol
- b. In most cases, a specific guideline will only be mentioned once within the protocol. All other circumstances where that guideline would be applicable will simply refer to the original guideline.
- c. Where applicable, a guideline mentioned in another section will have a hyperlink provided.
- d. Formatting
 - i. All attempts will be made to keep the protocol focused and specific.
 - ii. Extracurricular and enhancing information will be provided in an official study guide.
 - iii. All levels of providers will be addressed within a single protocol.
 - iv. Procedures and treatments marked with a diamond (♦) always require a physician's order.
 - v. Items enclosed in brackets ({ }) are at the option of the agency and their Medical Director.
 - vi. Sections that apply only to adults are bulleted with an "A".
 - vii. All pediatric treatments will be in pink and bulleted with a "P".
 - viii. There are also sections which apply to only Geriatric patients and are bulleted with a "G."

1001.6 Clinical Management Tables

- a. In addition to general statements, this protocol will utilize table-based algorithms where applicable.
- b. The table will demonstrate what care can be given at each provider level.
 - i. The level of certifications will be signified by the colored tabs to the right of each section.
- c. Even with a step-by-step algorithm in place, critical thinking is encouraged.
- d. While the table is sequential and listed by provider level, many elements in each section can be completed simultaneously.
- e. The following is an annotated example of a Clinical Management Table:

1001 – Introduction to Protocols Page 2 of 3

1001

Subject:

Introduction to Protocols

Effective:

June 1, 2021

Last Modified:

Dec. 21, 2021

Assessment Differential Diagnosis Pediatric Considerations Signs & Symptoms This is where pediatric specific info might go. This is where S&S will go This is where differentials will go Dosing and treatment will still be listed in the algorithm **Treatment Algorithm** This will be where guidelines for all certification levels will go EMR Any EMR and above information will be listed in this box. Treatment directives for the EMT and above will be here. If no EMT directives apply, then this box would read "No additional orders at this level". **AEMT** Treatment directives for the AEMT and above will be here. If no AEMT specific directives apply, then this box would read "No additional orders at this level". Treatment directives for the Paramedic will be listed here. If no Paramedic specific directives apply, then this box would read "No additional orders at this level". Consult If requirements exist for any level to call for orders, that will be listed here. If there is a guideline to call an alert, that will be listed here. If there is a recommendation to call for MCP advice, that will be listed here.

Clinical Pearls

Any important guidelines or clinical information will be added here.
This will not be a study guide nor a skill sheet. That information will be supplied in a separate format.

If there is a request to call the receiving facility prior to arrival, that will be listed here.

END OF SECTION

1001 – Introduction to Protocols Page 3 of 3

1002

Subject: Communication with Hospital or Medical Control

Effective: June 1, 2021

Last Modified:

Mar. 16, 2022

1002.1 Reasons to Contact the Hospital

- a. To notify the hospital when time is needed to prepare for patient arrival. Examples include:
 - i. Cardiac arrest
 - ii. Any of the defined alerts such as Cardiac Alert, Stroke Alert, Trauma Alert
 - iii. Indications of sepsis
 - iv. Significant communicable disease
 - v. Other serious patients that may require acute care
 - vi. Hazardous material exposures (mandatory)
 - vii. Bedbugs

1002.2 Reasons to Contact Medical Control

- a. To obtain orders for procedures or medications as indicated within the protocol.
- b. For field termination or DNR clarification.
- c. To obtain advice in a difficult situation or circumstance. Examples include:
 - i. Before a medication is given, even though protocol allows it to be used without permission.
 - ii. A situation where the patient has an unfamiliar condition.
 - iii. To discuss a destination decision.

1002.3 Call-in Procedures

- a. When contacting a hospital, make sure a clear picture is painted.
- b. When calling about a trauma patient, include:
 - i. MIVT Mechanism, Injuries, Vital Signs and Treatment
 - ii. Estimated time of arrival (ETA)
 - iii. The components of the Glasgow Coma Score (GCS)
 - iv. Patient assessment findings which are relevant to the decision to transport to a Trauma Center.
- c. If consultation with a physician is desired, specifically request the Medical Control Physician.
- d. When calling with an Alert (Cardiac, Stroke, Trauma, etc.):
 - i. Request to speak directly to the Medical Control Physician at the beginning of the call.
 - ii. Verbalize, "We recommend a Alert."
 - iii. The MCP has the discretion to withhold the Alert and may decide not to activate it.

1003

Subject: Non-Initiation of Care

Effective: June 1, 2021

Last Modified:

Feb. 8, 2022

1003.1 General Guidelines

- a. This protocol may be applied by EMT, AEMT and Paramedic providers only. The EMR cannot determine that a patient is deceased.
- b. Both Adult and Pediatric patients may meet criteria for non-initiation of care.
- c. If care had begun and is readily apparent to the provider that the patient meets non-initiation of care criteria, **RESUSCITATION EFFORTS MAY CEASE.**

1003.2 Criteria for Non-Initiation of Care

- a. Resuscitation will not be initiated in the following circumstances:
 - i. Deep, penetrating, cranial injuries
 - ii. Massive truncal wounds
 - iii. DNR Order—present and valid (see 1004 Do Not Resuscitate)
 - iv. Frozen body
 - v. Rigor mortis, tissue decomposition, or severe dependent lividity
 - vi. Triage demands
 - vii. For patients in arrest resulting from **BLUNT OR PENETRATING TRAUMA** consider not initiating care for injuries obviously incompatible with life.
 - 1. Prolonged arrest (greater than 10 minutes)
 - 2. Consider possibility of MIXED MECHANISMS

1003.3 Exclusionary Conditions

- a. The following conditions will not meet non-initiation of care criteria:
 - i. Traumatic arrest in female patient with either:
 - 1. Known pregnancy greater than 24 weeks or
 - 2. Uterine fundus palpable at or above the umbilicus
 - ii. Possible medical etiology for cardiac arrest
 - iii. Arrest witnessed by EMS providers
 - iv. Lightning strike
 - v. Signs or symptoms of a hypothermic patient
 - vi. Focused blunt trauma to the chest, (commotio cordis)

1003.4 For an inquiry about organ donation, direct the call to Life Connection of Ohio at 1-800-535-9206.

END OF SECTION

1003 – Non-Initiation of Care Page 1 of 1

1004

Subject: Do Not Resuscitate

Effective: June 1, 2021

Last Modified:

Aug 20, 2022

1004.1 General Guideline

- a. Per ORC <u>2133.21-2133.26</u>, providers will consider and honor all valid Ohio Do Not Resuscitate orders.
- b. The two valid DNR orders are DNR: Comfort Care and DNR: Comfort Care Arrest.

1004.2 Do-Not-Resuscitate Orders Defined

- a. Do-Not-Resuscitate: Comfort Care Arrest (DNR-CCA)
 - i. Permits any GMVEMSC Protocol treatment until the order is initiated.
 - ii. The order is initiated at the moment the patient goes into cardiac or respiratory arrest.
 - iii. Once the patient meets the above criteria, then only permitted DNR treatment is performed.
- b. Do-Not-Resuscitate: Comfort Care (DNR-CC)
 - i. Permits any medical treatment to diminish pain or discomfort
 - ii. No treatment should be used to postpone the patient's death.
 - iii. The order is initiated at the moment it is signed by the patient's physician.

1004.3 Permissible and Impermissible Treatments Once the DNR is Initiated

- a. The following treatments are permitted once an order is valid and effective:
 - i. Conduct an initial assessment
 - ii. Perform basic medical care
 - iii. Clear airway of obstruction or suctioning
 - iv. If necessary, for comfort or to relieve distress, may administer oxygen, CPAP or BiPAP
 - v. If necessary, may obtain IV access for hydration or pain medication to relieve discomfort, but not to postpone death
 - vi. If possible, may contact other appropriate health care providers
- b. The following treatments are not permitted once an order is valid and effective:
 - i. Perform CPR
 - ii. Administer resuscitation medications with the intent of restarting the heart or breathing
 - iii. Insert an airway adjunct
 - iv. Defibrillation, cardioversion or initiate pacing
 - v. Initiate continuous cardiac monitoring

1004.4 Stipulations

- a. If more than one living will declaration or DNR exists, the most recent supersedes the previous.
- b. The authority of a DPOA-HC supersedes the DNR <u>if</u> the DPOA-HC previously consented to the DNR.
- c. The GMVEMSC protocol will recognize the following special situations as valid. If these scenarios present, then contact MCP and request to honor the DNR with physician permission.
 - i. Out-of-State DNR orders
 - ii. Pediatric DNR orders
- d. Blood glucose checks and treatment of <u>4008 Diabetic Emergencies Hypoglycemia</u>, is acceptable even with a valid DNR.
- e. In situations where there are questions about the documents, try to keep the patient's intent in mind.
- f. If there is any confusion on scene, ♦ Call MCP for clarification.

END OF SECTION

1004 – Do Not Resuscitate Page 1 of 1

1005

General Patient Management Effective:

June 1, 2021

Last Modified:

Dec. 23, 2021

1005.1 Guideline

Subject:

- **a.** The General Patient Management protocol is to be applied to all patients.
- **b.** Once a primary impression and differential diagnosis is made, then the provider should look to specific treatment algorithms within these standing orders.

1005.2 Basic Patient Care

- a. The emphasis in patient care should ensure airway protection, oxygenation, and adequate ventilation without causing harm.
- b. Injury reduction strategies may include noninvasive ventilation when appropriate, titration of oxygen in certain settings, and being cautious not to over ventilate.
- c. Tailor treatment to the overall clinical picture.
- d. With the exception of suspected acute cerebral herniation, the rate and depth of ventilation in the prehospital setting should not be guided by the EtCO₂ reading alone.
- e. For the patient with cerebral herniation, ventilate the patient at approximately 20 times per minute to obtain an EtCO₂ of 30 mmHg.
- f. "Permissive hypercapnia" in most cases is appropriate, particularly in those with chronic lung disease who may chronically retain CO₂.
- g. It is recommended to listen to the chest to ensure that adequate exhalation is occurring during manual ventilation.

1005.3 EMT Assisting the Advanced Provider

- a. Per Ohio Revised Code, the EMT is permitted to assist the advanced provider with skills that are outside of the EMT's scope of practice.
- b. The EMT is only allowed to prepare ALS equipment under the direct supervision of the AEMT or Paramedic.
- c. The skills that an EMT may set up for and assist with are:
 - i. Endotracheal intubation
 - ii. Intravenous access
 - iii. IV fluid administration
 - iv. Saline locks
 - v. Placement of 4 Lead and/or {12 Lead EKG} for cardiac monitoring
 - vi. Accessing the GMVEMSC Drug Bag to locate drugs and/or to assemble pre-jects.

1005.4 General Patient Management

Assessment			
Pediatric Considerations	Signs & Symptoms	Differential Diagnosis	
 Pediatric patients are defined as patients 16 years old or younger. A Pediatric reference guide or length-based resuscitation tape may be used to reference pediatric equipment recommendations. Pedi-Wheel may be used as a reference for pediatric vital signs. Unless otherwise specified, the maximum dose for pediatric medication administration 	• None	None	
is the adult dose.			

Subject:

General Patient Management

Effective:

June 1, 2021

Last Modified:

Dec. 23, 2021

Treatment Algorithm

- Scene/Crew Safety/PPE; with appropriate equipment/medications to patient side.
- Initial Assessment/Physical Exam
- Follow basic life support and airway algorithms as indicated based on current AHA guidelines.
- An unresponsive patient with gasping breaths and poor color should get supplemental oxygen via BVM
- Obtain chief complaint, OPQRST, SAMPLE history, and other pertinent information.
- Vital Signs
 - Blood Pressure (EMR are limited to obtaining manual blood pressures) 0
 - Pulse, rate and quality 0
 - Respirations; Rate, quality, and work-of-breathing
 - Assess every 5 to 15 minutes per patient condition
 - Temperature as needed
- Utilize monitoring devices, pulse oximeter, CO-oximetry, capnography, etc. as appropriate and approved by medical direction.
- Perform blood glucose check.
- Where indicated, the EMT may obtain a {12 Lead EKG} for the purpose of transmission.
- The EMT may assist the advanced provider with:
 - {12 Lead EKG} application assisting a Paramedic who is present
 - Set up an IV administration kit in the presence of an AEMT or Paramedic
- Utilize cardiac monitor as appropriate.
- Where indicated, the AEMT may obtain a {12 Lead EKG} for the purpose of transmission.
- The AEMT may apply a {12 Lead EKG} when assisting a Paramedic who is present.
- Start IV crystalloid solutions or saline lock as appropriate.
- IV Therapy: Follow 4016 Shock Protocol.
 - For medical emergencies, head trauma, cardiac issues with stable BP, etc.: Use **TKO** rate.
 - Shock (not related to penetrating trauma):
 - Run IV fluid wide-open
 - Use macro-drip or blood tubing
 - Decrease fluid rate if SBP greater than 100
 - IV fluid 20 ml/kg using macro-drip tubing. Titrate to maintain adequate perfusion
- Use of IO devices for both Adults and Pediatrics is limited to patients who are unresponsive or hemodynamically unstable, and only when less invasive means are not available or are ineffective (e.g., Glucagon IM, Narcan IN, and Midazolam IN).
- Provide continuous cardiac monitoring, EtCO₂ and pulse oximetry (if available) for all patients with fentanyl, ketamine, morphine or midazolam if not already doing so.
- If a patient with an existing IV pump experiences an allergic reaction, consider discontinuing the pump.
- Use of an {IV pump} is optional for any agency with approval from their Medical Director.
- Existing central venous catheters, dialysis catheters, fistulas, or grafts may be utilized for infusion of IV fluids and medication if the patient is hemodynamically unstable. These may also be used when the patient is deteriorating rapidly.

Consult

- Do not stop the flow of medication in an established medication pump except under direct orders from Medical Control. There are some drugs such as Flolan that could kill the patient if stopped.
- If a patient with an existing IV pump experiences an allergic reaction, call the MCP for an order to discontinue the pump.
- Bring medications or a list of the medications to the hospital; include the dose and frequency of administration.

Clinical Pearls

- Crystalloid fluids include Normosol, Plasmalyte, Lactated Ringers or Normal Saline in that order. Their pH is closer to neutral.
 - Medical emergencies, head trauma, cardiac problems with stable BP: Use TKO rate.
- IV medication administration: Slow IV = over 2 minutes, unless otherwise specified.
- Any medication given IV can also be administered intraosseous, IO.
- Maintain normothermia.

Patient Abuse and Neglect

Effective:

June 1, 2021

Last Modified:

Feb. 9, 2021

1006.1 Guideline

Subject:

- a. EMS providers MUST, by law, report all alleged or suspected pediatric and adult abuse/neglect.
- b. Ohio Revised Code requires providers to report incidents of pediatric and adult abuse/neglect to:
 - A Their county's adult protective services agency (for patients over 60 years old)
 - P Their county's public children services agency
 - iii. Or for both adults and pediatrics; Law enforcement
 - iv. For adult patients see ORC 5101.63 and for pediatric patients see ORC 2151.421
- c. Simply notifying hospital personnel does not meet mandated EMS reporting responsibilities.
- d. Hospitals have copies of the EMS Social Services Referral Form, supplied by GDAHA, for documenting cases of abuse/neglect.
- e. Use of this form can help providers in providing information needed to their reporting agency, as well as provide for a continuum of care with hospital social services departments.
- f. Document on the Patient Care Report, all efforts that EMS made to report the suspected abuse; include name of agency notified, method used, and name of person contacted.

1006.2 Pediatric Abuse and Neglect

P Report all alleged or suspected child abuse or neglect to the appropriate agency.

Pediatric Public Social Services Agencies				
County	Phone	After Hours Phone	Fax	
Butler	513-887-4055	513-868-0888	513-887-4260	
Champaign	937-484-1500	Contact County SO: 937-484-6092	937-484-1506	
Clark	937-327-1700	937-324-8687	937-327-1910	
Darke	937-548-7129	937-548-2020	937-548-8723	
Greene	937-562-6600	937-372-4357	937-562-6650	
Miami	937-335-4103	Contact County SO: 937-440-3965	937-339-7533	
Montgomery	937-224-5437	937-224-5437 (same as daytime)	937-276-6597	
Preble	937-456-1135	937-456-1135 (same as daytime)	937-456-6086	
Shelby	937-498-4981	Contact County SO: 937-498-1111	937-498-1492	
Warren	513-695-1558	513-695-1600	513-695-1800	

1006.3 Adult Abuse or Neglect

A Report all alleged or suspected abuse or neglect to the appropriate agency.

Adult Public Social Services Agencies				
County	Phone	After Hours Phone	Fax	
Butler	513-887-4081	Contact County SO: 513-785-1000	513-785-5969	
Champaign	937- 484-1500	Contact County SO: 937-484-6092	937-484-1506	
Clark	937-327-1700	937-324-8687	937-327-1910	
Darke	937-548-7129	937-548-2020	937-548-4928	
Greene	937-562-6315	Contact County SO: 937-562-4800	937-562-6177	
Miami	937-440-3471	Contact County SO: 937-440-3965	937-335-2225	
Montgomery	937-225-4906	Contact County SO: 937-225-4357	937-496-7464	
Preble	937-456-1135	937-456-1135 (same as daytime)	937-456-6086	
Shelby	937-498-4981	Contact County SO: 937-498-1111	937-498-1492	
Warren	513-695-1420	513-425-1423	513-695-2940	

This Page Intentionally Left Blank

1007

Subject:

Basic Airway Maintenance

Effective: June 1, 2021

Last Modified:

Sept. 9, 2021

1007.1 Clinical Management

	Assessment	
Pediatric Considerations	Signs & Symptoms	Differential Diagnosis
Repeated and prolonged suctioning could cause hypoxia and bradycardia. Respirations by Age Up to 1 year 30-60 7-9 years 16-24 1-3 years 20-40 10-14 years 16-20 4-6 years 20-30 15+ years 12-20	 Respiratory difficulty or distress Poor SpO₂ or EtCO₂ Mechanism of Injury or Nature of Illness that would require O₂ therapy Impending airway issues Adventitious respiratory sounds 	• None
	Treatment Algorithm	
 Administer Oxygen as needed. Use the formula as a cannula (NC) formula and a cannula and a cannula (NC) formula and a cannula (NC) formula and	r patient with COPD, or as prescribed. for other patients. mask (NRM) for patients with increased respiratory rates ptomatic with an insufficient respiratory rate, depth or e respiratory distress with nasal congestion, cough, rales, way disease, breathing treatments: both nares (3-5 seconds) with an appropriate device sopharyngeal suctioning for 3-5 seconds grespiratory distress with agitation, upper airway noise, s ince as much as possible. blerates.	or effort. effort. rhonchi or wheezing - without tridor, and/or "barky cough,":
 If indicated, suction the tracheostomy. If patient has history of reactive airway d Consider the need for a supraglottic or du The EMT may only place a rescu 	appropriate selection of the airway adjunct. isease with prescribed breathing treatments then treat wal lumen rescue airway. ue airway in a pulseless, apneic patient.	
 For guidelines to placement of r Oxygen flow rate for nebulized medication 	rescue airways, see protocol <u>1008 Advanced Airway Man</u> ns should be 8-10 LPM .	
 Nebulized medication may be a 	dministered while ventilating a patient with a BVM. Prefe	erably use two oxygen sources.
If a foreign body is seen, attempt to remote When deciding whether to intubate, contained in the co	uccessful, try to visualize obstruction with laryngoscope. ove it using suction or Magill forceps. sider the following: ss than 10 or greater than 29, that are not rapidly contro	
Pallor or cyanosisCardiac dysrhythmias		
	Consult	
• None		

Clinical Pearls

COPD patients in severe respiratory distress or with chest pain need the same O₂ devices and flow rates as any other patient in such condition.

This Page Intentionally Left Blank

1008

Subject:

Advanced Airway Management

Effective: June 1, 2021

Last Modified:

Jan. 25, 2022

1008.1 Clinical Management

		Assessment	
ediatric C	onsiderations	Signs & Symptoms	Differential Diagnosis
None		Patient unable to manage their own airway	None
		Patient in cardiac arrest	
		Patient in respiratory arrest (AEMT & Paramedic)	
		Rapidly collapsing airway	
		Treatment Algorithm	
Advar	iced Airway Managemen	t is not an EMR skill	EMR
The El	MT may only place a resc	ue airway in a pulseless, apneic patient	
		such as the Supraglottic Airways or Dual Lumen Airways are appro	priate airway devices for both
adult	and pediatric patients.		
Confir	m correct placement of a	advanced airways by at least 5 methods, see protocol 1009 Advan	ced Airway Confirmation Devices
Reass	ess advanced airway plac	ement every time the patient is moved.	듭
An AE	MT may only intubate if	patient is apneic.	
		ny and condition for proper advanced airway device selection.	
If a to	·	an ET tube are not successful, move to a rescue airway.	
P		s recommended as the <u>primary airway</u> except in extreme cases suc	ch as airway edema.
		ace, preferably with a commercial tube-securing device.	
		naintaining patient's head in a neutral position during the intubati	on process.
		on pneumothorax and the patient is hemodynamically unstable:	
C		st with a 14-gauge or larger, 3 ¼" angiocath	
C	· ·		
		ifth intercostal space in the mid-axillary line	
		third intercostal space in the mid-clavicular line 8 years old, site choice will be limited to the 2nd or 3rd intercosta	al space at the mid clavicular line
Appro		tisfy the "rescue airway" component for 1010 (Sedate-to-Intubate	•
		intubation, consider the following:	<u> </u>
	A Apply Lidocaine Jelly		
Ā		(half dose per nostril) or nebulized with 8-10 LPM O₂ .	
F		nebulized with 8-10 LPM O₂ or IN . Maximum dose is 100 mg.	
		fter confirmed intubation:	
	•	00, consider Midazolam 2 mg slow IV .	
Ā		nsider Ketamine 100 mg slow IV .	
F		propriate consider Midazolam 0.1 mg/kg (max dose 2 mg), slow I	V.
Consid	der nasal intubation	3. 3	
		out is combative, agitated, or has jaws clenched, use 1010 {Sedate	to Intubate or RSI} procedures if
	ved to do so by Medical		
When	ever all reasonable atten	npts to provide an adequate airway by less invasive means have fa	ailed due to a total airway
	sion and you are unable t		
A	Perform a needle cri	cothyrotomy or surgical airway utilizing an approved method.	
F	Patient must be 8 ye	ars old or greater for a surgical airway.	
		Consult	
None			
		Clinical Pearls	

- For the EMT, AEMT and Paramedic, Dual Lumen Airways, King Airway or Laryngeal Mask Airways (LMA), are acceptable airway devices.
- For the AEMT and Paramedic, {Lighted Stylet Intubation} or {Camera Assisted Intubation} may be utilized.
- For the Paramedic, Nebulized Lidocaine can be administered simultaneously with Albuterol and Ipratropium.
 - o If feasible, wait one to two minutes before intubation

This Page Intentionally Left Blank

1009

Subject:

Advanced Airway Confirmation Devices

Effective: June 1, 2021

Last Modified:

Dec. 23, 2021

1009.1 General Guidelines

- a. Confirm correct placement of advanced airways with waveform capnography and at least 4 other methods as listed below.
- b. Reassess advanced airway placement every time the patient is moved.

1009.2 Confirmation Methods

	Assessment			
Pediatric Considerations	Signs & Symptoms	Differential Diagnosis		
See limitations for EDD	Inserted advanced airway	• None		
	Treatment Algorithm			
Advanced Airway Management is not an E	EMR skill		EMR	
for ventilation sounds. 3. Observe rise and fall of the chest of the Look for condensation in the tube condensation in the tube took at patient's appearance	advanced airway confirmation nings at the mid-axill with each breath		FMT	
P Proper endotracheal tube place P Depth of insertion (ler	be at the 21-23 cm mark at the teeth is recomment in the pediatric patient can be calculated leadth of tube at teeth or gum line) = Tube size x 3 possibility of a right main stem bronchus intubation.	oy: i.		AEMT
	ose is unlikely to reach the glottis in most cases ere is central facial movement or cerebrospinal f	•		
	Consult			
None				
	Clinical Pearls			
Intravenous sodium bicarbonate will prodEnd tidal capnography should be maintair	uce more carbon dioxide and affect EtCO ₂ value ned through transfer to the hospital	S.		

1009.3 Confirmation Devices

- a. These devices can help recognize esophageal intubation, but cannot identify bronchial placement.
- b. Maintain EtCO₂ devices until patient care is transferred to the receiving ED staff.
- c. Electronic End Tidal CO₂ (EtCO₂) Monitors (Capnography)
 - i. Continuous waveform capnography is a required confirmation device.
 - ii. EtCO₂ should be used on **EVERY** advanced airway
- d. End Tidal CO₂ Detector (EtCO₂) Colorimetric
 - i. In cardiac arrest, if there is no color change, use other confirmation methods.
 - ii. Secretions, emesis, etc. can ruin the device.
 - iii. Large amounts of carbonated beverage in the stomach can give a false positive.
 - iv. The device can be used for no more than two hours.

1009

Subject:
Advanced Airway Confirmation Devices

Effective: June 1, 2021

Last Modified:

Dec. 23, 2020

- v. Follow manufacturer's recommendations for weight restrictions.
- e. Esophageal Detector Device (EDD)
 - i. Use only for confirmation of endotracheal tube placement, not for any other advanced airways
 - ii. A large amount of gastric air can give a false positive finding.
 - iii. A cold device may give a false negative result.
 - iv. It cannot be used continuously, but may be reused after patient movement.
 - v. Tracheal obstructions in patients with morbid obesity, late pregnancy, status asthmaticus, or copious endotracheal secretions may yield misleading results
 - P Limited to pediatric patients who are more than 5 years old who weigh at least 20 kg (44 lbs)
- f. Beck Airway Airflow Monitor (BAAM) is authorized for use by the Paramedic during nasal intubation.

1010

Subject:

{Sedate to Intubate or RSI}

Effective: June 1, 2021

Last Modified:

Mar. 30, 2022

1010.1 General Guidelines

- a. Sedate to Intubate and Rapid Sequence Intubation are optional skills in the GMVEMSC protocol.
- b. These skills are to be performed by the Paramedic only.
- c. This standing order applies to agencies whose personnel have received the appropriate training and Medical Director's approval only.
- d. Under no circumstances is RSI to be used as "behavioral control" or restraint in patients with otherwise intact airways.
- e. Some Medical Directors may recommend Rapid Sequence Intubation as a primary airway control procedure.
- f. While this protocol recommends Succinylcholine and Vecuronium as short- and long-term paralytics respectively, a Medical Director may choose to use a different medication. Should a different paralytic than those listed be used, the Medical Director will be responsible to establish dosing and training.
- g. Inclusion criteria:
 - i. The patient must be 16 years old or older
 - ii. The patient cannot have suffered a paralyzing injury more than one week and less than 6 months ago (specific to Succinylcholine)

1010.2 Clinical Management

	Assessment	
Pediatric Considerations	Signs & Symptoms	Differential Diagnosis
This protocol does not apply to pediatric patients.	 Decreased LOC Ineffective or absent breathing Patient unable to maintain their own airway Respiratory failure or inevitable loss of airway 	 Cardiac arrest Anaphylaxis Esophageal obstruction
	Treatment Algorithm	
Sedate-to-Intubate nor Rapid Sequence Intu	ubation are EMR skills	EMR
Sedate-to-Intubate nor Rapid Sequence Intu	ubation are EMT skills	FM .
Sedate-to-Intubate nor Rapid Sequence Intu	ubation are AEMT skills	AEMI
 {If the paramedics double of the paramedics double of the paramedics double of the paramedics double of the paramedics of the paramed of the paramedics of the paramedics of the paramedics of the pa	Remove dentures or dental appliances.} It that they will be able to successfully intubate, the prefer in place} O.3 mg/kg IV (maximum dose 40 mg) OR In hemodynamically unstable patients), may repeat 10 OR IV (in patients who are normotensive), may repeat upquate relaxation is achieved, then intubate the patienty Plove Plocholine 200 mg IV ient and maintain continuous waveform capnograph tamine 100-200 mg IV tamine 100-200 mg IV	90 mg IV after 5 minutes} o to 10 mg } nt.

1010

Subject:

{Sedate to Intubate or RSI}

Effective: June 1, 2021

Last Modified:

Mar. 30, 2022

Consult

· Paramedics may seek guidance or approval from medical control prior to initiating the protocol; however, this is not required

Clinical Pearls

- Paralytics or sedation do not change poor airway anatomy.
- The most important decision may be when <u>NOT</u> to paralyze the patient or intubate them.
- Succinylcholine and Vecuronium paralyze the muscles but do not affect LOC. ALWAYS SEDATE THE PATIENT.
- Tachycardia may be a sign that the patient is paralyzed but not adequately sedated.
- No more than 2 intubation attempts.
- If you can still ventilate the patient with a BLS airway, a cricothyroidotomy is not necessary.

1010.3 RSI Educational Recommendations

- a. Rapid Sequence Intubation should not be available to all paramedics in the system.
- b. Only those paramedics willing to undergo additional initial training and continuing training should be allowed to perform it.
- c. In initial training, the paramedic should demonstrate proficiency during the following practical evaluations:
 - i. 2 endotracheal intubations on airway simulators
 - ii. 3 endotracheal intubations on airway simulator with C-spine immobilization
 - iii. 5 surgical cricothyrotomies on simulators using surgical technique or an approved device
 - iv. 4 intubations using the eschmann stylet (gum bougie) on airway simulators (optional)
 - v. 4 digital intubations on airway simulators
 - vi. 5 insertions of a rescue airway on airway simulators
- d. Once a quarter, the paramedic should demonstrate proficiency during the following practical evaluations:
 - i. 1 endotracheal intubation on airway simulators
 - ii. 2 endotracheal intubations on airway simulator with C-spine immobilization
 - iii. 1 surgical cricothyrotomy on airway simulator
 - iv. 1 intubation using the eschmann stylet (gum bougie) on airway simulators (optional)
 - v. 1 digital intubations on airway simulators
 - vi. 1 insertion of rescue airway on airway simulators
- e. Any of the above evaluations could be credited if the procedure is performed under direct supervision by the Medical Director, Supervisor or Training Officer the field or a clinical setting.

1011

Subject:

Tracheostomy and Laryngectomy Care

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

1011.1 General Guidelines

- a. Consult the patient's caregiver for assistance. They are typically trained to manage these airways.
- b. Find out why they have an artificial airway (cancer, stroke, ventilator dependent, etc.)
- c. Ask if there have been any prior difficulties (reinserting, plugging, etc).
- d. Find out when the airway was first placed (newer airways may be more difficult to replace).
- e. For assessing failed tracheostomies and laryngectomies, consider:
 - i. D displaced, dislodged or damaged
 - ii. O obstructed (mucus, food, blood, secretions)
 - iii. P pulmonary problems
 - iv. E equipment failure (bent tubing, ventilator malfunction, depleted oxygen supply
- f. Look for subcutaneous air in the neck as it might indicate a false passage of tube.

1011.2 Clinical Management

	Assessment	
diatric Considerations	Signs & Symptoms	Differential Diagnosis
None	Patient with tracheostomy or laryngectomy tube with signs of respiratory distress or failure	• None
	Treatment Algorithm	
Administer high-flow oxygen over the st Consider assisting ventilations using a b BVM typically will only attach If there is no inner cannula, ar be inserted into the outer can Consider infant BVM to stoma ventilation Assess EtCO ₂ Pre-oxygenate when possible for 30-60 sets Suction the tracheostomy tube if: Unable to ventilate with BVM. Coarse upper airway sounds are if respiratory distress continues if the airway tube has an inner of Use the patient's suctioning sup DO NOT force the suction cather Determine the proper suction cather beyond this measure. If no obturator is available: A Insert the suction cathered P Use the patient's pinky fing Consider inserting 2 - 3 mL of saline or net Suction on the way out, for no more than If respiratory distress continues, consider Inserting 2 - 3 mL of saline or net Suction on the way out, for no more than If respiratory distress continues, consider Inserting 2 - 3 mL of saline or net Suction on the way out, for no more than If respiratory distress continues, consider Inserting 2 - 3 mL of saline or net Suction on the way out, for no more than If respiratory distress continues, consider Inserting 2 - 3 mL of saline or net Suction on the way out, for no more than If respiratory distress continues, consider	ag-valve-mask attached to the device end. over the inner cannula a endotracheal tube adapter (BVM end of ETT) a half size is nula. In if the tracheostomy or laryngectomy tube has been rem conds prior to suctioning heard. despite BVM ventilation. annula, remove it prior to suctioning. plies or a catheter that is no more than 1/2 the tube diameter ter into the tracheostomy tube. atheter depth by measuring the length of the obturator or inn	arger than the trach tube may noved.
	oving respiratory status, consider replacing the airway tub	pe as defined in 1011.3
If measures have not succeeded in impr If no replacement tube is available, inse		pe as defined in 1011.3

1011

Subject:

Tracheostomy and Laryngectomy Care

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

Clinical Pearls

- Patients with laryngectomy airways have the larynx removed, completely separating oral- and nasal- pharynx from the trachea and lungs.
 - These patients are sometimes referred to as neck breathers.
- Established stomas are less likely to close off.
 - o Closed off stomas require surgical techniques to replace the tube and replacement should be avoided in the field.
- Often the cuff is deflated allowing the patient to have more air movement past the vocal cords thus enabling speech.
- There may also be speaking valve (a one-way valve allowing air in not out) attached to the outside end of the tracheal tube.
- Tube replacement is a clean procedure (mask, splash protection, and clean gloves). Keep the patient's airway as clean as possible.

1011.3 Artificial Airway Tube Replacement (AEMT & Paramedic)

- a. Necessary Equipment:
 - i. Replacement tracheostomy tube or laryngectomy tube (from the patient or care giver).
 - 1. If patient is pediatric, there is a one size smaller tracheostomy tube in the GoBag that should always be with the patient.
 - ii. If no replacement tracheostomy tube is available, use an ETT of similar internal diameter
 - iii. If possible, water-based lubricant jelly.

b. Procedure:

- i. Apply high-flow O₂, pulse oximetery, EtCO₂, and cardiac monitor.
- ii. Place patient semi-recumbent with slight neck extension (consider a roll under the neck).
- iii. Keep the head midline (May need additional personnel to maintain head position).
- iv. For adults, consider use of a bougie when removing the old tube. (this is not a pediatric practice)
- v. Lubricate the new tracheostomy tube or replacement ETT.
- vi. Deflate the old tracheostomy tube's balloon and remove during exhalation by gently pulling and rotating towards the patient's feet.
- vii. Remove the stoma dressing, then wipe area clean with only saline or medically packaged water.
- viii. Using the replacement tracheostomy tube's obturator or (in adults only)the bougie, gently advance the replacement tracheostomy tube in a fluid fashion, using the natural curvature of the tube until the flange is flush against the neck.
- ix. If present, remove the obturator and insert the hollow internal cannula
 - 1. Internal cannulas are not part of the most commonly used tracheostomy tubes for pediatric patients).
 - 2. If possible, use a non-fenestrated (no window) inner cannula.
 - a. Note: A fenestrated inner cannula will allow air leak through the glottis; potentially allowing air to enter the stomach and not allowing PEEP (positive end-expiratory pressure) to be achieved.
- x. If using an ETT as a replacement:
 - 1. Insert a bougie (adults only) into the stoma directed downward.
 - 2. Slowly advance the lubricated ETT into the stoma.
 - 3. Only advance the ETT a few centimeters into the stoma (as deep as the trach tube).
 - 4. Consider shortening the ETT by cutting the tube AFTER the takeoff for the pilot balloon.
- xi. Inflate the cuff of the replacement tracheostomy tube or ETT with the minimum amount of air to stop any audible leak at the stoma.
- xii. Place clean gauze around the stoma to absorb mucous.
 - 1. Never cut this gauze.

1011

Subject: Tracheostomy and Laryngectomy Care

Effective: June 1, 2021


Last Modified:


Dec. 8, 2021

- 2. Fold it to size, to avoid creating small particulates of lint that could enter the airway.
- xiii. Secure the device to the patient's neck.

c. Emergency Procedures

i. If the airway has been surgically altered and the glottis is hard to recognize, consider pushing on the chest to force air into the pharynx. Where air bubbles are seen, insert bougie (in adults) and/or insert the ETT into the opening.





This Page Intentionally Left Blank

General Protocol

1012

Subject: Intraosseous Infusion

June 1, 2021

Last Modified:

Dec. 8, 2021

1012.1 General Guidelines

- a. Use of IO devices is limited to patients who are unresponsive or hemodynamically unstable; and then, only when less invasive means are ineffective or not available (e.g., IM Glucagon, IN Narcan or Versed).
- b. In patients with acceptable perfusion, and all other routes of access have failed, then consider an intraosseous access of the proximal tibia.

Effective:

- c. For an adult in cardiac arrest, the preferable order of vascular access is:
 - i. External jugular (EJ) vein IV
 - ii. Antecubital (AC) vein IV
 - iii. Proximal humeral head IO (the proximal tibia is not to be used in cardiac arrest)

1012.2 Intraosseous Equipment Sizing

- A The longer yellow (45 mm) needle should be used for proximal humeral IOs in adults.
- **P** For pediatrics, access the proximal tibia in all cases.
 - **P** Use the blue IO needle for 3-30 kg.
 - P Use the pink IO needle for 0-3 kg.

1012.3 Clinical Management

	Assessment					
Pediatric Considerations	Signs & Symptoms	Differential Diagnosis				
Consider weight for IO selection	Hemodynamically unstable patient needing vascular access with no IV	• None				
	Treatment Algorithm					
IO Insertion is not an EMR skill		EMR	П			
IO Insertion is not an EMT skill						
 After IO confirmation, IV pressure bags may facilitate infusion. For the pain associated with infusion: A Lidocaine 2% 1.5 mg/kg via IO up to 100 mg. P Lidocaine 2% 0.5 mg/kg via IO (max 100 mg) 						
No additional orders at this level			4			
	Consult					
• None						
Clinical Pearls						
• None						
END OF SECTION						

1012 - Intraosseous Infusion Page 1 of 1

General Protocol

1013

Alternate Vascular Access

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

1013.1 General Guidelines

Subject:

a. This guideline is not for EMR, EMT or AEMT. Only Paramedics may utilize alternative vascular routes.

1013.2 Central Vascular Access Devices (CVAD)

- Patients who require long-term intravascular therapy may have Central Vascular Access Devices (CVAD).
- b. CVADs may be used for IV access if the patient is hemodynamically unstable or in arrest.
 - i. Central catheter: Catheter placed through chest wall into the internal jugular or subclavian vein.
 - 1. Central catheters can be single or multilumen.
 - 2. Distal portion of catheter has two access ports, either of which may be used for access.
 - ii. PICC Line: Catheter placed in arm.
 - 1. Distal portion of catheter is external with access port.
 - 2. Do not force fluids or drugs through the device or failure could result in an embolism.
 - 3. PICC line diameter creates significant resistance to fluid flow making it difficult to infuse large quantities of fluids.
 - 4. Dextrose 10% (D10) by PICC is preferable to IM Glucagon.
 - iii. Subcutaneously Implanted Port: Device surgically placed under the skin on the chest.
 - 1. No external access.
 - 2. PARAMEDICS ARE NOT PERMITTED TO ACCESS THIS DEVICE.

c. Complications of CVADs

- i. <u>Infection</u>: Thorough cleaning of the port must be done three times during the procedure:
 - 1. Before attaching each syringe
 - 2. Before attaching the IV tubing.
- ii. Air Embolism: The catheter must be clamped before attaching or removing the syringes.
- iii. <u>Heparin Bolus</u>: These catheters remain in place without fluids continually flowing through them. To prevent blood clot formation, a bolus of Heparin or other anticlotting agents will be in the catheter. Remove 5 ml of blood to insure that the Heparin is not systemically administered to the patient resulting in a potentially significant complication.
- iv. Catheter Damage:
 - 1. Use a 10 ml syringe or larger when drawing off the blood. Smaller syringes create too much pressure.
 - 2. After verifying blood return, flush catheter with 10 ml of NS with a 10 ml or larger syringe utilizing a pulsating technique.
 - 3. Administer medications slowly to avoid creating too much pressure. Do not use catheter if unable to get blood return.
 - 4. DO NOT USE A PRESSURE INFUSION DEVICE ON CVADs.

1013.3 Internal Dialysis Fistula

- a. An artificial passage between an artery and a vein used to gain access for hemodialysis.
- b. Usually located in the inner aspect of the patient's forearm or bicep.
- c. A bulge under the skin that should be visible or easily palpated.
- d. In cardiac arrest or with a profoundly unstable patient, a dialysis fistula may be used to administer IV fluids or medication.
 - i. Use aseptic technique.
 - ii. Be careful not to puncture back wall of vessel.
 - iii. Use IV pressure bag.
 - iv. Blood may still back-up into tubing.
 - v. Control bleeding with direct pressure.
- e. Dialysis patients are usually on anticoagulants.

END OF SECTION

1013 - Alternate Vascular Access Page 1 of 1

General Protocol

Subject:

Pain Management

Effective: June 1, 2021 Last Modified:

Dec. 8, 2020

1014.1 **General Considerations**

- This protocol is for management of acute moderate to severe pain, including pain from suspected cardiac events, trauma (including thermal and chemical burns), crush syndrome, frostbite, fractures, dislocations, sprains, and abdominal pain (including unilateral flank pain).
- **b.** It is not for the treatment of exacerbations of chronic pain.
- c. Prehospital pain management reduces time to pain relief, avoids exacerbation of pain during movement, is compassionate, and is good medical care.
- d. Ketamine is not to be administered to patients with suspected cardiac chest pain

1014.2 **Clinical Management**

Assessment Differential Diagnosis Signs & Symptoms **Pediatric Considerations** Severity of pain (pain scale) Chronic pain **Fentanyl** is <u>not</u> to be administered to anyone less than 2 years of age Quality (sharp, dull, etc.) To account for medication remaining in the Radiation of pain needle and syringe, add an additional 0.1 ml Pain upon movement Fentanyl for pediatric doses. Increased pain upon palpation **Ketamine** not to be administered for pain to anyone less than 16 years of age Fentanyl IN, is the first choice for pediatrics **Treatment Algorithm** Use ice packs, position of comfort, and splinting to reduce pain. Provide oxygen as indicated. No additional orders at this level. For an alert patient with moderate to severe pain, give Fentanyl for relief. Ketamine should be considered a second line medication for the management of pain If Fentanyl dosing does not relieve pain or if the patient refuses Fentanyl, then administer Ketamine ◆ Call for orders if you feel narcotics are needed for pain from a chronic condition. If SBP is greater than 100, then Fentanyl 50-100 mcg IV A A May repeat Fentanyl 50-100 mcg IV after 15 minutes. If no IV, Fentanyl 50-100 mcg IN or IM A May repeat **Fentanyl 50-100 mcg IN** or **IM** after 15 minutes. For pediatric patients in pain Fentanyl 1 mcg/kg IN, max 100 mcg May repeat Fentanyl 1 mcg/kg IN, max 100 mcg after 15 minutes If SBP is normal for patient's age (80 + 2 times age) then Fentanyl 1 mcg/kg IV, max 100 mcg P May repeat Fentanyl 1 mcg/kg IV, max 100 mcg after 15 minutes As a last resort, Fentanyl 1 mcg/kg IM, max 100 mcg P May repeat Fentanyl 1 mcg/kg IM, max 100 mcg after 15 minutes A Ketamine 25 mg IV A May repeat Ketamine 25 mg IV after 15 minutes If no IV, Ketamine 25 mg IN or 50 mg IM A May repeat **Ketamine 25 mg IN** or **50 mg IM** after 15 minutes No additional orders at this level. Consult Call for orders for management of chronic pain. ◆ MCP contact required before administration of Fentanyl for pediatric patients with abdominal pain. **Clinical Pearls** Always consider the weight of your patient when dosing pain meds, especially for the elderly. Document patient's reported pain during initial patient contact, during treatment, and after any intervention. **END OF SECTION**

1014 – Pain Management Page 1 of 1

2000 Series

Cardiac Protocol

2001

Subject:

Resuscitation Guidelines

Effective: June 1, 2021

Last Modified:

Oct. 21, 2021

2001.1 Guideline

- **a.** A patient's BEST CHANCE for resuscitation is at the scene with high quality CPR and code management.
- **b.** Paramedics are expected to provide ALS resuscitative care at the scene.

2001.2 Resuscitation and Field Termination

Assessment Differential Diagnosis Pediatric Considerations Signs & Symptoms FIELD TERMINATION DOES NOT APPLY TO Pulseless and apneic Meets Non-initiation of Care Guideline Does not meet Non-initiation of Care **PEDIATRIC PATIENTS** Guideline **Treatment Algorithm** The EMR will continue resuscitation until the patient is handed off to a higher level provider. The EMT will continue resuscitation until the patient is handed off to a higher level provider. If no higher level provider is available, then transport. ♦ If no ALS equipment is available at the scene, and transport time to a medical facility will exceed 20 minutes, field termination may be considered. Patients will require prolonged resuscitation efforts if: They have PEA with a rate greater than 40 per minute They have an upward trending or persistent EtCO₂ greater than or equal to 20 mmHg, refractory to VF or VT If arrest due to profound hypothermia, then rapidly transport to a Trauma Center ◆ Following all appropriate efforts, field termination requires MCP approval, and may only be considered when the following criteria are met: 18 years or older In asystole or PEA with rates less than 40 0 Not be in arrest due to hypothermia 0 0 Have an advanced airway in place 0 Have vascular access in place **AEMT** There are no signs of neurological function such as reactive pupils, response to pain or spontaneous movement The following should be rapidly transported to a cardiac interventional facility if less than a 30 minute transport and defibrillation is the only needed intervention to establish a perfusing rhythm: A documented STEMI and you witness the cardiac arrest ROSC after Ventricular Fibrillation or ROSC with evidence of ST elevation Consult When the AEMT or Paramedic contacts MCP directly to receive consent for field termination, they must provide the following information: The duration of the resuscitation How long the patient may have been in arrest prior to EMS arrival 0 Whether it was a witnessed or unwitnessed event 0 0 The current EtCO₂ The presenting rhythm 0 **Clinical Pearls** There are situations where resuscitation may take 30 minutes or more. Research has shown that CPR quality diminishes while being transported. Consider aeromedical transport for transports greater than 30 minutes if the patient has ROSC. In PEA, the patient may not be in true cardiac arrest, but simply not have palpable pulses due to profound shock.

END OF SECTION

2001 – Resuscitation Guidelines Page 1 of 1

Send a copy of the run sheet to the EMS Coordinator of the authorizing MCP's hospital.

2002

Subject:

Cardiac Arrest - BLS

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

2002.1 This protocol has adopted the 2020 American Heart Association CPR Guidelines

	ADULTS	CHILDREN	INFANTS	NEWBORNS
CPR Order	CAB: Compression, Airway, Breathing			
Compression to Breaths Ratio <u>Without</u> Advanced Airway	1 or 2 Rescuers 30:2	1 Rescuer - 30:2 2+ Rescuers - 15:2		3:1
Compression to Breaths Ratio <u>With</u> Advanced Airway	Continuous compressions at a rate of 100-120 /min. Give 1 breath every 6 seconds.	Continuous compressions at a rate of 100-120 /min. Give 1 breath every 2-3 seconds.		40-60 breaths/min
Compression Rate	100 to 120 per minute		120 per minute	
Compression Notes	Minimize interruptions in chest compressions. Limit interruptions to less			than 10 seconds
Compression Depth	At Least 2 Inches	1/3 Depth of Chest (About 2")	1/3 Depth of Chest (About 1 ½ ")	1/3 Depth of Chest
Rescue Breathing	1 breath every 5-6 seconds (10-12 breaths/min)	1 breath every 2-3 seconds (20-30 breaths/min)		40-60 breaths/min

2002.2 Basic Life Support

Assessment Pediatric Considerations Signs & Symptoms **Differential Diagnosis** Signs of irreversible death If available, use age-appropriate AEDs or Unresponsive pads Pulseless and apneic Other causes of unresponsiveness **Treatment Algorithm** If witnessed or unwitnessed arrest, initiate quality CPR for 1-2 minutes If available, initiate mechanical CPR using an approved device Attach and use AED as soon as possible after at least 2 minutes of CPR Utilize AED as it is programmed. (Even if it is not to AHA guidelines) EMR Repeat cycles of defibrillation and CPR for 2 minutes Obtain and transmit 12 Lead EKG if patient has ROSC **AEMT** Patient should be transported as appropriate. No additional orders at this level Paramedics are expected to provide resuscitative care at the scene. Cardiac arrests should not be transported unless: Return of Spontaneous Circulation (ROSC) 0 The airway cannot be secured Vascular access is not established MCP refuses to authorize Field Termination. Any ROSC patient should be transported to an interventional facility. Consult No consult required unless applying Field Termination Guideline **Clinical Pearls** Use jaw-thrust method to open airway on trauma patients Allow the chest to fully recoil after each compression Change person compressing chest every 2 minutes Resume CPR beginning with compressions after each defibrillation Minimize interruptions to compressions before and after each shock to less than 10 seconds For pregnant patients in cardiac arrest Consider need for manual uterine displacement In all cardiac arrests, consider the ACLS treatable causes (Hs & Ts) to your level of certification: **EMR EMT AEMT** Hypovolemia Hypoxia **Toxins** Tamponade, Cardiac Hypothermia Hydrogen Ion Thrombosis (Coronary, Pulmonary) Tension pneumothorax

June 1, 2021

2003

Subject: Cardiac Arrest:

Asystole or PEA

Effective:

Last Modified:

Oct. 10, 2021

2003.1 Guideline

- a. In all cardiac arrest patients, apply the 2002 Cardiac Arrest: Basic Life Support protocol.
- b. Apply the appropriate guideline after rhythm interpretation.
- c. The rhythms may change and will require flexibility to move between the different protocols.
- d. If ROSC, then follow 2001 Resuscitation Guidelines

2003.2 Asystole or PEA

	Assessment				
Pediatric Considerations • Pediatric dosing should never exceed adult doses	 Signs & Symptoms Unresponsive Pulseless and apneic Either: No electrical activity on cardiac monitor Electrical activity on monitor with no pulse present 	 Differential Diagnosis Ventricular Fibrillation Pulseless Ventricular Tachycardia Other causes of unresponsiveness Device (lead) error Signs of irreversible death 			
	Treatment Algorithm				
 Follow 2002 Cardiac Arrest -BLS pr Apply the Automatic External Defil If no defibrillation is indicated, cor Obtain and transmit {12 Lead EKG} 	orillator (AED) and check for a shockable rhythm. tinuous CPR	EMR			
 Consider possible causes Consider Field Termination as identified in 2001 Resuscitation Guidelines 					
A Epinephrine (1:10,000) 1 mg, IV or IO, repeat every 3-5 minutes. Epinephrine (1:10,000) 0.01 mg/kg, IV or IO, repeat every 3-5 minutes. The Paramedic may consider Field Termination after administering Epinephrine					
	Consult				
 No consult required unless applyin The AEMT or paramedic may consi Contact for Cardiac Alert if applica 	ult MCP to field terminate				
	Clinical Pearls				
 Contact receiving hospital prior to 	arrival				
END OF SECTION					



2004

Subject: Cardio

Cardiovascular Emergencies-Renal Failure/Dialysis Effective:


June 1, 2021 Last Modified:

Oct. 10, 2021

2004.1 Guideline

- a. This protocol is for cardiac patients who receive renal dialysis treatment and is only to be administered by Paramedics.
- **b.** Dialysis patients who are bradycardic or experience cardiac arrest should be given both calcium (chloride or gluconate) and sodium bicarbonate.

2004.2 Clinical Management



June 1, 2021

2005

Subject: Cardiac Arrest:

V-Fib or Pulseless V-Tach

Effective:


Last Modified:

Oct. 10, 2021

2005.1 Guideline

- a. In all cardiac arrest patients, apply the 2002 Cardiac Arrest: Basic Life Support protocol.
- b. Apply the appropriate guideline after rhythm interpretation.
- c. The rhythms may change and will require flexibility to move between the different protocols.
- d. If ROSC, then follow 2001 Resuscitation Guidelines

2005.2 Ventricular Fibrillation and Pulseless Ventricular Tachycardia



Medical Protocol

2006

Subject:

AICD Activations

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

2006.1 General Guidelines

a. A patient experiencing repeated AICD (Automatic Implantable Cardioverter-Defibrillator) activations should receive sedation or pain management from the AEMT or Paramedic.

2006.2 Clinical Management

	Assessment	
Pediatric ConsiderationsNone	Signs & Symptoms AICD in place and firing Sudden pain Muscle spasms	Differential Diagnosis ● None
	Treatment Algorithm	
 Monitor and be prepared to provide BLS care. Be prepared to defibrillate in the event of AICD 	failure.	EMR
Monitor and transport as indicated.Consider calling for ALS care.		TM
 Be prepared to defibrillate in the event of AICD Midazolam 2 mg slow IV for sedation. Consider 1014 Pain Management Protocol. 	failure.	AEMT
Be prepared to manually cardiovert in the ever	nt of AICD failure.	Paramedic A A A A A A A A A A A A A A A A A A A
	Consult	
• None	-	
	Clinical Pearls	
• None		
END OF SECTION		

2007

Subject: Ventricular Assist Devices

June 1, 2021

Last Modified:

Dec. 23, 2021

2007.1 General Guidelines

- a. It is important to recognize the patient with a ventricular assist device (VAD).
- b. Routinely, your agency will be advised when a VAD patient is in your community.
- c. Otherwise, these patients could be travelling through, or visiting in your jurisdiction.

Effective:

d. The patient or family members are generally knowledgeable about the VAD and how to troubleshoot it.

2007.2 Assessing the VAD Patient

- a. Skin color and mental status are the best indicators of stability in the VAD patient.
- b. A pulse is usually not palpable in the VAD patient. Nearly all VADs are continuous flow devices.
- c. If the device is a pulsatile flow device, a pulse should be palpable.
- d. Blood pressure may or may not be obtainable and auscultated readings are usually unreliable.
 - i. In a continuous flow device, mean arterial blood pressure (MAP) can be obtained by auscultating with a {Doppler}.
 - ii. The first sound heard during auscultation reflects the MAP.
 - iii. The MAP displayed by an automated non-invasive measurement may also be used.
 - iv. A normal MAP is 65 90 mmHg.
 - v. If the device is a pulsatile flow device, a blood pressure should be measurable.
- e. Pulse oximetry readings seem to be accurate, despite the manufacturer stating otherwise.
- f. Quantitative waveform capnography should be accurate and can be reflective of cardiac output
- g. An EtCO₂ of less than 30 mmHg can be indicative of low perfusion secondary to poor pump function.
- h. {ECG 12-lead} as usual, no interference from the VAD is expected
- i. Temperature should be measured as infection and sepsis are common.

2007.3 Transporting the VAD Patient

- a. Patients with or without a VAD problem should be transported to the nearest appropriate Hospital ED.
- b. Do NOT delay ground transportation waiting to speak with the patient's VAD Coordinator.
- c. Always bring the patients resource bag with you. It should contain:
 - i. Spare batteries and a battery charging unit
 - ii. Spare control unit
 - iii. Contact information for the VAD Coordinator.
 - iv. Directions for equipment and alarm troubleshooting.
- d. Always bring spare batteries for the VAD with the patient, even if it is not a VAD related problem.
- e. If the transport is going to be prolonged or it is expected that the patient will be away for a while, try to bring the VAD base power unit with you.
 - i. Alternately, you can ask the patient's family/caregiver to bring it to the hospital.
 - ii. There may be a need to bring it with the patient and plug it into an inverter for power.

2007 - Ventricular Assist Devices Page 1 of 2

2007

Subject:

Ventricular Assist Devices

Effective: June 1, 2021 Last Modified:

Dec. 23, 2021

2007.4 **Clinical Management**

diatric Considerations	Signs & Symptoms	Differential Diagnosis		
None	VAD equipment	• None		
	VAD vests or battery packs			
	Treatment Algorithm			
Determine if you have a patient with a VAD pro	blem, or a patient with a VAD that has a	medical/trauma problem.		
If there is no indication of possible VAD malfund	ction or failure, exit to appropriate proto	ocols.		
Assess the VAD:				
 Auscultate over the VAD pump location 	on (Should be just to the left of the epiga	strium, immediately below the heart)		
 If the pump is functioning, a 	a low hum should be audible.			
 Do not assume that the pun 	np is functioning just because the contro	ol unit does not indicate a problem.		
 Palpate the control unit. 				
	the pump may be working harder than it	t should be		
	problem such as a thrombosis.			
 Look at the alarms on the control pan 				
	sually be identified by an alarm.			
	The patient will usually have a resource guide to direct alarm troubleshooting. Ask if the place is a continuous and lottle flow the ince			
 Ask if the device is a continuous or pu Ask if the patient can receive electrical 				
 Ask if the patient can receive electrication Ask if chest compressions can be perf 	• •			
Inquire about DNR status.	offiled in the event of pump failure.			
If there is indication of possible device malfunct	tion or failure:			
Attempt to restart VAD if previously of the control of the co				
 If VAD off longer than 5 minutes, ther 				
	ency Contact Card"/VAD ID Card			
Contact the VAD coordinate				
 Discuss the plan with caregivers. 				
If a VAD patient is unresponsive and pulseless w	vith a non-functioning VAD and has previ	iously indicated a desire for resuscitative		
efforts, begin chest compressions.		·		
 AVOID THE USE OF MECHANICAL CPR 	DEVICES			
 Defibrillation pads should be placed a 				
<u> </u>	s (reconnecting wires, changing batteries	, , ,		
prior to starting chest compressions.			EMR	
Follow BLS protocol.				
Transport urgently.			EMT	
No additional directives at this level.			_ E	
No additional directives at this level.			TWIS C	
Only symptomatic dysrhythmias not at the patie	ent's baseline should be treated.			
If indicated, place electrical therapy/defibrillation	on pads away from VAD site and AICD.			
VAD patients may receive ACLS interventions.				
VAD patients may receive ACLS interventions.	Consult			

- Utilize the patient and family as a resource.
- Always contact the VAD Coordinator if there is a VAD related problem or question.
- Common complications in VAD patients include stroke (incidence up to 25%), bleeding, dysrhythmias, and infection.
- The most common causes of death in VAD patients are sepsis and stroke. Consider this with a VAD patient showing altered mental status.
- VAD patients are preload dependent. Consider that a fluid bolus can often reverse hypoperfusion.

END OF SECTION

2007 - Ventricular Assist Devices Page 2 of 2

2008

Subject:

Suspected Cardiac Chest Pain

Effective: June 1, 2021

Last Modified:

Aug. 9, 2022

2008.1 General Guidelines

a. Unstable cardiac patients are hypotensive, or have chest pain with poor skin color or diaphoresis.

2008.2 Clinical Management

	Assessment	
chiatric Considerations Chest pain in the pediatric patient is rarely related to a cardiac event. Assessment for other causes (e.g., muscle pain, respiratory difficulties, injury) should be completed to determine the source of pain. Apply supplemental oxygen and transport. THE REST OF CHEST PAIN ALGORITHM DOES NOT APPLY TO PEDS.	Signs & Symptoms Chest pain Shortness of breath Syncope Pallor, Diaphoresis Radiation of pain Weakness Nausea	Differential Diagnosis Pericarditis Pulmonary embolism Asthma/COPD Pneumothorax Aortic dissection or aneurysm GE reflux or hiatal hernia Chest trauma
NOT AFFEI TO FEBS.	Vomiting Treatment Algorithm	Esophageal spasm
Arrange for rapid ALS transport. Apply O₂ as appropriate. Oxygen saturations less than 94%, slow oxygen saturations 94% or higher, slow onto withhold oxygen from a patient with Scott of the state o	on the property of the propert	oms of Acute Coronary Syndrome (ACS). with vital signs between doses.
◆ Must obtain MCP permission to administer The AEMT must also transmit the {12-Lead EK Administer Nitroglycerin 0.4 mg SL, every 5 m	Gs}	h vital signs between doses.

Treat cardiogenic shock with or without pulmonary edema as identified in 4016 Shock.

- If evidence of STEMI, transport to an interventional cardiac catherization lab.
- The Paramedic should only transmit a {12-lead EKG} that meets Cardiac Alert criteria, or that is questionable.

IV fluid, up to 500 ml, may be administered to a patient with SBP less than 100 without pulmonary edema.

Consult

- Without consultation, the Suspected Cardiac Chest Pain protocol only applies to patients greater than 25 years old with ACS symptoms.
- Contact MCP for further advice with pediatric chest pain as needed.
- For the EMT, the following requires MCP orders:
 - o Aspirin administration
 - $\circ \quad \text{ Subsequent doses of the patient's own nitroglycerin}$
 - Accessing the GMVEMSC Drug Bag

Clinical Pearls

- No significant change in patient condition in the field should be expected from the administration of Aspirin.
- Patient must chew Aspirin.
- Do not administer Nitroglycerin (NTG) if the patient has taken Viagra, Cialis, Levitra, Revatio, or similar medications within the last 24 hours.

2009

Subject: Cardiac Alert Program

Effective: June 1, 2021

Last Modified:

Oct. 10,2021

2009.1 General Guidelines

- a. The intent of the Program is to decrease the "Door to Balloon" time for pre-hospital AMI Patients.
- b. Providers will make early notification to the receiving facility and speak directly with the Physician.
- c. The Physician may activate a Cardiac Alert, based on provider impression and {12 Lead EKG} interpretations.


2009.2 Inclusionary Criteria

- a. Patients presenting with anginal-type chest pain or an equivalent anginal event may be candidates.
- b. Evidence of an AMI (greater than 1mm ST elevation in 2 contiguous leads) on a diagnostic {12-lead EKG}.

2009.3 Exclusionary Criteria

- a. Patient with a Left Bundle Branch Block (QRS greater than 120 milliseconds).
- b. Patients with a pacemaker rhythm.

2009.4 Clinical Management



END OF SECTION

2009 – Cardiac Alert Program Page 1 of 1

Transporting the patient to would cause a critical shortage of local EMS resources. Patient requests transport to a different facility, despite EMS education of patient.

It is unsafe to transport the patient directly due to adverse weather/ground conditions or excessive transport time.

2010

Subject:

Bradycardia

Effective: June 1, 2021


Last Modified:

Oct. 10,2021

2010.1 General Guidelines

- a. Bradycardia is any rate less than 60 bpm.
- b. Non-symptomatic bradycardia may be a normal finding in otherwise healthy individuals.
- c. Assess the patient and determine medical history.
- d. Treat unexplained or symptomatic bradycardia

2010.2 Clinical Management



END OF SECTION

2010 – Bradycardia Page 1 of 1

2011

Subject: Tachyo

Tachycardia

Effective: June 1, 2021


Last Modified:

Oct. 10, 2021

2011.1 General Guidelines

- a. Tachycardia is any heart rate greater than 100 bpm.
- b. Assess the patient and determine medical history.
- c. Treat unexplained or symptomatic tachycardia

2011.2 Clinical Management



END OF SECTION

2011 - Tachycardia Page 1 of 1

3000 Series

Trauma Protocol

Trauma Protocol

3001

Subject:

General Trauma Management

Effective: June 1, 2021


Last Modified:

Dec. 8, 2021

3001.1 General Guidelines for Care of a Trauma Patient

- **a.** Minor trauma patients may be transported to non-trauma centers.
- **b.** Major trauma patients are to be transported as soon as possible to the nearest appropriate facility.
- **c.** Scene size-up, with rapid assessment and recognition of major trauma/multiple system trauma and effective evaluation of the mechanism of injury are essential to the subsequent treatment.
- d. If patient meets criteria as defined in 3019 Trauma Transport Guidelines, then call "Trauma Alert".
- e. If transporting by helicopter, ensure a copy of the patient care report gets to the receiving facility.

3001.2 Clinical Management



Trauma Protocol

3002

Subject:

Major Trauma

Effective: June 1, 2021

Last Modified:

Jan. 25, 2022

3002.1 Clinical Management

	Assessment	
ediatric Considerations None	Signs & Symptoms • Significant injuries or life threats	Differential Diagnosis ■ None
	Treatment Algorithm	
Place the patient in a correct position Open pneumothorax: cover wound Tension pneumothorax: lift one side	with an occlusive dressing, tape down three sides. e of any occlusive dressing. th a gloved hand, then immobilize with a bulky dressing or	r towels taped to the chest
No additional orders at this level.		EMT
Perform needle deco Decompres Location op F S P	onfuse right main stem intubation for a pneumothorax. mpression as indicated as the chest with a 14-gauge or larger, 3 ½" angiocath otions include: ourth or fifth intercostal space in the mid-axillary line econd or third intercostal space in the mid-clavicular line (a patients less than 8 years old, decompression site choice intercostal space at the mid-clavicular line	
No additional orders at this level.		
Contact Modical Control and advice	Consult them of patient condition with MIVT, ETA, and GCS comp	openets
Contact Medical Control and advise	Clinical Pearls	onents.

END OF SECTION

3002 – Major Trauma Page 1 of 1

3003

Subject: Glasgow Coma Score

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3003.1 General Guideline

a. When assessing the level of consciousness, use the Glasgow Coma Score.

b. All patients should have at least one recorded and reported GCS.

	LESS THAN 2 YEARS OLD		ADULT & PEDIATRIC OVER 2 YEARS OLD	
	SPONTANEOUSLY	4	Spontaneously	4
EYES	To voice	3	To voice	3
ETES	TO PAIN	2	TO PAIN	2
	No response	1	No response	1
	COOS, BABBLES	5	ORIENTED	5
	IRRITABLE CRY, CONSOLABLE	4	Confused	4
VERBAL	CRIES TO PAIN	3	INAPPROPRIATE WORDS	3
	MOANS TO PAIN	2	GRUNTS, GARBLED SPEECH	2
	No response	1	NO RESPONSE	1
	NORMAL MOVEMENTS	6	OBEYS COMMANDS	6
	WITHDRAWS TO TOUCH	5	LOCALIZES PAIN	5
MOTOR	WITHDRAWS TO PAIN	4	WITHDRAWS TO PAIN	4
MOTOR	FLEXION (DECORTICATE)	3	FLEXION (DECORTICATE)	3
	EXTENSION (DECEREBRATE)	2	EXTENSION (DECEREBRATE)	2
	NO RESPONSE	1	No response	1

END OF SECTION

3003 – Glasgow Coma Score Page 1 of 1

3004

Subject: Trauma Arrest

Effective: June 1, 2021

Last Modified:

May 2, 2022

3004.1 General Guidelines

- a. Traumatic cardiac arrest care will follow the same algorithm as other cardiac arrest scenarios.
- **b.** If appropriate, providers may consider termination of resuscitation (TOR).

3004.2 Termination of Resuscitation

- a. Emergency medical responders (EMRs) may <u>not</u> terminate a trauma cardiac arrest.
- b. The criteria for termination of resuscitation in arrest from blunt or penetrating trauma is:
 - i. No immediately reversible cause can be determined after rapid primary survey and treatment.
 - ii. No signs of life after BLS (e.g. respiratory effort, purposeful movement, reactive pupils, etc.)
 - iii. Sustained EtCO₂ of below 10 mmHg
 - iv. If no ALS equipment is available at the scene and transport will exceed 20 minutes.
- c. Continue care and transport if patient arrests **after** in the care of EMS.

3004.3 Clinical Management

		Assessment	
lf	tric Considerations The pediatric patient does <u>not</u> meet non- nitiation criteria, then <u>begin</u> resuscitation.	 Signs & Symptoms Cardiac arrest with traumatic injury or significant mechanism of injury Unresponsive, pulseless and apneic Excessive hemorrhage 	 Differential Diagnosis Signs of irreversible death Other causes of unresponsiveness Meets 1003 Non-initiation of Care Protocom
		Treatment Algorithm	
In Co	nitiate basic life support as defined in 2002 nternal/External hemorrhage control (e.g., consider the possibility of both medical and nitiate a Rapid Primary Survey for reversible ardiac monitoring/defibrillations via AED.	tourniquets, pelvic binders, etc.)	OULD BE A PRIORITY.
*	Consider Termination of Resuscitation. (A	EMT and Paramedic will continue through the alg	orithm before termination).
Bi	 Fourth or fifth intercostal spanning of the patients less than 8 years of mid-clavicular line Repeat needle decompression as indicated administer rapid IV fluid administration: P Administer up to 1000 ml IV P Administer 20 ml/kg of IV fluid from the patients 	pace in the mid-clavicular line (use nipple line as a bold, decompression site choice will be limited to the continued high airway pressure).	guide)
N	lo additional orders at this level		
	Contact MCP for Field Termination See ready to provide the following information Duration of resuscitation How long the patient was in arres Witnessed or unwitnessed cardiac Capnography values Presenting rhythm (for AEMT and	t prior to EMS arrival c arrest	
	<u> </u>	Clinical Pearls	

3004 – Trauma Arrest Page 1 of 1

3005

Subject:

Burns and Smoke Inhalation

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

3005.1 General Guidelines

- a. It is strongly recommended that at dispatch, agencies immediately call for the nearest available cyanide antidote cache whenever any of the following occur:
 - i. Dispatched on a report of a person trapped with exposure to fire or smoke in an enclosed area.
 - ii. Dispatched on a report of an incident involving hydrogen cyanide.
 - iii. Report of a Mayday or firefighter down with exposure to fire or smoke in an enclosed area.
- b. Estimate and report total Body Surface Area (BSA) involved using universally accepted methods.
 - i. BSA estimates should include only full and partial thickness burns.
- c. Inhalation injuries with an unsecured airway should be transported to the nearest facility.
- d. Chemical burns are hazardous material situations and must be grossly decontaminated at the scene.

3005.2 Specific Care for Different Burns

- a. Radiation burns:
 - i. If there is radioactive material on the patient, then they must be decontaminated.
 - 1. Consider contacting a Hazardous Materials Team for assistance with decontamination.
 - 2. Contact the hospital prior to arrival like with any other hazardous materials case.
 - ii. Treat critical medical conditions first.
 - iii. Treat injuries like thermal burns once the area is decontaminated

3005.3 Clinical Management

	Assessment	
ediatric Considerations None	Signs & Symptoms Burns, pain, swelling Loss of consciousness Hypotension/shock Airway compromise/distress Singed facial or nasal hair Hoarseness/wheezing	 Differential Diagnosis Superficial burns Partial thickness burns Full thickness burns Chemical, Thermal, Electrical, Radiatic burns
	Treatment Algorithm	
If available, use {CO oximeter}. For inhalation burns: Administer h Keep patient warm. Superficial or partial thickness bur Burns greater than 10% BSA may Do not apply ice or ice packs to bu Remove clothing and jewelry from	dor, hoarseness, sooty sputum, singed eyebrows and nar igh flow oxygen via non-rebreather mask. Ins less than 10% BSA may have wet dressings applied. The covered with clean, dry sheets or dressings. The covered with clean with the covered with the cov	MR
If available deliver {humidified} ox	ygen.	<u> </u>
Apply cardiac monitor, especially Provide endotracheal intubation i Administer fluids to maintain perf	usion, do not overhydrate. Fluids should be a balanced elewith burnt tissue if necessary and before intraosseous ne	ectrolyte solution when available.
	ot wait for complete airway obstruction or respiratory ar	rest.
· · · · · · · · · · · · · · · · · · ·	oisoning, use 3014 Cyanide Poisoning and Antidotes	
_	Consult	
None		
	Clinical Pearls	

3005 - Burns and Smoke Inhalation

END OF SECTION

BP may be taken over damaged tissue if no other site is accessible.

Page 1 of 1

3006

Subject:

Carbon Monoxide Poisoning

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3006.1 Clinical Management

	Assessment	
Pediatric Considerations None	Signs & Symptoms Malaise, fatigue, drowsiness Flu like symptoms Headache Dyspnea Nausea/vomiting Diarrhea Abdominal pain Syncope Seizures	Differential Diagnosis Flu/Severe cold Chronic fatigue Myocardial infarction Diabetic crisis Altitude sickness Ingested toxins Hypothyroidism
	Treatment Algorithm	
 Remove patients from the enviro Provide high flow O₂ to all suspect Pulse oximeter will give false read {CO oximeter} Contact MCP to discuss transport No additional orders at this level. No additional orders at this level. 	ted carbon monoxide poisonings. lings and should not be utilized. considerations.	EMT EMR
	Consult	
Look to Medical Control for guida	nce on transport destination.	
	Clinical Pearls	
Underlying cardiovGreater than 60 year	cal symptoms, such as any interval of unconsciousness, lo	ness of breath

END OF SECTION

3007

Subject:

Crush Syndrome Trauma

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3007.1 Clinical Management

		Assessment		
20	iatric Considerations No pediatric medication doses should exceed total adult doses.	Signs & Symptoms Patient entrapped Patient under a heavy load and crushed Hypotension Hypothermia Abnormal ECG findings Pain Anxiety	• None	
		Treatment Algorithm		
	 Contact MCP immediately and prior to relievi Prepare for the patient to decompensate when Monitor and reassess 			EMR
	{12-lead ECG} as soon as feasible			EMT
	1 liter IV fluid bolus IV. Then 500 ml/hour IV			
	IV fluid, 20 ml/kg IV			
	Follow 1014 Pain Management protocol			
	If hypotensive and the patient has been entrap	ped > 1 hour:		
	A Give additional IV fluid, 1 liter IV. P Give additional IV fluid, 20 ml/kg IV.			
	P Give additional IV fluid, 20 ml/kg IV. ◆ Consider sedation:			
	A Ketamine 250 mg IM, may repeat aft	er 2 minutes		
	P Ketamine 5 mg/kg IM, max dose of 2			
	Monitor for fluid overload			
	Normal ECG and hemodynamically stable, imme	ediately prior to extrication:		
	A Sodium Bicarbonate 100 mEq IV P Sodium Bicarbonate 1mEq/kg IV			
	1 Sociali bicarbonate Inteq/kg iv			
<u>r</u>				
1	Abnormal ECG and hemodynamically unstable:			
	o If after release, hyperkalemia causes	greater than or equal to 0.12 seconds		
	■ QT ≥ 0.46 seconds	greater than or equal to 0.12 seconds		
	Loss of P wave			
	 Bundle Branch Blocks 			
	Premature ventricular conti	ractions		
	Bradycardia Consider Calcium Chloride, 1 gm fl	ush line well before Sodium Bicarbonate		
	 Consider Calcium Chloride, 1 gm, †l Albuterol 10 mg nebulized 	ush line well before soulum bicarbonate		
	A Sodium Bicarbonate 100 mEq IV			
	P Sodium Bicarbonate 1mEq/kg IV			
		Consult		
•	Contact MCP immediately and prior to relieving	g the load.		
	MCP orders needed for sedation. The paramedic must call MCP for orders to give	Calcium Chlorida to the unstable patient		
•	The parametric must call MCP for orders to give	Clinical Pearls		
,	Consider the potential for multiple system trau			
	Consider the potential for hypo or hyperthermi			

3008

Subject:

Cyanide Poisoning & Antidotes

June 1, 2021

Last Modified:

Dec. 8, 2021

3008.1 General Guidelines

a. Cyanide antidotes are located in multiple caches in each of the counties throughout the region, and are available by contacting 937-333-USAR (8727).

Effective:

b. The cache agency closest to your incident will be dispatched, which will respond with both a Cyanokit and 3 doses of Sodium Thiosulfate, to provide for the potential of multiple patients.

3008.2 Indications To Call For The Cache

- a. It is strongly recommended that agencies immediately call for the nearest available cyanide antidote cache at the time of dispatch whenever any of the following occur:
 - i. Report of a person trapped with exposure to fire or smoke in an enclosed area.
 - ii. Report of an incident involving hydrogen cyanide.
 - iii. Report of a Mayday or firefighter down with exposure to fire or smoke in an enclosed area.

3008.3 General Treatment

a. Treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity.

3008.4 Clinical Management

		Assessment		
Pediatric Consider	ations	Signs & Symptoms	Differential Diagnosis	
None		Known or strongly suspected cyanide exposure	• None	
		Altered mental status		
		Seizures		
		Shock		
		Difficulty breathing		
		Treatment Algorithm		
Provide 100%	O ₂ via non-rebreather mask			EMR
 If unconscious 	s, provide 100% O ₂ by BVM			들
 Consider CPAI 	ofor suspected smoke inhal	ation.		EMT
Intubate if part	tient is apneic			
 Establish one 	IV in each arm if possible.			AEMT
 It is critical to 	control any seizure activity,	as defined in 4014 Seizures		Ā
 If available co 	nsider {BiPAP} for suspected	smoke inhalation.		
 ♦ Hydroxocob 	alamin (Cyanokit):			
	A ◆ Administer 5 grams via slow IV infusion over 15 minutes at a rate of 15 ml/min.			
	· · · · · · · · · · · · · · · · · · ·	V infusion over 15 min to 2 hours, depending on clinical	response.	
		over 15 minutes; max dose of 5000 mg (5 grams);		
	ay repeat 35 mg/kg slow IV	max dose 2500 mg (2.5 grams), depending on clinical re	esponse.	
or •				
		ter 12.5 grams (50 ml) 25% solution slow IV.		
		412.5 mg/kg (1.65 ml/kg) 25% solution, slow IV (max de	oso 12 5 a (50 ml))	
A VII	1033 than 23 kg. Authillister	Consult	53C 12.5 g (50 Hil)).	
Orders for cva	inide antidotes are <u>not</u> need			
•		ocobalamin (Cyanokit) and Sodium Thiosulfate to the sa	me nationt	
• • Contact Mc	to administer both riyarox	Clinical Pearls	me patient.	
If a patient is:	n arrest administer Hydrox	ocobalamin as quickly as possible.		
•		pinephrine should precede use of the cyanide antidotes		
•		umerous drugs including Diazepam.	•	
•	•	n a different vein or limb, one for standard protocol dru	as and one for cyanide antidotes	

While IV infusion is the preferred method of cyanide antidote administration, in extreme cases the medications could be given via IO.

If administering cyanide antidotes via IO, a traditional drip set may not be effective and measures may need to be taken to slowly

push the medication in.

3009

Subject: Drowning

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3009.1 Clinical Management

	Assessment	
Pediatric Considerations None	Signs & Symptoms History of submersion Period of unconsciousness Decreased or absent vital signs Vomiting Coughing	 Differential Diagnosis Trauma Pre-existing medical problem Barotrauma (diving) Decompression sickness
	Treatment Algorithm	
 Consider Spinal Motion Restriction Consider possibility of hypotherm Evaluate neurological status. 	a. If present follow <u>3016 Hypothermia</u>	EMR
 Drowning patients should be trans 	ported to a Trauma Center.	
Establish vascular access.		AEMI
No additional orders at this level		
	Consult	
• None		
	Clinical Pearls	

3009 - Drowning Page 1 of 1

3010

Subject:

Extremity Injuries

Effective: June 1, 2021 Last Modified:

Oct. 10, 2021

3010.1 **Clinical Management**

	Assessment				
Pediatric ConsiderationsNone	Signs & Symptoms Deformities Inflammation Pain upon movement Immobility Paresthesia	Differential Diagnosis ● None			
	Treatment Algorithm				
 If practical consider elevating the limb. Apply appropriate splinting device. If the extremity is severely angulated and puls 	ct pressure and cover with dry, sterile dressing. es are absent, apply gentle traction in an attempt to buntered, splint the extremity in the angulated posit	. •	EMT	1	
Consider 1014 Pain Management Protocol No additional orders at this level					
No additional orders at this level					
Consult					
• None					
	Clinical Pearls				

- Document distal motor, sensation and circulation before and after splinting, or spinal motion restriction.
- Open wounds should be covered with a sterile dressing before splinting.
- Immobilize above and below the injury.
- The patient who requires a load and go approach can be adequately immobilized by careful packaging on the long spine board. Do additional splinting enroute to the hospital as time and the patient's condition permit.

END OF SECTION

3010 – Extremity Injuries Page 1 of 1

3011

Subject:

Eye Injuries

Effective: June 1, 2021

Last Modified:

Oct. 11, 2021

3011.1 Clinical Management

	Assessment			
Pediatric Considerations None	Signs & Symptoms Irritation to eye Visual disturbances or loss of vision Obvious penetrating injury Burns Nausea	Differential DiagnosisHypertensionContact lens issue		
	Treatment Algorithm			
Use nasal cannula with IV tubing for Chemical Burns: Irrigate immediately with Determine chemical involvements of Donot irrigate if there is Cover both eyes to limit	h IV fluid or water for a minimum of 30 minutes or until pa olved. Bring Safety Data Sheets, if available. penetrating trauma to the eye. movement. absorbent dressing on or near any eye that may have rupt		EMR	
 No additional orders at this level. 			EMT	
No additional orders at this level.				AEMT
——————————————————————————————————————	or significant eye pain, Tetracaine 2 drops in affected eye. tracaine if penetrating trauma to the eye is present. la with IV tubing for irrigation.			
	Consult			
• None				
• None				
None	Clinical Pearls			

END OF SECTION

3011 – Eye Injuries Page 1 of 1

3012

Subject: Frostbite

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

3012.1 Clinical Management

	Assessment	
Pediatric Considerations None	Signs & Symptoms	 Differential Diagnosis Head Injury Spinal cord injury
	Treatment Algorithm	
 Protect injured areas. Remove clothing and jewelry from injured parts. Do not attempt to thaw injured part with local heat. Maintain core temperature. 		EMR
Severe frostbite injuries should be transported to a Burn Center.		m T T T T T T T T T T T T T T T T T T T
Establish vascular access and coConsider 1014 Pain Manageme		AEMT
No additional orders at this lev	el	
	Consult	
• None		
	Clinical Pearls	

3012 - Frostbite Page 1 of 1

3013

Subject:

Head Injury

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3013.1 Clinical Management

	Assessment	
Pediatric Considerations Assess the fontanelles in younger patients	Signs & Symptoms Visible head trauma Altered LOC Cushing's Triad or similar V/S Ataxic Respirations Increased B/P Bradycardia Pupillary changes Posturing	Differential Diagnosis Alcohol/Acidosis Epilepsy/Endocrine Infection Overdose/Oxygen Deficiency Uremia Tumor Insulin Psychogenic/Poison Stroke/Shock
	Treatment Algorithm	- Strokey Shock
 Evaluate level of consciousness, pupillary size Establish Glasgow Coma Score and reassess fr Ventilate at 20 breaths per minute when signs {Ventilate to maintain EtCO₂ reading Never ventilate at less than 8 per minute P Ventilate at a rate of ten faster than normal reads 	equently. s of cerebral herniation are present: gs of 30 mmHg (30 torr)}. inute.	rniation are present.
No additional orders at this level		<u> </u>
 No additional orders at this level No additional orders at this level 		AEMT
	Consult	
• None		
	Clinical Pearls	
 Signs of cerebral herniation: Dilated and unres Hyperventilation will decrease intracranial pre 		eased mental status.

END OF SECTION

3013 – Head Injury Page 1 of 1

3014

Subject:

Heat Exposure

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3014.1 Clinical Management

	Assessment	
Pediatric Considerations May not exhibit typically Do not thermoregulate well	Signs & Symptoms History of heat exposure Cramping Hot or flushed skin Excessive sweating Nausea/vomiting Mental status changes	Differential Diagnosis Thyroid storm Excited delirium Malignant hyperthermia Alcohol Epilepsy Insulin Trauma Infection Psychosis Stroke
	Treatment Algorithm	
 Apply cold packs to underarms and Cold water submersion is an accept bags. The goal is to lower temperarely or estimate the prepared for seizures 	table method for cooling heat stroke patients. You may	y encounter patients in cooling body
Hyperthermia patients should be t		T T
 If hypotensive or mental status ch A IV fluid 500 ml IV P IV fluid 20 ml/kg IV (ma May repeat both adult and pediate Additional IV fluid, if indicated Consider other medical conditions 	× 500)	ngly
No additional orders at this level		
	Consult	
• For additional (more than 2) fluid	challenges in adults	
	Clinical Pearls	
Other contributory factors may incHeat exposure can occur due to in	ts, patients with a history of spinal injury, and diabetics clude heart medications, diuretics, cold medications, are creased environmental temperatures, prolonged exerc	nd psychiatric medications

END OF SECTION

3014 – Heat Exposure Page 1 of 1

Environments with temperatures above 90°F and humidity over 60% present the most risk

3015

Subject:

Hemorrhage Control

Effective: June 1, 2021

Last Modified:

Nov. 5, 2021

3015.1 Clinical Management

Signs & Symptoms Shock-like symptoms Shock-like symptoms Freatment Algorithm Control of life-threatening external hemorrhage takes priority over any other treatment. Constant, direct pressure is the primary method of bleeding control. If direct pressure fails to control bleeding from extremities, use a tourniquet. (Commercial tourniquets such as the CAT or SOFTT are recommended) Only use wide, flat materials such as cravats or BP outfis as improvised tourniquets Place a tourniquet as proximal as possible to the torso on the femur or humerus If bleeding persists, place another tourniquet abutted to the first tourniquet Document time and location Be sure that the ER staff is aware of the tourniquet For life-threatening hemorrhage that can't be controlled by tourniquets, consider hemostatic dressings}. Combat Gauze, or ChitoFlex PRO are examples These can be used on or in the chest or abdomen Place in direct contact with the source of bleeding and apply a pressure dressing or use Kerlix DO NOT USE GRANULAR AGENTS (Wound Packing may be performed by providers at any level, as long as they have received proper training) This procedure is not necessary and may be harmful. Apply a pressure dressing and manual direct pressure over the packed wound for at least 3 minutes Do not remove wound packing once placed in the cavity Notify the ED staff of the use of wound packing on arrival at the destination Treat for hypovolemic shock as indicated. No additional orders at this level Consult None		Assessment				
Control of life-threatening external hemorrhage takes priority over any other treatment. Constant, direct pressure is the primary method of bleeding control. If direct pressure fails to control bleeding from extremities, use a tourniquet. (Commercial tourniquets such as the CAT or SOFTT are recommended) Only use wide, flat materials such as cravats or BP cuffs as improvised tourniquets Place a tourniquet as proximal as possible to the tors on the femur or humerus Tighten the tourniquet until the bleeding stops If bleeding persists, place another tourniquet abutted to the first tourniquet Document time and location Be sure that the ER staff is aware of the tourniquet (For life-threatening hemorrhage that can't be controlled by tourniquets, consider hemostatic dressings). Combat Gauze, or ChitoFlex PRO are examples These can be used on or in the chest or abdomen Place in direct contact with the source of bleeding and apply a pressure dressing or use Kerlix DO NOT USE GRANULAR AGENTS (Wound Packing may be performed by providers at any level, as long as they have received proper training) This procedure is not to be used on open wounds to the head Use sterile gauze or approved hemostatic products Gauze should be placed as deeply in the wound as possible using a gloved digit and continuous pressure Excessive force is not necessary and manual direct pressure over the packed wound for at least 3 minutes Do not remove wound packing once placed in the cavity Notify the ED staff of the use of wound packing on arrival at the destination Treat for hypovolemic shock as indicated. No additional orders at this level No additional orders at this level No additional orders at this level		Significant bleeding	_			
Constant, direct pressure is the primary method of bleeding control. If direct pressure fails to control bleeding from extremities, use a tourniquet. (Commercial tourniquets such as the CAT or SOFTT are recommended) Only use wide, flat materials such as cravats or BP cuffs as improvised tourniquets Place a tourniquet as proximal as possible to the torso on the femur or humerus Tighten the tourniquet and the bleeding stops If bleeding persists, place another tourniquet abutted to the first tourniquet Document time and location Be sure that the ER staff is aware of the tourniquet (For life-threatening hemorrhage that can't be controlled by tourniquets, consider hemostatic dressings). Combat Gauze, or ChitoFlex PRO are examples These can be used on or in the chest or abdomen Place in direct contact with the source of bleeding and apply a pressure dressing or use Kerlix DO NOT USE GRANULAR AGENTS (Wound Packing may be performed by providers at any level, as long as they have received proper training) This procedure is not to be used on open wounds to the head Use sterile gauze or approved hemostatic products Gauze should be placed as deeply in the wound as possible using a gloved digit and continuous pressure Excessive force is not necessary and may be harmful. Apply a pressure dressing and manual direct pressure over the packed wound for at least 3 minutes Do not remove wound packing once placed in the cavity Notify the ED staff of the use of wound packing on arrival at the destination Treat for hypovolemic shock as indicated. No additional orders at this level No additional orders at this level Consult None Clinical Pearls		Treatment Algorithm				
If direct pressure fails to control bleeding from extremities, use a tourniquet. (Commercial tourniquets such as the CAT or SOFTT are recommended) Only use wide, flat materials such as cravats or BP cuffs as improvised tourniquets Place a tourniquet as proximal as possible to the torso on the femur or humerus Tighten the tourniquet until the bleeding stops If bleeding persists, place another tourniquet abutted to the first tourniquet Document time and location Be sure that the ER staff is aware of the tourniquet {For life-threatening hemorrhage that can't be controlled by tourniquets, consider hemostatic dressings}. Combat Gauze, or ChitoFlex PRO are examples These can be used on or in the chest or abdomen Place in direct contact with the source of bleeding and apply a pressure dressing or use Kerlix DO NOT USE GRANULAR AGENTS {Wound Packing may be performed by providers at any level, as long as they have received proper training} This procedure is not to be used on open wounds to the head Use sterile gauze or approved hemostatic products Gauze should be placed as deeply in the wound as possible using a gloved digit and continuous pressure Excessive force is not necessary and may be harmful. Apply a pressure dressing and manual direct pressure over the packed wound for at least 3 minutes Do not remove wound packing once placed in the cavity Notify the ED staff of the use of wound packing on arrival at the destination Treat for hypovolemic shock as indicated. No additional orders at this level	Control of life-threatening external hemorrhage	e takes priority over any other treatment				
Commercial tourniquets such as the CAT or SOFTT are recommended) Only use wide, flat materials such as cravats or BP cuffs as improvised tourniquets Place a tourniquet as proximal as possible to the torso on the femur or humerus Tighten the tourniquet until the bleeding stops If bleeding persists, place another tourniquet abutted to the first tourniquet Document time and location Be sure that the ER staff is aware of the tourniquet {For life-threatening hemorrhage that can't be controlled by tourniquets, consider hemostatic dressings}. Combat Gauze, or ChitoFlex PRO are examples These can be used on or in the chest or abdomen Place in direct contact with the source of bleeding and apply a pressure dressing or use Kerlix DO NOT USE GRANULAR AGENTS {Wound Packing may be performed by providers at any level, as long as they have received proper training} This procedure is not to be used on open wounds to the head Use sterile gauze or approved hemostatic products Gauze should be placed as deeply in the wound as possible using a gloved digit and continuous pressure Excessive force is not necessary and may be harmful. Apply a pressure dressing and manual direct pressure over the packed wound for at least 3 minutes Do not remove wound packing once placed in the cavity Notify the ED staff of the use of wound packing on arrival at the destination Treat for hypovolemic shock as indicated. No additional orders at this level No additional orders at this level No additional orders at this level Consult None Clinical Pearls	Constant, direct pressure is the primary method	d of bleeding control.				
Combat Gauze, or ChitoFlex PRO are examples These can be used on or in the chest or abdomen Place in direct contact with the source of bleeding and apply a pressure dressing or use Kerlix DO NOT USE GRANULAR AGENTS {Wound Packing may be performed by providers at any level, as long as they have received proper training} This procedure is <u>not</u> to be used on open wounds to the head Use sterile gauze or approved hemostatic products Gauze should be placed as deeply in the wound as possible using a gloved digit and continuous pressure Excessive force is not necessary and may be harmful. Apply a pressure dressing and manual direct pressure over the packed wound for at least 3 minutes Do not remove wound packing once placed in the cavity Notify the ED staff of the use of wound packing on arrival at the destination Treat for hypovolemic shock as indicated. No additional orders at this level No additional orders at this level Consult None Clinical Pearls	 {Commercial tourniquets such as the Only use wide, flat materials such as of Place a tourniquet as proximal as position Tighten the tourniquet until the bleed If bleeding persists, place another tou Document time and location 	CAT or SOFTT are recommended} cravats or BP cuffs as improvised tourniq sible to the torso on the femur or humer ling stops urniquet abutted to the first tourniquet		ı		
This procedure is <u>not</u> to be used on open wounds to the head Use sterile gauze or approved hemostatic products Gauze should be placed as deeply in the wound as possible using a gloved digit and continuous pressure Excessive force is not necessary and may be harmful. Apply a pressure dressing and manual direct pressure over the packed wound for at least 3 minutes Do not remove wound packing once placed in the cavity Notify the ED staff of the use of wound packing on arrival at the destination Treat for hypovolemic shock as indicated. No additional orders at this level No additional orders at this level Consult None Clinical Pearls	 Combat Gauze, or ChitoFlex PRO are 6 These can be used on or in the chest 6 Place in direct contact with the source 	examples or abdomen		ı		
No additional orders at this level No additional orders at this level No additional orders at this level Consult None Clinical Pearls	 This procedure is <u>not</u> to be used on operations. Use sterile gauze or approved hemost Gauze should be placed as deeply in the Excessive force is not necessary and not apply a pressure dressing and manuation. Do not remove wound packing once processing and manuation. 	pen wounds to the head tatic products he wound as possible using a gloved digi nay be harmful. I direct pressure over the packed wound placed in the cavity	t and continuous pressure	ı		
No additional orders at this level No additional orders at this level Consult None Clinical Pearls	Treat for hypovolemic shock as indicated.			EMR		
No additional orders at this level Consult None Clinical Pearls	No additional orders at this level					
No additional orders at this level Consult None Clinical Pearls	No additional orders at this level				AEMT	
Consult None Clinical Pearls						
None Clinical Pearls	No additional orders at this level	Consult				
	None					
	None	Chilical Featis				

3015 – Hemorrhage Control Page 1 of 1

This Page Intentionally Left Blank

3016

Subject:

Hypothermia

Effective: June 1, 2021

Last Modified:

Oct. 11, 2021

3016.1 Clinical Management

	Assessment			
Pediatric Considerations None	Signs & Symptoms Cold, clammy skin Shivering Mental status changes Extremity pain or sensory abnormality Bradycardia Hypotension or shock	Differential Diagnosis		
	Treatment Algorithm			
 Avoid any rough movement that may c It may be beneficial to consider spinal r Assess neurological status. Oxygenate the patient with 100% O₂. If patient goes into cardiac arrest: CPR continuously In severe hypothermia (less the 	move all wet clothing, dry the patient, and cover with blause cardiac dysrhythmias or cardiac arrest. notion restriction measures. han 86°F [30°C]), limit defibrillation attempts to one excent than 86°F [30°C]), follow normal arrest protocols.		EMR	
 If available, provide {warmed and humi Hypothermic patients should be transp Resuscitative efforts should be continued 			EMT	
 Use the least invasive means possible t Intubate if necessary, as gently as possi Establish vascular access and consider { 	ble.			AEMT
Treat bradycardia only if patient is hypo	otensive.			
	Consult			
 All levels should consult with 	nagement of the severely hypothermic patient. MCP for orders to administer second and subsequent den MCP for orders to administer cardiac arrest medication			
	Clinical Pearls			
	respirations for up to 45 seconds to confirm arrest. present, no matter how slow.			

END OF SECTION

3016 - Hypothermia Page 1 of 1

This Page Intentionally Left Blank

3017

SALT Triage System

Effective: June 1, 2021

Last Modified:

Dec. 30, 2021

3017.1 General Guidelines

- a. SALT stands for Sort, Assess, Life-Saving Intervention, and Treatment/Transport.
- b. Developed by the Centers for Disease Control and Prevention to address limitations in other systems.
- c. The CDC has proposed SALT as the national standard for Mass Casualty Incident (MCI) triage.
- d. SALT has the advantage of being the **fastest mass casualty triage system**.
- e. Notify hospitals of any MCI, especially a MCI involving contaminated patients.
 - i. Consider use of the 3020 Regional Hospital Notification System (RHNS)

3017.2 Primary and Secondary Triage Prior to Transport

a. Initial Triage:

- i. Use triage ribbons (color-coded strips), not triage treatment tags, during initial triage.
 - 1. Treatment tags slow the process and should be used later, in the treatment areas.
 - 2. Treatment tags do need to be used at some point as they are sometimes the only documentation of EMS assessments and treatments.
- ii. Tie the triage ribbon to an upper extremity in a VISIBLE location (on the right wrist, if possible).
- iii. SALT Triage Levels:
 - 1. RED Immediate
 - 2. YELLOW Delayed
 - 3. GREEN Minimal
 - 4. GRAY Expectant (The patient is unlikely to survive given the current resources)
 - 5. **BLACK Dead** (black & white zebra stripe for easier visibility in low light)
 - 6. **ORANGE and Polka Dot** used in addition to one of the above ribbons to indicate victim has been contaminated with a hazardous material.
- iv. Move as quickly and safely as possible; making quick decisions.
- v. Victims will be re-triaged, probably multiple times. Revise the triage category as often as indicated.
- vi. Over-triage can be as harmful as under-triage. If everyone is tagged red, those who are truly red will receive delayed treatment, delayed transport, and delayed definitive care.
- vii. Treatment and transport should NOT be delayed especially for critical patients. Get the reds out.
- viii. If there are extensive delays in the field, consider requesting orders for palliative care, e.g., pain medications if time and resources allow.

b. Secondary Triage:

- i. Reassess (i.e. secondary triage) as often as practical, including when the patient is moved to the Casualty Collection Point (CCP) or Treatment Area, and on all victims prior to transport.
 - 1. Also reassess patients when their condition or resources available change.
- ii. Apply Treatment Tags after patients enter the CCP, or in the Transport Area (by the Transport Officer/Group) if the patient is being directly removed without going to the Treatment Area.
- iii. Crews can also fill in pertinent and available information on the Tag during transport.
- iv. Use the patient's ribbon to tie on the triage treatment tag
 - 1. Use triage treatment tags with individual barcodes consistent with this Standing Order and the Ohio patient tracking system (OHTrac).
- v. Orange & Polka-dot ribbons (indicating contaminated patients) are removed after decontamination.
 - Each contaminated patient initially receives two ribbons: one with the triage category (Red, Yellow, Green, Gray, or Black), and the second, the Orange & Polka-dot ribbon indicating contamination.
 - 2. EMS is responsible for performing primary decontamination prior to transport. However, the hospital must be made aware of both contamination and the

3017 – SALT Triage System Page 1 of 4

3017

SALT Triage System

Effective: June 1, 2021

Last Modified:

Dec. 30, 2021

decontamination procedures taken.

- 3. Make sure to decontaminate under the ribbons.
- 4. After decontamination, remove the **Orange & Polka-dot** ribbon.
- 5. Mark triage treatment tags for contaminated patients with two check marks on the orange strip:
 - a. Mark both the "dirty" and "decontaminated" boxes.
 - b. This indicates to the hospital personnel that the patient has had field decontamination, but may still be somewhat "dirty".

c. Transport

- i. Treatment Area or Transport Group personnel determine priority for transport.
- ii. Distribution of patients among various hospitals is one of EMS' most crucial tasks.
- iii. **Do not overload any hospital**, regardless of transport distance to other hospitals.
- iv. In an MCI, transport trauma patients to non-Trauma Centers as necessary.
 - 1. All hospitals will accept and stabilize trauma patients during MCIs.
 - 2. Consider transporting minor (GREEN) patients to Freestanding EDs to relieve pressure on Trauma Centers and other hospitals.
- v. When assigning patient allocation, consider the likelihood that the closest hospitals may be overwhelmed by patients who were not transported by EMS.
- vi. In large scenarios, consider activation of the Forward Movement of Patients Plan as defined in 3021.0 Crisis Standards of Care in Massive Events.

3017.3 Sort, Assess, Life-Saving Intervention, Treatment/Transport Process

- a. **S**ort
- i. Global Sorting: Action 1
 - 1. Action: "Everyone who can hear me please move to [designated area] and we will help you" (use loudspeaker if available)
 - 2. Goal: Group ambulatory patients using voice commands
 - 3. Result: Those who follow commands are *last* priority for individual assessment (Green)
 - 4. Assign someone to keep them together and notify Incident Command or EMS Group/Branch of number of patients and their location.
 - 5. Do not forget these victims.
 - 6. Someone must re-triage them as soon as possible.
 - 7. In smaller incidents, such as a motor vehicle crash with few victims that you do not want to move on their own, skip Action 1, and go to Global Sorting Action 2
- ii. Global Sorting: Action 2
 - 1. Action: "If you need help, wave. We will be there to help as soon as possible"
 - 2. Goal: Identify non-ambulatory patients who can follow commands or make purposeful movements
 - 3. Result: Those who follow this command are second priority for individual assessment
- iii. Global Sorting: Result
 - 1. Casualties are now prioritized for individual assessment
 - a. Priority 1: Still, and those with obvious life threat
 - b. Priority 2: Waving or purposeful movements
 - c. Priority 3: Walking
- iv. Begin assessing all non-ambulatory victims where they lie, performing Life Saving Interventions (LSIs) as needed, within your scope of practice, using the equipment is readily available.

3017 – SALT Triage System Page 2 of 4

3017

SALT Triage System

Effective: June 1, 2021

Last Modified:

Dec. 30, 2021

b. Assess

- i. Is the patient breathing?
 - 1. If not, open the airway. In children, consider giving two rescue breaths.
 - 2. If the patient is still not breathing, triage them to **BLACK** (dead).
 - 3. Do not move patients triaged **BLACK** except to gain access to a living patient.
 - 4. If patient is breathing, conduct next assessment.
- ii. Assess for the following:
 - 1. Can the patient follow commands or make purposeful movements?
 - 2. Does the patient have a peripheral pulse?
 - 3. Is the patient not in respiratory distress?
 - 4. Is hemorrhaging under control?

iii. Grading the Assessment

- 1. If the answer to <u>any</u> of those questions is <u>no</u> (bad) and the patient <u>IS</u> likely to survive given current resources, tag them as <u>RED</u> (<u>Immediate</u>).
- 2. If the answer to <u>any</u> of those questions is <u>no</u> (bad) and the patient is <u>NOT</u> likely to survive given current resources, tag them as **GRAY** (Expectant).
- 3. If the answer to <u>all</u> of those questions is <u>yes</u> but injuries are not minor and require care, tag patient as <u>YELLOW</u> (Delayed).
 - a. YELLOWs have serious injuries and need care, though not as urgently as REDs.
 - b. On secondary triage, some Yellows will need higher priority transport than others.
- 4. If the answers to <u>all</u> of those questions is <u>yes</u> and the injuries are minor, tag patient as **GREEN** (Minimal).

Two mnemonics to remember the four assessment questions	
C – follows <u>C</u> ommands	Think of the questions in terms of "bad" or "good"
R – No Respiratory distress	
A – No (uncontrolled) <u>A</u> rterial bleeding	If the answer to any of the questions is "bad" then the patient is
P – <u>P</u> eripheral <u>P</u> ulse <u>P</u> resent	tagged either RED (Immediate) or GRAY (Expectant)

c. Life Saving Interventions

- i. Only correct life-threatening problems during triage.
 - 1. Control major hemorrhage
 - 2. Open airway (if child, consider giving two rescue breaths)
 - 3. Needle chest decompression
 - 4. Auto injector antidotes
 - 5. See 3017.5 Special Situations

d. <u>Treatment/Transport</u>

- i. Transport/treatment priority is typically given (in order) to
 - 1. **RED** (Immediate)
 - 2. YELLOW (Delayed)
 - 3. **GREEN** (Minimal)
 - 4. GRAY (Expectant) patients should be treated and transported as resources allow.

3017.4 General Considerations

a. Patients must be reassessed periodically, including when moved to the CCP, or when their condition or resources change.

3017 – SALT Triage System Page 3 of 4

3017

SALT Triage System

Effective: June 1, 2021

Last Modified:


Dec. 30, 2021

- b. Even after applying triage treatment tags, the main indicator of patient condition is the triage ribbon.
- c. Continue to use the same tag, even if the condition changes repeatedly, changing the ribbon to indicate the patient's current condition.
- d. If the patient's condition or the triage priority changes, indicate that on the tag.

3017.5 Special Considerations

- a. SALT is a clinical guideline, not an absolute.
- b. Every MCI is extraordinary use your clinical judgement
- c. A patient who is **GRAY** (Expectant) initially can become **RED** (Immediate) as soon as resources are available.
- d. MCIs with patients suffering traumatic (aka, compression) asphyxia who are not breathing initially, may start breathing after just a few ventilations.
 - i. Common to crowding situations and crowd surges (i.e the Houston Astroworld Music Fest), it is worth attempting a few ventilations during the LSI step, even in adults.
- e. In MCIs due to lightning strikes, the pathology can be very complex.
 - i. Consider attempting ventilation or defibrillation, depending on resources and the conditions of other victims.

3017.6 SALT Triage Flow Chart



END OF SECTION

3017 – SALT Triage System Page 4 of 4

3018

Spinal Motion Restriction

Effective: June 1, 2021

Last Modified:

Aug. 12, 2021

3018.1 General Guidelines

- a. Studies indicate traditional spinal restriction has risks and may even cause harm in some cases.
- b. Spinal Motion Restrictions allows for an assessment based management of the injured patient.
- c. Spinal precautions should always be taken when dealing with at risk patients.
- d. This protocol does not indicate that providers do not immobilize the spine; it simply provides a different means of restriction in selected patients.
- e. These guidelines apply to providers at all certification levels.

3018.2 Blunt Trauma Patients – Full Immobilization

- A All patients with clinical indications of a spinal injury <u>and/or</u> with altered levels of consciousness must be immobilized with both a C-collar and a spinal restriction device. (e.g., spine board, KED, vacuum splint).
- **P** Pediatric trauma patients less than 3 years of age with a GCS of less than 15 must be immobilized with both a C-collar and a spinal restriction device.

3018.3 Blunt Trauma Patients – SMR

- a. Other alert trauma patients, including all those listed below, should have a c-collar placed and moved with caution in-line as a unit to the cot. They would not need a backboard:
 - i. Patients with neck pain
 - ii. Patients with midline neck or spinal tenderness
 - iii. Patients with pain upon motion of the neck
 - iv. Cases with high risk mechanism (high speed MVC, fall greater than 10 feet, axial loading injury)

3018.4 Penetrating Trauma

- a. Patients with penetrating trauma do not need immobilization with either a cervical collar or backboard.
- b. Delays in transport are to be minimized and place the patient at greater risk.

3018.5 Airway or Ventilatory Management

- a. Patients who are immobilized and require airway and or ventilatory interventions (including intubation) may have the cervical collar removed during the intervention.
 - i. In-line stabilization should be maintained while the intervention is performed.
- b. The cervical collar should be reapplied after the intervention is either accomplished or abandoned.

3018.6 Equipment Issues

- a. In an emergency situation with equipment intensive sports such as football, hockey and lacrosse, the protective equipment shall be removed prior to transport to an emergency facility.
- b. Helmets of any kind that prevent either effective SMR or airway management should be removed.

3018.7 Other Considerations

a. Patients older than 69 y/o should be considered "high risk" patients for spinal injury and require closer assessment. With these patients, lean towards applying a cervical collar.

3018 – Spinal Motion Restriction

3018

Subject:

Spinal Motion Restriction

Effective:

June 1, 2021

Last Modified:

Aug. 12, 2021

- b. If the patient meets the standards for a Trauma Alert Activation, consider a cervical collar at a minimum.
- c. Patients who do not tolerate any level of restriction should have that restriction adjusted to the point of removal if necessary based on clinical response.
 - i. Examples include shortness of breath, anxiety, and body habitus
 - ii. They should be transported in the manner of restriction that they can tolerate.
- d. Spinal restriction of the purpose of patient movement
 - i. Spinal restriction devices may be utilized for movement from a site of injury to the cot.
 - ii. Patients who do not require restriction should be removed from the device prior to transport.

3018.8 Clinical Management

Full Spinal Motion Restriction

- Patients with GCS less than 15 including confusion and intoxication
- Patients with altered LOC
- Patients with neurologic deficits including paralysis
- Patients with clinical indications of a spinal injury
- Patients less than 3 y/o with GCS less than 15

C-Collar and Move Inline to Cot

- Patients that have a GCS of 15 and present with:
 - Neck pain
 - Midline neck tenderness
 - o Pain on motion of the neck

SMR Is Not Required

- Penetrating trauma
- Patients that do not fall into the other two conditions

EXCEPTIONS

- Patients who require airway or ventilatory intervention may have the collar removed with inline stabilization during the intervention.
- Patients who do not tolerate restriction should have it adjusted to the point of removal if necessary.

END OF SECTION

3019

Subject: Trauma Transport Guidelines

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

3019.1 State of Ohio Trauma Triage Age Considerations

- a. For the purposes of trauma guidelines the criteria for patient age is:
 - i. Less than 16 years old will be pediatric patients
 - ii. 16 years old to 69 years old will be adult patients
 - iii. Greater than 69 years old will be geriatric patients

3019.2 Trauma Center or Facility Capabilities:

- a. Level I and II Trauma Centers can care for the same trauma patients.
- b. Level III Trauma Centers offer services, based on individual hospital resources that provide for initial assessment, resuscitation, stabilization, and treatment of the trauma patient.
- c. In some areas of the region a Level III Trauma Center is the only trauma facility within 30 minutes ground transport time. This hospital may act as the primary receiving facility for the critically injured patient.
- d. In areas where the trauma patient is closer to a Level III Trauma Center, but a Level I or Level II Trauma Center is still within 30 minutes, the EMS Provider should decide whether the patient would benefit more from an immediate evaluation, stabilization, and treatment at the Level III Trauma Center, or from direct transport to a Level I or Level II Trauma Center.
- e. In areas of the region where there are no Trauma Centers within 30 minutes ground transport time, the acute care hospital may act as the primary receiving facility for critically injured trauma patients, or EMS Provider may arrange for air medical transport from the scene.
- P If a pediatric patient meets the trauma triage guidelines, transport to a Pediatric Trauma Center.
- **P** Pediatric patients should be transported in an appropriately sized child restraint system.
- f. If transportation time is > 30 minutes, transport to the nearest acute care hospital, or EMS providers may arrange for air medical transport from the scene.
- g. All pregnant trauma patients should be rapidly transported to the nearest Adult Trauma Center with labor and delivery capabilities, unless transport time is greater than 30 minutes.

3019.3 Air Medical Transportation:

- a. Prolonged delays at the scene waiting for air medical transport should be avoided.
- b. Cardiac arrest is not appropriate for air transport.
- c. In the rural environment, direct transfer of trauma patients by air medical transport may be appropriate and should be encouraged.

3019.4 Exceptions to Transportation Guidelines:

- a. It is medically necessary to transport the victim to another hospital for initial assessment and stabilization before transfer to a Trauma Center.
- b. It is unsafe to transport the victim directly to a Trauma Center due to adverse weather or ground conditions or excessive transport time.
- c. Transporting the victim to a Trauma Center would cause a shortage of local EMS resources.
- d. No Trauma Center is able to receive and provide trauma care to the victim without undue delay.
- e. Before transport begins, the patient requests to be taken to a particular hospital even if it is not a Trauma Center.
 - i. If the patient is a minor or otherwise considered incapable of making medical decisions, an adult relative or other legal representative may make this request.

3019.5 Trauma Criteria:

- a. Anatomical Criteria:
 - i. All penetrating trauma to head, neck, torso, and extremities proximal to elbow or knee with neurovascular compromise.

3019

Subject: Trauma Transport Guidelines

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

- ii. Abdominal injury with tenderness, distention, or seat belt sign
- iii. Chest injury: flail chest or tension pneumothorax
- iv. Two or more proximal long bone fractures
 - **G** One proximal long bone fracture in MVC only
- v. Evidence of pelvic fracture (exception: isolated hip fracture)
- vi. Spinal cord injury with paralysis
- vii. Burns greater than 10% total body surface area (BSA) or other significant burns involving the face, feet, hands, genitals or airway
 - P Burns greater than 5% total BSA or other significant burns involving the face, feet, hands, genitals or airway
- viii. Amputation proximal to wrist or ankle
- ix. Evidence of serious injury of 2 or more body systems
- x. Crush injury to head, neck, torso, or extremities proximal to knee or elbow
- xi. Open skull fracture

Meets Above Criteria = Transport to Trauma Center	Does Not Meet Above Criteria = Assess Physiologic
Call Trauma Alert	

b. Physiological Criteria:

- i. Adult Physiological Criteria
 - A GCS less than or equal to 13
 - A Loss of consciousness greater than five minutes at any time
 - A Alteration in level of consciousness with evidence of head injury at time of exam or thereafter
 - A Failure to localize pain
 - A Respirations less than 10 or greater than 29
 - A Needs ventilatory support
 - **A** Tension pneumothorax
 - A Pulse higher than 120 in combination with any other physiologic criteria
 - A SBP less than 90 or absent radial pulse with carotid pulse present
- ii. Pediatric Physiological Criteria:
 - P GCS less than or equal to 13
 - P Loss of consciousness greater than five minutes at any time
 - P Alteration in level of consciousness with evidence of head injury at time of exam or thereafter
 - P Failure to localize pain
 - P Evidence of poor perfusion (e.g., weak distal pulse, pallor, cyanosis, delayed capillary refill, tachycardia)
 - P Evidence of respiratory distress or failure (e.g., stridor, grunting, retractions, cyanosis, nasal flaring, hoarseness, or difficulty speaking)
 - P Respiratory rate less than 20 per minutes in infants less than 1 year old.

iii. Geriatric Physiological Criteria:

- G GCS less than 15 with evidence of TBI
- G Loss of consciousness greater than five minutes at any time
- **G** Alteration in level of consciousness with evidence of head injury at time of exam or thereafter
- G Failure to localize pain
- G Respirations less than 10 or greater than 29

Greater Miami Valley EMS Council

Trauma Protocol

3019

Subject: Trail

Trauma Transport Guidelines

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

- G Needs ventilatory support
- **G** Tension pneumothorax
- G Pulse higher than 120 in combination with any other physiologic criteria
- G SBP less than 100 or absent radial pulse with carotid pulse present
- G Known or suspected proximal long bone (femur/humerus) fracture sustained in MVC
- G Multiple body regions injured

Meets Above Criteria = Transport to Trauma Center

Does Not Meet Above Criteria = Evaluate Mechanism of Injury

Call Trauma Alert

c. Mechanism of Injury:

- i. Auto-pedestrian/auto-bicycle injury with significant (faster than 5 mph) impact
- ii. Death in same passenger compartment
- iii. Ejection from motor vehicle
- iv. Extrication time longer than 20 minutes
- v. Fall of more than 20 feet
 - P Fall greater than 3 times child's height
 - G Falls, even from a standing position, with evidence of Traumatic Brain Injury
- vi. High-speed auto crash
 - 1. Estimated speed faster than 40 mph
 - 2. Intrusion into passenger compartment of more than 12 inches
 - 3. Major auto deformity of more than 20 inches
- vii. Open motor vehicle crashes faster than 20 mph or with separation of rider from vehicle
- viii. Pedestrian thrown or run over
- **G** Pedestrian struck by a motor vehicle
- ix. Unrestrained rollover
- x. Vehicle telemetry data consistent with high risk of injury

Meets Above Criteria = Consider Trauma Center	Does Not Meet Above Criteria = Check Special Situations	
Consult with Medical Control if Necessary		

d. Special Situations:

- i. Pre-existing cardiac or respiratory disease
- ii. Insulin dependent diabetes, cirrhosis, morbid obesity, seizure disorder
- iii. Patient with bleeding disorder or on anticoagulants
- iv. Immuno-suppressed patients (renal dialysis, transplant, cancer, HIV)
- v. Congenital disorders

e. Geriatric Considerations:

i. Special consideration should be given for the geriatric trauma patient to be evaluated at a Trauma Center if they have diabetes, cardiac disease, clotting disorders, immunosuppressive disorder, are on anticoagulants, or require dialysis.

Meets Above Criteria = Consider Trauma Center

Does Not Meet Above Criteria = Go to closest appropriate Hospital



Last Modified:

Dec. 8, 2020

3020.1 **General Guidelines**

System (RHNS)

a. The purpose of the Regional Hospital Notification System is to provide one number for EMS, hospitals, and EMAs to call that will make rapid, simultaneous notifications in a Mass Casualty Incident or Event (MCI/MCE), or other major emergency.

b. The system can be used when an incident could involve a significant number of the region's hospitals.

3020.2 **RHNS Activation**

- To activate the system, an incident commander calls 937-333-USAR (8727), and requests a "Regional Hospital Notification."
- b. The agency calling must ask for a Dispatch Supervisor, and should provide the information below:
 - i. Name of agency
 - ii. Nature of emergency
 - iii. Location of emergency
 - iv. General statement on severity, such as approximate number of victims
 - v. Any other information to be conveyed
- c. The Montgomery County Regional Dispatch Center (RDC) will immediately put out a computerized message to the RHNS Group with the information provided.



Trauma Protocol

3021

Subject: Crisis Standards of Care in

Massive Events

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

3021.1 General Guidelines

- a. Some incidents are so large as to require extraordinary EMS procedures. Those scenarios are sometimes referred to as Mass Casualty Events (MCEs), instead of Mass Casualty Incidents (MCIs).
- b. These EMS procedures should be utilized in very large emergency scenarios, or when the duration is extended.
- c. In the event of an MCE, especially one lasting days or longer, Greater Miami Valley EMS Council, with the approval of the Regional Physicians Advisory Board (RPAB), may promulgate "Just in Time Standing Orders" (JITSO).
- d. With approval from Ohio Department of Public Safety, these orders might include triage standards for transport to other healthcare facilities and other crisis standards of care; possibly exceeding the standard scope of practice for EMS.
- e. Full information on the process can be found in the Dayton MMRS Regional MCI Plan Template

3021.2 Alternate Transports

- a. In some circumstances, EMS may be authorized to triage selected patients for transport to other healthcare facilities, including:
 - i. Urgent Care Centers
 - ii. Acute Care Center (ACC)
 - iii. Neighborhood Emergency Help Center (NEHC)
 - iv. Disaster Medical Assistance Team (DMAT)

3021.3 Forward Movement of Patients

- a. Planned by Dayton MMRS
- b. The intent is to relieve the burden on local hospitals by transporting patients, possibly directly from the scene, to more distant hospitals.

3021.4 Functional Needs Shelter Triage

- a. A regional protocol for Functional Needs Shelter Triage has been added to the Optional Standing Orders Manual and is also available at gmvemsc.org on the Training Materials page.
- Will help determine whether individuals with functional needs can be safely sheltered in a Red Cross Shelter during a disaster
- c. This Shelter Triage Protocol is a pre-approved Just-In-Time Standing Order (JITSO), authorized by the RPAB for use by an EMS agency assisting the Red Cross with shelter triage.
- d. It is intended to be printed and given to paramedics, nurses, and other healthcare personnel at the time of a shelter operation.
- e. At the option of local department chiefs and medical directors, the same protocol can be used during a
 disaster to determine patients who would be more appropriate for transport to Red Cross Shelters than
 to hospitals.
- f. In those cases, EMS should, if possible, contact the shelter before transporting.
- g. If locations or contact information for shelters is not known, contact the County EMA or the Red Cross.
- h. When transporting these non-emergency patients to shelters, it is critical that the patients bring their medications and medical equipment with them.

4000 Series

Medical Protocol

4001

Subject: Abdom

Abdominal Pain

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

4001.1 General Guidelines

- a. Ensure an abdominal exam which includes inspection, auscultation and palpation is performed and documented on every patient with abdominal pain.
- b. Assess all abdominal pain patients for trauma, pregnancy, illness, or potential ingestion.

4001.2 Clinical Management

Pediatric Considerations None None Pain (location/migration) Nausea and/or vomiting Nausea and/or vomiting Differential Diagnosis Hepatitis Peptic ulcer disease/gastritis Gallbladder Pancreatitis Abdominal aneurysm Abdominal aneurysm Appendicitis Pelvic (PID, ovarian cyst, ectopic pregnancy) Diverticulitis Abdominal aneurysm Appendicitis Pelvic (PID, ovarian cyst, ectopic pregnancy) Diverticulitis Bladder/prostate disorders Kidney stone Myocardial infarction Pneumonia Pulmonary embolus Treatment Algorithm Place patient in position of comfort. Give nothing by mouth. No additional orders at this level. A Consider Ondansetron (Zofran) 4 mg PO dissolving tablet for nausea or active vomiting. Pondansetron (Zofran) 4 mg PO if patient is 12 y/o or older and weight is more than or equal to 40 kg. For pain relief, including with unilateral flank pain, consider 1014 Pain Management Protocol. PFor pain relief, call MCP for orders. A For active vomiting, Ondansetron 4 mg slow IV.		Assessment					
Place patient in position of comfort. Give nothing by mouth. No additional orders at this level. Consider Ondansetron (Zofran) 4 mg PO dissolving tablet for nausea or active vomiting. Pondansetron (Zofran) 4 mg PO if patient is 12 y/o or older and weight is more than or equal to 40 kg. For pain relief, including with unilateral flank pain, consider 1014 Pain Management Protocol. For pain relief, call MCP for orders.	Pediatric Considerations None Signs & Symptoms Pain (location/migration) Tenderness (point, palpation, rebound) Nausea and/or vomiting Diarrhea Dysuria Constipation Vaginal bleeding/discharge Peregnancy Pediatric Considerations Differential Diagnosis Hepatitis Peptic ulcer disease/gastritis Gallbladder Pancreatitis Abdominal aneurysm Appendicitis Pelvic (PID, ovarian cyst, ectopic pregnancy) Diverticulitis Gastroenteritis Bladder/prostate disorders Kidney stone Myocardial infarction Pneumonia						
 Give nothing by mouth. No additional orders at this level. A Consider Ondansetron (Zofran) 4 mg PO dissolving tablet for nausea or active vomiting. P Ondansetron (Zofran) 4 mg PO if patient is 12 y/o or older and weight is more than or equal to 40 kg. A For pain relief, including with unilateral flank pain, consider 1014 Pain Management Protocol. P For pain relief, call MCP for orders. 							
A For active vomiting, Ondansetron 4 mg slow IV.	 Give nothing by mouth. No additional orders at this level. A Consider Ondansetron (Zofran) 4 mg PO dissolving tablet for nausea or active vomiting. P Ondansetron (Zofran) 4 mg PO if patient is 12 y/o or older and weight is more than or equal to 40 kg. A For pain relief, including with unilateral flank pain, consider 1014 Pain Management Protocol. 						
 A For nausea or if no IV access established, Ondansetron (Zofran) 4 mg PO (dissolving tablet) or consider administering 4 mg/2 ml of the IV form PO by discharging into the patient's mouth. P Ondansetron 0.1 mg/kg IV (max 4 mg). 	P ◆ For pain relief, call MCP for orde						
Consult	A For active vomiting, Ondansetron A For nausea or if no IV access estable of the IV form PO by discharging in	olished, Ondansetron (Zofran) 4 mg PO (dissolving to the patient's mouth.	tablet) or consider administering 4 mg/2 ml				
The AEMT and Paramedic need MCP orders when providing abdominal pain relief to pediatric patients.	A For active vomiting, Ondansetron A For nausea or if no IV access estable of the IV form PO by discharging in	olished, Ondansetron (Zofran) 4 mg PO (dissolving to the patient's mouth. I mg).	tablet) or consider administering 4 mg/2 ml				
Clinical Pearls	A For active vomiting, Ondansetron of A For nausea or if no IV access estable of the IV form PO by discharging in P Ondansetron 0.1 mg/kg IV (max 4)	olished, Ondansetron (Zofran) 4 mg PO (dissolving to the patient's mouth. Emg). Consult					
The Paramedic can administer the IV form of Ondansetron orally to adults by spraying it into the patient's mouth.	A For active vomiting, Ondansetron of A For nausea or if no IV access estable of the IV form PO by discharging in P Ondansetron 0.1 mg/kg IV (max 4)	olished, Ondansetron (Zofran) 4 mg PO (dissolving to the patient's mouth. Imp). Consult CP orders when providing abdominal pain relief to					

END OF SECTION

4001 – Abdominal Pain Page **1** of **1**

This Page Intentionally Left Blank

4002

Subject:

Allergic Reaction/Anaphylaxis

Effective: June 1, 2021

Last Modified:

Aug. 28, 2021

4002.1 General Guidelines

- a. Epinephrine is the mainstay of anaphylaxis in allergic reaction treatment.
- b. Epinephrine is particularly important in cases of any airway edema, hypotension, or when multiple body systems are involved.
- c. Advanced age is not a contraindication to epinephrine.

4002.2 Clinical Management

	Assessment					
Ped	liatric Considerations None	Signs & Symptoms Itching Hoarseness or stridor Wheezing Respiratory distress Altered level of consciousness Cyanosis Pulmonary edema Facial/airway edema Urticaria/hives	Differential Diagnosis Rash only Shock (vascular effect) Angioedema Aspiration/airway obstruction Vasovagal event Asthma			
		Treatment Algorithm	<u></u>			
•	 Provide O₂ as needed. If allergic reaction: If equal to or greater than 30 kg, give both Adult EpiPen and EpiPen Jr. P If less than 15 kg, EpiPen Jr. P If equal to or greater than 15 kg and less than 30 kg, Adult EpiPen If applicable, apply ice pack. ♦ If symptoms persist, may repeat Epinephrine in 5 minutes. Call for transport. 					
•	If patient develops wheezing, assist them with their prescribed metered dose inhaler or					
• • • • • • • • • • • • • • • • • • •	P If hypotensive, IV fluid 20 ml/kg IV to maintain adequate BP. A Diphenhydramine 50 mg IM or IV					
A P P	A For patients unresponsive to Epinephrine, Glucagon, 1mg IV or if no IV, then IM P For patients unresponsive to Epinephrine, and less than 8 years old then Glucagon, 0.5 mg IV or if no IV, then IM			AEMT	Paramedic	



4002

Subject:

Allergic Reaction/Anaphylaxis

Effective:

June 1, 2021 Last Modified:

Aug. 28, 2021

- If patient deteriorating or unresponsive, consider early intubation, possibly with a smaller than normal size endotracheal tube
- If a conscious patient requires intubation:
 - A Lidocaine 100 mg IN half dose per nostril or added to nebulizer with breathing treatment.
 - P Lidocaine 1.5 mg/kg nebulized with O₂ 8-10 LPM or IN. Maximum dose is 100 mg.
- A If patient remains hypotensive after IV fluid, Epinephrine (1:10,000) 0.1 mg, slow IV, every 3 minutes up to 0.5 mg.
- A Solu-Medrol 125 mg IV
- P Solu-Medrol 2 mg/kg IV, max dose 125 mg

Consult

- The EMR and EMT need MCP orders to administer repeat epinephrine.
- EMT needs MCP orders to administer breathing treatments.

Clinical Pearls

- · No significant change in patient condition in the field should be expected from the administration of Solu-Medrol.
- Solu-Medrol will be given to all patients treated within the allergic reaction or anaphylaxis protocol only <u>after</u> all other applicable first-line medications have been delivered.

Subject:

Asthma/Emphysema/COPD

Effective: June 1, 2021 Last Modified:

May 2, 2022

4003.1 **Clinical Management**

Assessment Differential Diagnosis Pediatric Considerations Signs & Symptoms Younger patients may exhibit Shortness of breath Anaphylaxis nasal flaring Pursed lip breathing Aspiration Pleural effusion Increased respiratory rate and effort Wheezing, rhonchi Pneumonia Accessory muscle use Pulmonary embolus Cough Pneumothorax Tachycardia Cardiac event (AMI or CHF) Tripod position Pericardial tamponade Hyperventilation Inhaled toxins **Treatment Algorithm** Provide O2 as needed. Call for transport.

If patient develops wheezing, assist them with taking their prescribed metered dose inhaler.

- ♦ Consider Albuterol 2.5 mg and Ipratropium 0.5 mg, nebulized with O₂ flowing at 8-10 LPM
- ♦ May repeat Albuterol 2.5 mg nebulized X 2.
- For any patient who is bronchial constricted: CPAP
- Transport unless ALS intercept is less than 5 minutes.
- No orders needed for Albuterol 2.5 mg and Ipratropium 0.5 mg, nebulized with O2 flowing at 8-10 LPM
- If patient intubated, Albuterol 2.5 mg by nebulizer into the ETT. If Ipratropium not given before intubation, add to first Albuterol.
- After intubation of an asthma patient, limit rate of ventilation to avoid auto-PEEP and hypotension, provided that you can adequately oxygenate the patient at below rate:
 - o 8-10 breaths per minute for adults
 - 10-15 breaths per minute for pediatric patients
- Consider needle decompression in the presence of auto-PEEP or hyperinflation:
 - If the patient is in cardiac arrest, perform bilateral needle decompression
 - If unilateral or bilateral diminished breath sounds and the patient is hemodynamically unstable, consider decompression of only the affected sides
 - Decompression sites:
 - Fourth or fifth intercostal space in the mid-axillary line
 - Second or third intercostal space in the mid-clavicular line (use nipple line as a guide)
 - In patients less than 8 years old, decompression site choice will be limited to the 2nd or 3rd intercostal space at the mid-clavicular line
- Asthmatics in severe distress (NOT for emphysema or COPD):
 - If equal to or greater than 30 kg, give both Adult EpiPen and EpiPen Jr or Epinephrine (1:1,000) 0.5 mg IM
 - If less than 15 kg, EpiPen Jr or Epinephrine (1:1,000) 0.01 mg/kg IM (max 0.1
 - If equal to or greater than 15 kg and less than 30 kg, Adult EpiPen or Epinephrine (1:1,000) 0.01 mg/kg IM (max 0.3 mg) 0
 - May repeat Epinephrine (1:1,000) 0.5 mg IM after 5 minutes.
- If a conscious patient requires intubation:
 - **Lidocaine 100 mg IN** half dose per nostril or added to nebulizer with breathing treatment.
 - ocaine 1.5 mg/kg nebulized with O₂8-10 LPM or IN. Maximum dose is 100 mg
- For any patient who is bronchial constricted: CPAP or {Bi-PAP}
- Solu-Medrol 125 mg IV

Consult

The EMT needs MCP orders to administer breathing treatments.

Clinical Pearls

- A patient who has received a breathing treatment should be transported for evaluation.
- No significant change in patient condition in the field should be expected from the administration of Solu-Medrol.

END OF SECTION

AEMT

4004

Subject:

Behavioral Emergencies

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

4004.1 **General Guidelines**

- a. Per Ohio Revised Code, EMS providers may not "pink slip" an individual even if they are threatening harm to themselves or others.
- b. Only a health officer such as a police officer, crisis worker, psychiatrist or licensed physician can administer an involuntary admission form ("pink slip") for a patient.
- c. Each EMS department, in consultation with its medical director and local law enforcement, should have a procedure to deal with these types of situations.

4004.2 **Precautions**

- a. Consider staging until law enforcement has made the scene safe.
- Have law enforcement search patient for weapons.
- Consider possible medical causes for patient's condition:

viii. Pulmonary embolism Anemia i. Hemorrhage ii. Hypoxia ix. iii. Metabolic disorders Hypoglycemia x. Stroke Seizures and postictal states iv. xi. Dysrhythmias xii. Shock

Hypertension Infection (especially meningitis /encephalitis) vi. xiii.

Toxicological ingestion Electrolyte imbalance vii. xiv.

xiv. Myocardial ischemia or infarction

Head trauma or intracranial

xvi. Drug or alcohol intoxication, side effects, drug withdrawal

4004.3 **Clinical Management**

	Assessment		
Pediatric Considerations None	 Signs & Symptoms Anxiety, agitation, confusion Affect change, hallucinations Delusional thoughts, bizarre behavior Violent or combative Expression of suicidal/homicidal ideations 	Differential Diagnosis Other altered mental status issues Alcohol intoxication Substance abuse Medication effect/overdose Withdrawal symptoms Depression Bipolar (manic-depressive) Schizophrenia Anxiety disorders	
	Treatment Algorithm	,	
 Determine patient capacity and consent. Take actions to prevent imminent harm to the patient or others, if it is safe to do so. Do not judge, just treat. Consider possible medical causes for patient's condition If patient is unwilling to go to a facility, consider whether they are a candidate for a "pink slip" Transport all patients who are not making rational decisions and who are a threat to themselves or others for medical evaluation. A If possible, transport a mental health patient to the facility where the individual has been previously treated. A In all other cases, patients should be transported to the closest ED. Pediatric patients with mental health issues should be transported to a facility with pediatric mental health capabilities. 			
r Pediatric patients with mental nea	iti issues should be trunsported to a racinty with pediatric in	entar nearth capabilities.	
·	in issues should be transported to a facility with pediatric in	Error recipromities.	
No additional orders at this level.	gency, and should be treated. See <u>4007 Combative Patient/E</u>		
No additional orders at this level.			



4004

Subject:

Behavioral Emergencies

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

Clinical Pearls

- Consider that a patient may be incapable to make medical decisions (incompetent) if they are:
 - Suicidal
 - o Confused
 - o Severely developmentally or mentally disabled
 - o Intoxicated
 - o Injured/ill with an altered mental status
 - Physically/verbally hostile
 - Unconscious
- When obtaining medical history, determine:
 - o Suicidal or violent history
 - o Previous psychiatric hospitalization, when and where
 - o Location where patient receives mental health care
 - Medications
 - o Recreational drugs/alcohol: amount, names
- Exceptions to the outlined transport recommendations include:
 - o It is medically necessary to transport the patient to the closest hospital for stabilization.
 - It is unsafe to transport the patient to the preferred/recommended facility due to adverse weather or ground conditions or excessive transport time.
 - Transporting the patient to the preferred/recommended facility would cause a critical shortage of local EMS resources.
 - Patient requests transport to a different facility.

4005

Subject: Childbirth

Effective: June 1, 2021

Last Modified:

Dec. 31, 2021

4005.1 General Guidelines

- a. Obtain history of patient condition and pregnancy, including:
 - i. Contraction duration and interval
 - ii. Gestation age should be expressed in weeks whenever possible
 - iii. Due date
 - iv. First day of last menstrual period
 - v. Number of pregnancies and number of live births (gravida/para)
 - vi. Presence or absence of prenatal care
 - vii. Possibility of multiple births
 - viii. Any possible complications
 - ix. Any drug use by the mother
- b. The patient should be transported to a hospital with obstetrical capabilities
 - i. Unless delivery is imminent (the baby is crowning during a contraction).
 - ii. ABSOLUTELY NO PREGNANT PATIENTS TO DAYTON or CINCINNATI CHILDREN'S HOSPITALS.
- Visualize the perineal area only when contractions are less than five minutes apart.
- d. Run reports must be completed for each patient. The newborn is a separate patient from the mother.

4005.2 Clinical Management

Assessment Pediatric Considerations Signs & Symptoms **Differential Diagnosis** None, unless the pregnant Spasmodic pain Abnormal presentations (foot, and, buttocks) Vaginal discharge or bleeding patient is under 16 years old, Prolapsed cord then manage in the same Lengthening and narrowing contractions Placentia previa manner. Urge to push Abruptio placenta Crowning The EMR may only assist with emergency childbirth management Apply gentle pressure on the baby's head with a flat hand to prevent an explosive delivery. Place a gloved hand inside the birth canal only in the case of: Breech delivery with entrapped head Prolapsed umbilical cord limiting fetal circulation Keep the newborn warm. Cut the umbilical cord and then place the baby to suckle at the mother's breast. Obtain one, five and ten minute APGAR scores if time and patient condition permit. (see table below) Establish an IV for patients in active labor. No additional orders at this level. Consult None **Clinical Pearls** Changes in fundal (upper part of the uterus) height during pregnancy: Above the symphysis pubis = Greater than 12 to 16 weeks gestation o At the level of the umbilicus = Greater than 20 weeks gestation Near the xiphoid process = Within a few weeks of term

APGAR Score	0	1	2
Appearance	Full body cyanosis	Cyanosis at the extremities	No cyanosis present
Pulse	Absent	Slow (less than 100)	Greater than 100
Grimace	Flaccid	Grimace with stimulation	Cough or sneeze with stimulation
Activity	Absent	Some flexion of extremities	Active motion
Respiratory Effort	Absent	Slow or irregular	Good, vigorous cry

END OF SECTION

4005 - Childbirth Page 1 of 1

4006

Subject: Childbirth with Complications

Effective: June 1, 2021

Last Modified:

Sept. 9, 2021

4006.1 General Guidelines

- a. With all complicated childbirth scenarios, evaluate the need for rapid transport to a birthing center or possibly, the nearest hospital.
- b. These guidelines apply to all levels of certification.
- c. In all complicated childbirth scenarios, place the mother on oxygen by non-rebreather mask.

4006.2 Clinical Management

a. Cord around Baby's Neck:

- i. As baby's head passes out of the vaginal opening, feel for the cord.
- ii. Initially try to slip cord over baby's head.
- iii. If too tight, clamp cord in two places and cut between clamps.

b. Breech Delivery:

- i. When an appendage or buttocks first becomes visible, position patient to discourage delivery, coach patient to avoid pushing and transport patient immediately to the nearest facility.
- ii. If the delivery is in progress, take care to support the baby's body.
- iii. If the head is caught in the birth canal:
 - 1. Apply gentle pressure above the pubis symphysis as the mother pushes.
 - 2. If the head will not deliver, you must create an airway for the baby.
 - 3. Support the body and insert two fingers into the birth canal, forming a "V" around the mouth and nose.

c. Prolapsed Cord:

- i. When the umbilical cord is exposed prior to delivery, check cord for pulse.
- ii. Transport immediately with hips elevated and a moist dressing around cord.
- iii. Insert two fingers into the birth canal to displace the presenting part away from cord, distribute pressure evenly if occiput presents.
- iv. Do not attempt to reinsert cord.

d. Excessive Bleeding:

- i. Treat for shock.
- ii. Post-delivery, massage uterus firmly and put baby to mother's breast.

4007

Subject: Combative Patients/Emergency Sedation

Effective:

June 1, 2021

Last Modified:

Jan. 6, 2022

4007.1 General Guidelines

- a. Restrained patients should not be transported in a prone position with hands & feet behind their back.
- b. Restrained patient should **not** be sandwiched between backboards or other items.
- c. Always maintain the ability to remove restraints if the patient vomits or develops respiratory distress

4007.2 Combative Patients

- a. Identified as irrational behavior like aggression, violence, and/or paranoia in the patient.
- b. This state can result from a number of causes including:
 - i. Stimulant intoxication
 - ii. Psychiatric illness
 - iii. Hypoglycemia
 - iv. Other medical illnesses.
- c. In excited delirium the patient often becomes significantly hyperthermic and/or hypoxic.

4007.3 Clinical Management

	Assessment	
Pediatric Considerations None	 Signs & Symptoms Patient out of control and dangerous to self or others. Restraint required for patient control without causing harm Combative or violent patient 	 Differential Diagnosis Alcohol intoxication Substance abuse Medication effect/overdose Withdrawal symptoms Mental health history
	Treatment Algorithm	
Explain the need for restraint to the Recheck often a restrained patient's No additional orders at this level.	patient. s ability to breathe and distal circulation.	EMT
Ketamine 250 mg IM (in anterolate No change after 5 minutes, conside	ral thigh) <u>or</u> Ketamine 100 mg slow IV . r additional dosing: AMINE AND MIDAZOLAM SIMULTANEOUSLY.	
A Ketamine 250 mg IM (in one AND/OR: A Midazolam 10 mg IN (5 mg A If necessary, repeat Midazolam A Repeat Midazolam or repeat Midazolam A or repeat Midazolam A or repeat Midazolam A secondary or repeat Midazolam A secondar	lative time to work before moving on to a secondary medication opposite anterolateral thigh) or repeat Ketamine 100 mg IV. In g in each nostril), or Midazolam 2 mg slow IV, or Midazolam 4 colam doses: am 5 mg IN (2.5 mg in each nostril) after 5 minutes. It is a mg slow IV after 5 minutes. It is a mg IM after 10 minutes.	
	nsider Ketamine 1 mg/kg slow IV (max dose 100 mg) <u>or</u> Ketami	ne 5 mg/kg IM (max dose 250).
 Midazolam 0.2 mg/kg IN (max IN d (max IM dose 4 mg) 	ose 10 mg) or Midazolam 0.1 mg/kg slow IV (max IV dose 2 mg)	or Midazolam 0.2 mg/kg IM
◆ Call MCP for additional Ketamine	or Midazolam.	AE
If an excited delirium patient goes in	nto arrest: ♦ Consider Sodium Bicarbonate 100 mEq IV	
MCD Lafe line	Consult	
MCP needed for pediatric repeat m	edications and (for the paramedic) Sodium Bicarbonate in cardia Clinical Pearls	ac arrest.
	sedated should be <u>constantly</u> monitored for an effective airway	
Patients who have been sedated wi	th Ketamine can be deeply unconscious and present with hyper	salivation. Management should include use o

4008

Subject:

Diabetic Emergencies - Hypoglycemia

Effective: June 1, 2021 Last Modified:

Aug. 28, 2021

4008.1 **General Guidelines**

a. Hypoglycemia is defined as a blood glucose level less than 60, or there is strong suspicion of hypoglycemia despite glucometer readings

4008.2 **Clinical Management**

	Assessment		
Pediatric Considerati None	Signs & Symptoms Altered level of consciousness Dizziness Irritability Diaphoresis Seizures Seizures Hunger Confusion Signs & Symptoms Alcohol related issues Toxic overdose Stroke or TIA Pre-existing condition		
	Treatment Algorithm		
Provide basic caCall for transpor	I S		
Maintain normo In a diabetic pat A Administer Dext P Administer Dext P For newborn, Do A If unable to esta P Less th P 8 year Dextrose 10% (I	thermia. Unconscious diabetics are often hypothermic. Ident with an insulin pump and blood glucose less than 60, treat the hypoglycemia. Incose 10% (D10), 250 ml at wide open rate, (250 ml = 25 g of Dextrose) Incose 10% (D10) 5 ml/kg, maximum single dose of 250 ml. Incose 10% (D10) 2 ml/kg if BGL is less than 40. Incose 10% (D10) 2 ml/kg if BGL is less than 40. Incomparison of the comparison of the compa	EMT	AEMT
	Consult		
• None			
readings. Oral glucose ma placed in the lat When documen Insulin Pumps Fig. D	Clinical Pearls Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia who then must Indicated for any conscious but disoriented patient with end under the tongue or between the gum and cheek of an unresponsive patient who then must Indicated for any conscious but disoriented patient with end under the tongue or between the gum and cheek of an unresponsive patient who then must Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in a strong suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in the suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in the suspicion of hypoglycemia despite Indicated for any conscious but disoriented patient with BS less than 60, or in the suspicion of hypoglycemia despite Indi		

4008 - Hypoglycemia Page **1** of **1**



4009

Subject: Diabetic Emergencies – Refusal of Transport

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

4009.1 General Guidelines

- a. EMTs and above may allow for diabetic patients to refuse transport after treatment.
- b. EMRs should call for transport or a provider of a higher level certification.

4009.2 Procedures

- a. Patients 18 years of age or older may be permitted to refuse. Follow these guidelines:
 - i. Repeat physical examination and vital signs. Patient must be A&O x 3.
 - ii. Warn the patient that there is a significant risk of going back into hypoglycemia, especially if on oral hypoglycemics.
 - iii. Advise the patient to eat something substantial immediately.
 - iv. Advise the patient to contact their family physician as soon as possible to minimize future episodes.
 - v. Advise the patient to stay with someone.
 - vi. Follow normal patient refusal procedures.
- b. If the diabetic patient is under 18, but a parent or guardian is present, then the responsible adult may refuse patient trasnportation under the same guidelines as listed above in 4009.2.a.
- c. Send a copy of the run sheet to the EMS Coordinator of the hospital that replaces your Drug Bag and supplies.

4010

Subject:

Extrapyramidal (Dystonic) Reactions

Effective:

June 1, 2021

Last Modified:

Dec. 8, 2021

4010.1 General Guidelines

- a. A patient who is currently on a phenothiazine (e.g., Phenergan, Thorazine, Compazine) or a butyrophenone (e.g., Haldol, Droperidol) and exhibiting signs of acute muscle spasm or motor restlessness may be suffering from an Extrapyramidal Reaction.
- b. Extrapyramidal reactions can occur with ingestion of recreational drugs
- c. Physical examination findings may include any of the following:
 - i. Oculogyric crisis (spasmodic deviation of eyes in all directions generally fixed upward.)
 - ii. Buccolingual crisis (protrusion of tongue with slurred speech)
 - iii. Trismus (closing of the jaw due to spasm of the muscles also called lockjaw.)
 - iv. Difficulty in speaking
 - v. Facial grimacing
 - vi. Torticollis crisis (stiff neck with deviation of the head with the chin pointing to the other side)
 - vii. Opisthotonus (extreme back arching)
 - viii. Tortipelvic crisis—Involves hip, pelvis, and abdominal wall muscles, causes difficulty walking.
 - ix. Mental status is unaffected.
 - x. Vital signs are usually normal.
 - xi. Remaining physical examination findings are normal.

4010.2 Clinical Management

	Assessm	nent	
Pediatric ConsiderationsNone	Signs & Symptoms • As listed above	Differential Diagnosis Alcohol intoxication Toxin/substance abuse Medication effect Withdrawal syndromes Anxiety disorders Mental health history	
	Treatment A	lgorithm	
Provide basic care.Call for transport.			EMR
	n 60, or there is strong suspicion of hypoglycemi <u>cies - Hypoglycemia</u> protocol	a despite glucometer readings, then follow	EMT
 Initiate IV fluid to mainta Diphenhydramine 50 r Diphenhydramine 1 m 	•		AEMT
Paramedics do not need	a MCP order to administer Diphenhydramine .		
	Consu	ılt	
The AEMT needs orders	for Diphenhydramine		
	Clinical P	earls	
• None			
END OF SECTION			· · · · · · · · · · · · · · · · · · ·

4011

Subject: Obstetrical Emergencies

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

4011.1 General Guidelines

- a. Consider the possibility of ectopic pregnancy in females of child-bearing age.
- b. Ask for first day of last menstrual period.
- c. Gestational age should be expressed in weeks whenever possible.
- d. Aggressively treat for hypovolemic shock (do not rely on standard vital sign parameters).
- e. Give psychological support to patient and family.
- f. Be sure to take all expelled tissue with you to the hospital.

4011.2 Transport Decisions

a. ABSOLUTELY NO PREGNANT PATIENTS TO DAYTON or CINCINNATI CHILDREN'S HOSPITAL.

- b. Pregnant patients 20 weeks or greater gestation should be taken to a maternity department.
- c. Pregnant patients less than 20 weeks gestation should go to the emergency department.
- d. If unsure of time of gestation, then consider transport to a maternity department
- e. Pregnant patients with non-obstetric complaints should go to the emergency department.
- f. Pregnant trauma patients should be rapidly transported to the ED at an Adult Trauma Center with labor and delivery capabilities.
- g. Transport the pregnant patient with consideration for postural hypotension caused by fetus pressure on venous return.
- h. Passively or actively move the fetus off the vena cava by doing either:
 - i. Place in left lateral recumbent position or place a pillow under the right abdominal flank/hip.
 - ii. Apply continuous manual displacement of the uterus towards the patient's left side.

4011.3 Cardiac Arrest In Pregnancy

- a. Causes of cardiac arrest in pregnant patients can include:
 - i. Pulmonary embolism
 - ii. Trauma
 - iii. Hemorrhage
 - iv. Congenital or acquired cardiac disease.
- b. Load and go to the closest hospital and follow all cardiac arrest protocols enroute.

4011.4 Third Trimester Bleeding

a. Aspirin is contraindicated in third trimester.

END OF SECTION

4011 – Obstetrical Emergencies Page **1** of 1

4012

Subject:

Overdose/Poisoning

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

4012.1 General Guidelines

- a. ♦ EMS personnel should contact MCP for direction on suspected poisonings.
- b. Poison Control is intended for use by the general public.
- c. If possible, provide receiving facility all available information about the substance:
 - i. Safety data sheets (SDS)
 - ii. The container (if it is safe to do so)
 - iii. The label or an image of the label and warning information if it is unsafe or unpractical to transport the actual substance container

4012.2 Clinical Management

Assessment Differential Diagnosis Pediatric Considerations Signs & Symptoms Most pediatric patients with respiratory Mental status changes Respiratory depression depression do not have narcotic overdose. They Hypo/hypertension Insecticides (organophosphates) are either septic or have respiratory failure. Decreased respiratory rate Solvents, cleaning agents Cardiac medications Tachy/bradycardia Cardiac dysrhythmias Stimulants Siezures Depressants **Treatment Algorithm** If respirations are impaired or there is suspicion of narcotic overdose: A Administer Naloxone, up to 4 mg IN (half dose per nostril) A May repeat Naloxone doses in 2 minutes Less than or equal to 20 kg then **0.1 mg/kg IN**, (max dose 2 mg), may repeat x one Greater than 20 kg 2 mg, IN, may repeat as needed Titrate Naloxone to adequate respirations. Consider patient restraint before administration of Naloxone. No additional orders at this level. • If patient has a pulse, Naloxone should be administered before inserting an ETT. When given IV or IN, the onset of action for Naloxone is approximately 2 minutes. If respirations are impaired or there is suspicion of narcotic overdose: Administer Naloxone, up to 4 mg IN, 2mg IV or 4 mg IM May repeat Naloxone doses in 2 minutes. Consider repeat IV dosing if no or inadequate response is noted Naloxone: Less than or equal to 20 kg then 0.1 mg/kg IN, IV, IM (max dose 2 mg), may repeat x one Greater than 20 kg 2 mg, IN, IV, IM, may repeat as needed Naloxone slow IV is preferred, but it may be given IN or IM before IV is established. Titrate to adequate respirations. If using IN route and respirations don't improve after 2 minutes, establish IV and administer IV dose. Stimulant Overdose (cocaine, methamphetamines, amphetamines, crack cocaine) with chest pain: Nitroglycerin 0.4 mg SL, if SBP >100, every 5 minutes to a total of three doses with vital signs between doses A Midazolam 10 mg, IN (5 mg in each nostril) or 2 mg slow IV, or 4 mg IM Repeat Midazolam 5 mg IN (2.5 mg in each nostril) or 2 mg slow IV or 4 mg IM for unrelieved chest pain **Calcium Channel Blocker Overdose:** ♦ Glucagon 1 mg IM or IV ◆ Less than 8 years old then Glucagon, 0.5 mg IM or IV ♦ 8 years old or older then Glucagon, 1 mg IM or IV Beta Blocker Overdose: ♦ Glucagon 1 mg IM or IV Less than 8 years old then Glucagon, 0.5 mg IM or IV **AEMT** ♦ 8 years old or older then Glucagon, 1 mg IM or IV

4012 – Overdose or Poisoning Page **1** of **2**

4012

Subject:

Overdose/Poisoning

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

- <u>Tricyclic Antidepressant Overdose</u> may be evidenced by bradycardia, tachycardia, hypotension and prolongation of the QRS complex. Risk of rapid deterioration or sudden onset V Fib is high.
 - A ◆ Sodium Bicarbonate 100 mEq, slow IV
 - Sodium Bicarbonate 1 mEq/kg slow IV
 - A ◆ Repeat Sodium Bicarbonate 50 mEq, slow IV for persistent QRS prolongation
 - P ◆ Repeat Sodium Bicarbonate 0.5 mEq/kg slow IV for persistent QRS prolongation
- <u>Calcium Channel Blocker Overdose:</u>

 - P Calcium Chloride, 0.2 ml/kg (20 mg/kg) slow IV (max dose 500 mg)
 - A ◆ Glucagon 1 mg IM or IV
 - P Less than 8 years old then Glucagon, 0.5 mg IM or IV
 - P 8 years old or older then Glucagon, 1 mg IM or IV

Consult

- For guidance on suspected poisonings contact MCP.
- Calcium Channel Blocker, Beta Blocker and Trycyclic antidotes in this protocol are by MCP order only.

Clinical Pearls

- Consider other causes of altered mental status such as hypoglycemia, head trauma, sepsis, and stroke.
- When Naloxone is given intranasal (IN), the onset of action is approximately 2 minutes.
- Naloxone is not felt to be effective in the reversal of cardiac arrest from opioid overdose. Airway control, ventilation, and quality CPR are still the mainstay of treatment.
- Ondansetron (Zofran) is NOT to be given prophylactically with Naloxone.
- Tricyclic Antidepressant Examples:
 - o Amitriptyline (Elavil, Endep, Etrafon, Limbitrol)
 - Nortriptyline (Pamelor, Aventyl)
 - Amoxapine (Asendin)
 - Clomipramine (Anafranil)
 - Desipramine (Norpramine)
 - Doxepin (Sineguan)
 - Imipramine (Tofranil)
 - Protriptyline (Vivactil)
 - Trimipramine (Surmontil)
- Calcium Channel Blocker examples:
 - Amlodipine (Norvasc)
 - o Diltiazem (Cardizem, Dilacos)
 - o Felodipine (Plendil)
 - Isradipine (Dynacirc)
 - o Nifedipine (Procardia, Adalat)
 - Verapamil (Calan, Isoptin, Verelan)
- Beta Blocker examples
 - o Acebutolol (Sectral)
 - o Atenolol (Tenormin)
 - Carvedilol (Coreg)
 - o Corzide, Inderide, Lopressor, HCT, Tenoretic, Timolide, Ziac
 - Labetalol (Normodyne, Trandate)
 - Metoprolol (Topral, Lopressor)
 - Nadolol (Corgard)
 - Pindolol (Viskin)
 - Propranolol (Inderal)
 - Sotalol (Betapace)
 - o Timolol (Blocadren)

END OF SECTION

4012 – Overdose or Poisoning Page 2 of 2

aramedic

4013

Subject:

Respiratory Distress/Pulmonary Edema

Effective: June 1, 2021

Last Modified:

Sept. 9, 2021

4013.1 Clinical Management

	Assessment		
Pediatric Considerations None	Signs & Symptoms Cyanosis Clammy skin Presence/Absence of fever Coughing Wheezing Labored breathing Diaphoresis Pitting edema Bilateral lower lobe rales Tachypnea Apprehension Jugular vein distension (JVD) Inability to talk.	Differential Diagnosis Myocardial infarction Congestive heart failure Asthma Anaphylaxis Aspiration Chronic obstructive pulmonary disease Pleural effusion Pneumonia Pulmonary embolus Pericardial tamponade	
	Treatment Algorit	hm	
If Pulmonary Edema: A CPAP use is encouraged p A If patient has SBP greater	ous Positive Pressure Airway (CPAP) prior to the initiation of drug therapy. Than 100, Nitroglycerin 0.4 mg SL up to 3,	1 every 5 minutes.	AEMT
	ncouraged prior to the initiation of drug the le early endotracheal intubation. Consult	erapy.	Paramedic
None	Consuit		
 Wheezes: treat cause Rales: treat cause (e Diminished or abser Unilateral Bilateral: t 	treat cause (e.g., pneumothorax, hemothorated treat cause (e.g., respiratory failure, COPD,	orax, pneumonia, surgically removed lung). asthma).	
Pneumonia may look like CHF with FND OF SECTION	pulmonary edema. However, the pneumo	nia patient is often dehydrated and has an elevated tempera	iture.

4014

Subject: Seizures

Effective: June 1, 2021

Last Modified:

Sept. 9, 2021

4014.1 Clinical Management

	Assessment	
ediatric Considerations None	Signs & Symptoms Decreased mental status Sleepiness Incontinence Observed seizure activity Evidence of trauma	Differential Diagnosis Head trauma Tumor Metabolic, hepatic or renal failure Hypoxia Electrolyte abnormality Drugs, medications Infection/fever Alcohol withdrawal Eclampsia Stroke/TIA Hyperthermia Psychogenic Non-epileptic Seizures
	Treatment Algorit	hm
Maintain normothermia. Obtain Pulse Oximeter and If glucose less than 60, or t		ucometer readings, then follow 4008 Hypoglycemia
A If still seizing, rep A Repeat A Or report A Or report P For actively seizing pediatr P Midazolam 0.2 r mg/kg IM (max I) P If still seizing, rep P Repeat P Or report	g IN (5 mg in each nostril), or Midazolam 2 mg slow beat Midazolam doses: Midazolam 5 mg IN (2.5 mg in each nostril) after 5 eat Midazolam 2 mg slow IV after 5 minutes. Eat Midazolam 4 mg IM after 10 minutes. Eat Midazolam 4 mg IM after 10 minutes. Eat Midazolam 10 mg IM after 10 minutes. Eat Midazolam 10 mg IM dose 4 mg IM dose 4 mg IM dose 4 mg IM dose 5 mg IM (max IN dose 5 mg) after Eat Midazolam 0.1 mg/kg slow IV (max IV dose 2 mg Eat Midazolam 0.1 mg/kg slow IV (max IV dose 4 mg) are Midazolam 0.2 mg/kg IM (max IM d	minutes. g/kg slow IV (max IV dose 2 mg) or Midazolam 0.2 5 minutes ng) after 5 minutes
No additional orders at thi	s level.	
	Consult	
None		
	Clinical Pearls	
	sure to include the following:	

END OF SECTION

4014 - Seizures Page 1 of 1

This Page Intentionally Left Blank

4015

Subject: Sepsis

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

4015.1 General Guidelines

- a. Severe sepsis is characterized by poor perfusion, leading to a buildup of serum lactate and resulting metabolic acidosis.
- b. To compensate for metabolic acidosis, patients increase their minute ventilation.
- c. This increased respiratory rate "blows off" carbon dioxide and lowers EtCO₂.
- d. EtCO₂ levels decline in the setting of both poor perfusion and metabolic acidosis.
- e. Poor tissue perfusion decreases the amount of blood flow to the alveoli of the lungs, reducing the amount of carbon dioxide that can be exhaled
- f. Sepsis is often associated with a high mortality rate. The key to improve patient outcomes in septic shock is early recognition, fluid resuscitation, O₂ therapy and rapid transport.

4015.2 Clinical Management

	Assessment	
Pediatric Considerations None	Signs & Symptoms • Known or suspected infection • EtCO ₂ less than 32 or greater than 47 with 2 or more of the following criteria: • Respiratory rate greater than or equal to 22 • Altered mental status (GCS less than 13) • Temperature over 100.4 (38 C) or under 96.8 (36 C) • Heart rate greater than 90 • Systolic BP less than 100 or Mean Arterial Pressure (MAP) below 65	
	Treatment Algorithm	
Administer oxygenCall for transport immediateNo additional orders at this		EMR
 Administer a bolus of 1 liter For additional fluid admini 		AEMT
	by adding 4 mg to 250 ml of IV fluids. Infuse starting at 30 drops per minute (max. 45 c fect. Increase by 5 drops/minute every 5 minutes.	drops) with 60
	Consult	
Consult with MCP to give meThe paramedic should consult	ore than 1 liter of fluids. Ilt on the use of Norepinephrine.	
	Clinical Pearls	
MAP = (SBP + 2 X DBP) / 3 atPatients may be in septic sh	P) is considered to be the organ perfusion pressure. nd is normally 70 – 110 mm/hg. ock with a normal blood pressure. picious of sepsis in geriatric patients with altered mental status	

4015 - Sepsis Page **1** of **1**

4016

Shock Shock

Effective: June 1, 2021

Last Modified:

Dec. 23, 2021

4016.1 General Guidelines

- a. Shock is inadequate tissue perfusion.
- b. Be proactive in treatment of shock. Do not wait for symptoms to present.
- c. Management of shock should include trying to find and correct the underlying cause (if possible).

4016.2 Clinical Management

	Assessment	
ediatric Considerations Pediatric patients will compensate longer than adults. Apparent signs and symptoms of shock can indicate a critical patient.	Signs & Symptoms Restlessness, confusion Weakness and dizziness Tachycardia Tachypnea Hypotension Decreased mentation Pale, cool, clammy skin	Differential Diagnosis Hypovolemia Cardiogenic Septic Neurogenic Anaphylactic Pulmonary emboli Tension pneumothorax Medications or overdose Vasovagal hypotension
	Treatment Algorithm	
Call for transport immediately. Provide O_2 as appropriate Keep patient warm. Control external bleeding and treat for hypovo	lemic shock as indicated.	EMR
Transport immediately unless ALS intercept is I	ess than 5 minutes.	EMT
	na: Patient does not have JVD, edema, or le perfusion. on. d. needed.	esent.
	The manual adequate periodicin	\
For non-traumatic shock: O Treat arrhythmias as indicated.		
·	orepinephrine by adding 4 mg to 250 ml	of IV fluids. Infuse starting at 30 drops per
11	tuhing and titrate to effect. Increase by 5	drons/minute every 5 minutes
minute (max 45 drops) with 60 drop		urops/minute every s minutes.
, ,	Consult	arops, minute every 3 minutes.

END OF SECTION

4016 - Shock Page 1 of 1

Perform manual BP on all patients presenting with signs and symptoms of shock.

4017

Page 1 of 2

Subject: Stroke

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

4017.1 General Guidelines

- a. If one or more signs of the Cincinnati Prehospital Stroke Scale are abnormal, and less than <u>24 hours</u> since patient was last seen normal, call a "Stroke Alert", and transport to the closest Stroke Center.
- b. With such a diverse group of agencies covered by this protocol, agencies should discuss "best practice" stroke transport destinations with their individual Medical Directors.
- c. State actual clock time for last known normal. Do not say, "20 minutes ago."

4017.2 Stroke Centers

- a. <u>Telemedicine Stroke Center with tPA Ready</u>: Also known as drip and ship, has tPA capabilities and immediate access to a Neurologist via telemedicine.
- b. Primary Stroke Center: Facility with capability to administer tPA and also has an ICU.
- c. Comprehensive Stroke Centers: Facilities with 24/7 endovascular capabilities.
 - i. Miami Valley Hospital
 - ii. Kettering

4017.3 Clinical Management

■ Gaze deviation/abnormal eye movement (indicative of large vessel occlusions) ■ Treatment Algorithm ■ A patient in respiratory distress with pale, moist skin and altered mental status should get oxygen via Ni ■ Be prepared to assist ventilations with OPA/NPA and Bag-valve-mask. ■ If signs of cerebral herniation are present, ventilate at the following rates: ■ A Approximately 20 times per minute. ■ Ventilate at a rate of ten faster than normal respiratory rate if the signs of cerebral herniation □ {If numeric EtCO₂ readings are available, ventilate at a rate to maintain readings at approxima □ Never ventilate at less than 8 per minute. ■ A patient with indications of stroke with a SpO₂ less than 94%, should be given oxygen via NC and titrate ■ A patient with indications of stroke with a SpO₂ greater than 94%, should not get any oxygen. ■ Transport the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay possible to the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay possible the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay possible the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay possible the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay possible the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay possible the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay possible the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay possible the patient with the previous 14 days ■ Major surgery or serious non-head trauma in the previous 14 days ■ History of gastrointestinal or urinary tract hemorrhage within 21 days ■ Current (within the last 48 hours) use of anticoagulants. Examples include: ■ Warfarin (Coumadin, Jantoven)	sis
A patient in respiratory distress with pale, moist skin and altered mental status should get oxygen via Ni Be prepared to assist ventilations with OPA/NPA and Bag-valve-mask. If signs of cerebral herniation are present, ventilate at the following rates: A Approximately 20 times per minute. P Ventilate at a rate of ten faster than normal respiratory rate if the signs of cerebral herniation of lif numeric EtCO2 readings are available, ventilate at a rate to maintain readings at approxima Never ventilate at less than 8 per minute. A patient with indications of stroke with a SpO2 less than 94%, should be given oxygen via NC and titrate A patient with indications of stroke with a SpO2 greater than 94%, should not get any oxygen. Transport the patient with the bed flat, if able to tolerate. If showing signs of increased ICP, do not lay power with the determining a transport destination, the following contradictions to tPA will be considered: Major surgery or serious non-head trauma in the previous 14 days History of gastrointestinal or urinary tract hemorrhage within 21 days Current (within the last 48 hours) use of anticoagulants. Examples include: Warfarin (Coumadin, Jantoven)	olic disorders (e.g., hypoglycemia
Be prepared to assist ventilations with OPA/NPA and Bag-valve-mask. If signs of cerebral herniation are present, ventilate at the following rates: A Approximately 20 times per minute. P Ventilate at a rate of ten faster than normal respiratory rate if the signs of cerebral herniation of the signs of the signs of cerebral herniation of the signs of the signs of cerebral herniation of the signs of the	
When determining a transport destination, the following contradictions to tPA will be considered: Major surgery or serious non-head trauma in the previous 14 days History of gastrointestinal or urinary tract hemorrhage within 21 days Current (within the last 48 hours) use of anticoagulants. Examples include: Warfarin (Coumadin, Jantoven) Edoxaban (Savaysa)	present. 30 mmHg (30 torr)} 0 94%.
	THE HALL
 Apixiban (Eliquis) Abigatran (Pradaxa) If glucose is less than 60, or there is strong suspicion of hypoglycemia despite glucometer readings, then 	low
4008 Diabetic Emergencies - Hypoglycemia protocol	EMT
No additional orders at this level	
No additional orders at this level	

4017 - Stroke

4017

Subject: Stroke

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

Clinical Pearls

- Cincinnati Prehospital Stroke Scale: (normal or abnormal)
 - Facial Droop (patient shows teeth or smiles).
 - o Arm Drift (patient closes eyes and holds both arms straight out for about 10 seconds).
 - o Abnormal Speech (have patient say "You can't teach an old dog new tricks." or any other phrase).
- The presence of a single abnormal finding in the Cincinnati Prehospital Stroke Scale should dictate a stroke alert and transport to a stroke center
- Possible indicators of a large vessel occlusion (LVO):
 - o The presence of abnormal findings in all three categories of the Cincinnati Prehospital Stroke Test increase the possibility of LVO
 - Visual neglect, gaze deviation, or abnormal eye movement are key clinical findings
 - o New onset loss of balance or coordination may indicate a possible LVO stroke
- Arrange for transport a historian with patient both to provide patient history and for permission to treat.

END OF SECTION

4017 - Stroke Page **2** of 2

5000 Series

Pediatric Protocol

Pediatric Protocol

5001

Subject:

Apparent Life Threatening Event (ALTE)

Effective:

June 1, 2021

Last Modified:

Jan. 8, 2021

5001.1 General Guidelines

- a. An Apparent Life-Threatening Event involves any infant under 1 year of age that is witnessed with a frightening event by an observer and involves some combination of the following:
 - i. Apnea
 - ii. Choking or gagging
 - iii. Color change (cyanosis, pallor)
 - iv. Change in muscle tone (limpness, sometimes rigidity)
- b. Also referred to as a BRUE (Brief Resolved Unexplained Event)
- c. Children who experience an ALTE event often have a normal exam on assessment.
- d. A cause cannot be determined in 50% of ALTE cases.

5001.2 Important Information to Gather:

- a. Document the symptoms of the event given by the observer:
 - i. Was the child apneic, cyanotic or limp during event?
 - ii. Infant's color, respirations and muscle tone
 - iii. Was seizure-like activity noted?
 - iv. Was any resuscitation attempted or did event resolve spontaneously?
 - v. How long did the event last?
- b. Obtain past pertinent medical history:
 - i. Recent trauma, infection (e.g., fever, cough)
 - ii. History of gastroesophageal reflux (GERD)
 - iii. History of congenital heart disease
 - iv. History of seizures
 - v. Medication history
 - vi. Birth defects

5001.3 Clinical Management

- a. Support airway, breathing, circulation.
- b. Keep warm.
- c. Head-to-Toe exam for trauma, bruising, or skin lesions.
- d. Check anterior fontanel: is it bulging, flat or sunken?
- e. Pupillary exam.
- f. Respiratory exam for rate, pattern, work of breathing and lung sounds.
- g. Cardiovascular exam symmetry of brachial and femoral pulses.
- h. Neuro exam for level of consciousness.
- i. Observe for repetition of reported occurrences.
- j. The patient should be transported to the hospital for further assessment.

5001.4 Management and Transport of Febrile Pediatric Patients

a. Transport all infants less than 2 months of age with a history or reported temperature of greater than 38.0 C (100.4 F) or less than 35.6 C (96.0 F).

Pediatric Considerations

5002

Subject:

Newborn Care and Resuscitation

Effective: June 1, 2021

Last Modified:

Mar. 4, 2021

5002.1 General Guidelines

- a. Maintain airway. Place in the sniffing position (1" towel under shoulders).
- b. If drying and suctioning has not provided enough tactile stimulation, flick the infant's feet or rub the infant's back.
- c. Suction only infants in distress, until airway is clear of all secretions. Bulb suctioning is preferred.
- d. If meconium staining is present:
 - i. Newborn is vigorous, with strong respirations, good muscle tone, and heart rate greater than 100 BPM; monitor the patient and maintain a patent airway.
 - ii. Newborn is depressed, has poor respiratory effort, decreased muscle tone, or heart rate less than 100 BPM; clear the airway by suctioning before taking other resuscitative steps.
- e. Avoid direct application of cool oxygen to infant's facial area as may cause respiratory depression due to a strong mammalian dive reflex present immediately after birth.
- f. If stimulation does not improve the infant's breathing, then BVM assist may be necessary.

5002.2 Viable Fetus

- a. If the fetus is greater than 23 weeks gestation, follow normal resuscitative procedures.
- b. A fetus is viable if:
 - i. Eyelids not fused
 - ii. If measurable or known, must be greater 500 grams

5002.3 Clinical Management

		Assessment		
Ped	diatric Considerations	Signs & Symptoms	Differential Diagnosis	
•	Nothing additional	Respiratory distress	 Peripheral cyanosis (normal) 	
		Central cyanosis	 Infection 	
		Altered level of consciousness	Maternal medication effect	
		Bradycardia	Hypothermia, hypoglycemia,	hypovolemia
		Treatment Algorith	ım	
P P P	After delivery of the infant; P Assess the airway and P Warm, dry and stimul P Position head lower the second sec	ate han body. inute to increase HR (if less than 100) or for apn begin CPR.	nea or persistent central cyanosis.	EMR
P	Obtain APGAR scores at 1, 5 and	d 10 minutes post-delivery.		EMT
P	If hypovolemic, IV fluid 10 ml/k	g over 5-10 minutes.		
P	Consider Naloxone 0.1 mg/kg,	IV, IO or IM every 3 minutes until respirations		AEMT
P	improve. NEWBORN: Dextrose	10% (D10) 2 ml/kg if blood glucose less than 40).	T T
P	If heart rate remains less than 6	60 bpm after CPR:		
	P Epinephrine 1:10,000	, 0.01 mg/kg IV		
	P If no response, repeat	Epinephrine 1:10,000, 0.01 mg/kg IV, every 3-	5 minutes.	
		Consult		
	Contact MCP for instructions ar	d guidance when attempting to determine the	viability of a fetus.	
•	Contact Micr for instructions ar			
•	CONTact WICE for instructions at	Clinical Pearls		
•		Clinical Pearls tape on all neonatal resuscitations.		

Pediatric Considerations

5003

Subject:

Pediatric Assessment Triangle

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

5003.1 General Guidelines

- a. The Pediatric Assessment Triangle establishes a level of severity, assists in determining urgency for life support measures, and identifies key physiological problems using observational & listening skills.
- b. This assessment tool can be utilized by providers of all certification levels.

5003.2 Appearance

- a. Appearance reflects adequacy of: oxygenation ventilation, brain perfusion, CNS function.
 - i. The mnemonic used for pediatric assessment of appearance is: TICLS.
 - 1. Tone- Moves spontaneously, sits or stands (age appropriate)
 - 2. Interaction- Alert, interacts with environment
 - 3. Consolability- Stops crying with comfort measures (holding, warmth, distraction)
 - 4. Look/gaze Makes eye contact with clinician, tracks objects
 - 5. **S**peech/cry Uses age appropriate speech or crying


5003.3 Work of Breathing

- a. WOB is a more accurate indicator of oxygenation and ventilation than respiratory rate or breath sounds.
- b. Assess for effort in breathing, accessory muscle use, and depth of breathing.
- c. Capillary refill is an accurate predictor of pediatric oxygenation.
- d. Under work of breathing, the patient should fall into one of four categories:
 - i. Normal Breathing
 - ii. Respiratory difficulty
 - iii. Respiratory failure
 - iv. Respiratory arrest

5003.4 Circulation

- a. Circulation reflects adequacy of cardiac output and perfusion of vital organs (core perfusion).
- b. Cyanosis reflects decreased oxygen levels in arterial blood, vasoconstriction and respiratory failure.
- c. Mottling of the skin indicates hypoxemia, vasoconstriction and respiratory failure.

5003.5 The Pediatric Assessment Triangle



5004

Safe Harbor

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

5004.1 General Guidelines

- a. Safe Harbor is for the voluntary separation of newborn infant.
- b. It is designed to allow desperate parents to separate from their babies to hospitals, EMS, or law enforcement agencies, confidentially.

5004.2 Clinical Management

- a. Stipulations of separation:
 - i. Infant can be no older than be 30 days old.
 - ii. Infant can have no signs of abuse or neglect
- b. History which should be obtained:
 - i. Date and time of birth
 - ii. Any pertinent family medical history
 - iii. Information regarding prenatal care
 - iv. Information concerning the birth.
- c. Information should be obtained in a manner, which will not lead to the revealing of the identity of the parents.
- d. Information collected should be based on patient (infant) care needs and assure confidentiality.
- e. Transport the infant to the hospital.

END OF SECTION

5004 – Safe Harbor Page 1 of 1

6000 Series

Special Operations Protocol

Hazardous Material Protocol

6001

Subject:

General Management for Haz Mat

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

6001.1 General Guidelines

- a. This section will provide the responders with direction toward the management and mitigation of Hazardous Material events.
- b. The initial goal of any hazardous materials release is to isolate and identify.

6001.2 Initial Actions

- a. Personnel safety:
 - i. Consider potential for secondary devices
 - ii. Don appropriate PPE
 - iii. Stage personnel & equipment
- b. Call for additional resources. (Haz Mat Teams, Decon crews, Law Enforcement, etc.)
- c. Field decontamination:
 - i. Remove all contaminated clothing
 - ii. Thoroughly wash the patient with {Dawn} dishwashing detergents
 - iii. Pay special attention to skin folds and other areas where simple irrigation may not remove it
 - iv. If a patient has been contaminated with any fuel, irrigate well
- d. Contact Medical Control and the hospital immediately to allow time for their set-up of decontamination equipment.
 - i. Provide the following information:
 - 1. Estimated number of confirmed or potential adult and pediatric patients
 - 2. Signs and symptoms exhibited by the patients
 - 3. Name and identification information of the contaminant if known, or as much information as possible
 - 4. Form of the contaminant (liquid, gas, etc.) if known
 - 5. Routes of exposure of the patients (percutaneous, inhalation, ingestion, etc.) if known
 - 6. Additional anticipated decontamination needs if necessary.
 - ii. Obtain permission from hospital upon arrival before entering with a potentially contaminated patient or crew.
- e. In the event of an MCI involving cyanide or nerve agents, request an "Antidote free" order, allowing you to treat all of the patients on the scene with the appropriate antidote, rather than calling for patient orders individually.
- f. Do **not** transport a patient until gross decontamination is completed.
- g. Decontaminate EMS vehicles prior to leaving hospital.

This Page Intentionally Left Blank

6002

Subject: Antidote Resources

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

6002.1 Antidote Options

a. {EMS Departments are authorized to stockpile **Atropine**, **2-PAM**, auto-injectors, and antidote delivery supplies at their own expense}

b. Dayton MMRS Caches

- i. Dayton MMRS stores additional supplies of organophosphate and cyanide antidotes in each county in Ohio Homeland Security Region 3.
- ii. To obtain Dayton MMRS antidotes: call 937-333-USAR (8727).
- iii. The closest department with an antidote cache will respond as a mutual aid request.
- iv. Dayton MMRS antidotes may be requested for incidents too small to require a CHEMPACK.
- v. If requesting a CHEMPACK, simultaneously request MMRS antidotes.

c. CHEMPACK Resources:

- i. Store of antidotes to treat about 500 victims of a nerve agent or organophosphate incident
- ii. Pre-hospital CHEMPACK contents:
 - 1. Atropine—blocks effects of excess acetylcholine
 - a. **0.5 mg AtroPen** auto-injectors (for patients less than 20 kgs)
 - b. 1.0 mg AtroPen auto-injectors (for patients 20-40 kgs)
 - c. Multi-dose vials
 - 2. **Pralidoxime Chloride (2-PAM)**—reduces levels of acetylcholine
 - a. 600 mg auto-injectors
 - b. Multi-dose vials
 - 3. Diazepam (Valium)—treats seizures.
 - a. Convulsive Antidote, Nerve Agent (CANA) (10mg Diazepam auto-injector)
 - 4. Multi-dose CHEMPACK types (both contain same drugs)

iii. Hospital CHEMPACK contents

- 1. More multi-dose vials for more precise dosing of children and long-term patients.
- 2. Hospital CHEMPACKs are partitioned into thirds
 - a. Marked with a red, yellow, or blue dot.
 - b. Hospitals have the option to keep the red dot materials for use at their hospital.
- 3. If a hospital opens its CHEMPACK, it must notify OSP Central Dispatch.
- 4. Hospitals may request materials from Dayton MMRS by calling 937-333-USAR (8727).

iv. CHEMPACK Limitations

- 1. Only useful against nerve agents or organophosphate
- 2. Only to be utilized when other resources are inadequate for number of victims.
- 3. CHEMPACKs opened contrary to guidelines will not be replaced by CDC and will result in the loss of a \$250,000 asset.

6002 – Antidote Resources Page 1 of 2

6002

Subject: Antidote Resources

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

- v. CHEMPACK procurement:
 - 1. ♦ Obtain MCP approval
 - 2. ♦ Contact OSP Central Dispatch 866-599-LERP (5377) and request a CHEMPACK
 - 3. You must indicate that the scenario meets both of the following criteria:
 - The agent has been identified, or patients are exhibiting signs and symptoms of organophosphate/nerve agent exposure.

AND

- b. The need for antidotes is greater than the available resources.
- 4. Simultaneously contact 937-333-USAR (8727) and request MMRS caches.
- 5. OSP Central Dispatch will:
 - a. Notify closest CHEMPACK hospital
 - b. Dispatch Troopers to deliver the CHEMPACK to the MCI's staging area.
 - c. Troopers will expect EMS to sign a form indicating receipt.

6002 – Antidote Resources Page 2 of 2

6003

Subject:

Hazardous Drug Exposure

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

6003.1 Identification or Recognition of a Hazardous Drug Situation

- a. Hazardous drug situations include:
 - i. Patients who have just had IV chemotherapy at the clinic or hospital
 - 1. Body fluids could have traces of hazardous drugs for up to 48 hours.
 - ii. Patients taking oral chemotherapy drugs.
 - iii. Patients who have continuous IV chemotherapy at home.
- b. Potential routes of exposure include:
 - i. Absorption through skin or mucous membranes
 - ii. Accidental injection by needle stick or contaminated sharps
 - iii. Inhalation of drug aerosols, dust, or droplets
 - iv. Ingestion through contaminated food, tobacco products, beverage, etc.
- c. Don PPE listed below whenever there is a risk of hazardous drug being released into the environment.
 - i. When handling leakage from tubing, syringe, and connection sites.
 - ii. When disposing of hazardous drugs or items contaminated by hazardous drugs.
 - iii. When handling the body fluids of a patient who received hazardous drugs in the past 48 hours.
 - iv. When cleaning hazardous drug spills

6003.2 Guidelines for Personal Protective Equipment:

- a. Gloves: two sets of nitrile gloves are recommended. Change gloves every 30 minutes.
- b. Disposable, non-permeable gowns
- c. NIOSH-approved respirator masks
- d. Eye and face protection: wear a face shield whenever there is a possibility of splashing.

6003.3 Procedures:

- a. Wipe up liquids with an absorbent pad or spill-control pillow.
- b. If necessary, consult with the appropriate Haz-Mat team.
- c. Dispose hazardous drugs or contaminated materials per MSDS or Haz Mat Team direction.
- d. Report and document spills as required.
- e. <u>For accidental skin exposure</u>: Remove contaminated garments, place in leak-proof plastic bag, and immediately wash contaminated skin with soap and water. Rinse thoroughly.
- f. <u>For accidental eye exposure</u>: immediately flush eye with saline solution or water for at least 30 minutes or until patient transport is completed.

6003.4 Identification or Clarification

- a. For more information about a hazardous drug or handling procedures, contact:
 - i. The homecare agency that is supplying the infusion.
 - ii. The physician who ordered the infusion.
 - iii. A hospital pharmacy, if necessary (there should be a label on the IV bag with the drug's name, concentration, and dosage.

This Page Intentionally Left Blank

6004

Subject:

Hydrofluoric Acid Exposure

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

6004.1 Clinical Management

	Assessme	nt	
ediatric Considerations None	Signs & Symptoms Breathing difficulty Abdominal pain Chest pain Burns (with blisters) Stridor (if inhaled)	Differential DiagnosisChemical burns	
	Treatment Algo	orithm	
Flush affected eyes and skin vortions of the Continue flush until	nders. rigate the chemical burn with water as quickly with copious amounts of water or IV Fluids fo patient transport is completed. Initing. Dilute with water or milk.		EMR
{Perform a 12-lead EKG and t	ransmit it to the hospital}		EMT
Intubate if apneic. Consider 1014 Pain Managen	u <u>ent</u> Protocol		
 Magnesium Sulfate Getting water on th Do not delay irrigat If available, use {Ep If ingested, in addition to wat Intubate if unconscious or at Perform a 12-lead EKG and m Apply {magnesium-containin Omit if topical agen If patient with HF exposure Calcium Chloride 1 Only ABCS, defibrilli 	ation, intubation and Epinephrine should pre-	salt. minutes. maining antacid (i.e., Maalox or Mylanta)}. distress. urned areas. ter Calcium Chloride 10% 1 g (10 ml), IV. urdiac arrest associated with Hydrofluoric Acid.	
	Consult		
The paramedic should contac	t MCP for administration of Calcium Chloride	10%	
	Clinical Pea	ris	
Death due to Hydrofluoric Ac	d has been reported from burns involving les	s than 3% hody surface area	
	a has seen reported from barris involving les	3 than 370 33dy Juniuce area.	

This Page Intentionally Left Blank

6005

Subject:

Organophosphate or Nerve Agent Exposure

ffective: June 1, 2021

Last Modified:

Oct. 10, 2021

6005.1 Clinical Management

	Assessmen	t en
Pediatric Considerations None	Signs & Symptoms Salivation Lacrimation Urination Defecation Gastrointestinal Issues Emesis Miosis Muscle Twitching	Differential Diagnosis None with a recent history of exposure to nerve agents
	Treatment Algo	rithm
• •	<u> </u>	~
◆ Treat seizures with Mida	zolam or Diazepam Auto-injector (CANA).	TWIST OF THE PROPERTY OF THE P
O Atropine may be A ◆ Adults and child P ◆ Children 20 – 4 P ◆ Children less th A ◆ Follow Atropine with 2-PA	y 5 minutes (up to a total of three doses), as avagiven IV, IM, IO or by AtroPen auto-injector for Iren greater than 40 kgs, give DuoDote, or Atropo 0 kg, give 1.0 mg Atropine, or the 1.0 mg Atrope an 20 kg, give 0.5 mg Atropine, or the 0.5 mg At (Pralidoxime) 600 mg IM. If DuoDote was us n should recieve Pralidoxime, 25-50 mg/kg IV or	children, or by DuoDote . ine 2 mg, IV, IM. n auto-injector. ropen auto-injector. ed, no second auto-injector is needed.
	lam or Diazepam Auto-injector (CANA).	
	Consult	
Contact MCP for administra	ation of medications listed above.	
	Clinical Pear	ls
Treat any case of known or	suspected Organophosphate or Carbamate (e.g.	, insecticides such as Parathion or Malathion); or nerve agent (e.g.

- Treat any case of known or suspected Organophosphate or Carbamate (e.g., insecticides such as Parathion or Malathion); or nerve agent (e.g., Tabun, Sarin, Soman, VX) exposure.
- Mild to moderate cases should be treated with one or two doses of **Duodote**.
 - Severe cases will generally require repeating every 5 minutes up to 3 doses.
 - o Organophosphate poisonings may require more Atropine (3 DuoDotes).
 - o Atropine in these circumstances is <u>not</u> for bradycardia, which may or may not be present.
- Procedures for DuoDotes, pediatric AtroPens, and Diazepam auto-injectors are the same as administering an Epi-Pen.
- Primary endpoints for treatment are diminished airway secretions (lungs are clear to auscultation), hypoxia improves, airway resistance decreases, and dyspnea improves

This Page Intentionally Left Blank



6006

Subject: Other Hazardous Materials

June 1, 2021

Last Modified:

Dec. 8, 2020

6006.1 General Guidelines:

- a. These guidelines are for the management of specific materials.
- b. Unless otherwise noted, these orders apply to all certification levels.

6006.2 Specific Materials

a. <u>Biological materials</u>

 i. ◆ {For the possibility of a bioterrorist attack, agencies may store their own supply of Ciprofloxacin (Cipro) or Doxycycline.}

Effective:

- ii. They can also provide prophylaxis against Anthrax, Cholera, and some protection against Plague.
- iii. Dayton MMRS maintains a supply of Cipro and Doxy sufficient to provide treatment for the first three days for all firefighters, EMS personnel, law enforcement officers, EMA personnel, public safety dispatchers, and their immediate families in the event of a bioterrorist attack.
- iv. The cache may be obtained by contacting 937-333-USAR (8727).

b. Pepper Spray

i. **{Sudecon Wipes}** can assist in the decontamination of patients or public safety personnel who have been sprayed with Pepper Spray.

END OF SECTION

6006 – Other Hazardous Materials Page 1 of 1

This Page Intentionally Left Blank

7000 Series

Administrative

This Page Intentionally Left Blank

June 1, 2021

7001

Subject: Drug Bag Exchange Program:

General Operating Guidelines

Effective:

Last Modified:

Mar. 1, 2022

7001.1 Drug Bag Exchange Committee Make-up

- a. Co-Chairpersons:
 - i. One Hospital EMS coordinator
 - ii. One Hospital pharmacy representative from each participating county
- b. Members:
 - i. EMS Coordinator from each participating hospital
 - ii. Pharmacy representative from each participating hospital
 - iii. Any interested GMVEMSC (Greater Miami Valley EMS Council) member
- c. Meetings
 - i. Two scheduled meetings per year
 - ii. Unscheduled as needed to discuss problem areas

7001.2 General Operating Guidelines

- a. In order to participate in the GMVEMSC Drug Bag program, an agency must have the capability to communicate with Medical Control at participating hospitals.
- b. There are two types of drug bags: ALS/BLS and BLS (fanny pack style).
- c. All drug bags, both ALS/BLS and BLS, are the property of the GMVEMSC
- d. GMVEMSC drug bags are only for use by EMS providers located or stationed within GMVEMSC's region.
- e. Agencies may not use GMVEMSC drug bags for runs originating from stations outside of or responding to an address outside of GMVEMSC's region (except in case of mutual aid responses to those areas).
- f. Except in extreme circumstances, a GMVEMSC drug bag should not be used on multiple runs.
- g. There is an initiation fee for each new bag that EMS agencies add to the program.
- h. There is an annual maintenance fee for each ALS/BLS bag and BLS bag.
- i. For replacement of lost or stolen drug bags, see 7005 Lost or Stolen Drug Bag Policy.
- j. To maintain the integrity of the drug bag contents, pharmacy departments' seal each compartment of stocked drug bags with a blue plastic device. The seal should only be broken for administration of prehospital emergency medical treatment by approved EMS personnel. After prehospital emergency medical treatment use, the drug bag should be cleaned and re-sealed with the red plastic device contained inside each drug bag compartment.
- k. The following actions may be taken for any department found to be in non-compliance with the Drug Bag Exchange Program Operating Guideline regarding opening and resealing the drug bag:
 - i. Notification of the Fire Chief, EMS Administrator, or Private Ambulance Administrator.
 - ii. The governing agency, e.g., city council, trustees, EMFTS for private ambulance service, will be notified that action is being initiated for the Fire, EMS and Private ambulance service.
 - iii. Removal of all drug bags from all locations of said Fire, EMS and Private ambulance service.
 - iv. Written notification to the following that the said service is in violation of the operating policy of the Drug Bag Exchange Program:
 - 1. Medical Director
 - 2. Regional Physician Advisory Board
 - 3. Ohio State Pharmacy Board
 - 4. Ohio Division of EMS
 - 5. All hospitals participating in the drug bag exchange program



7001

Subject: Drug Bag Exchange Program: **General Operating Guidelines**

June 1, 2021

Last Modified:

Mar 1, 2022

- I. GMVEMS Council maintains an information database for all EMS personnel authorized to participate in the Drug Bag Exchange Program.
- m. Rosters with certification expiration dates for EMS providers are available via an online database for review and updates.

Effective:

7001.3 **Participation Requirements**

- a. Active membership in the GMVEMS Council.
- b. Each agency in GMVEMSC must understand that Council typically communicates with departments and agencies via email, and that some of those messages concern changes to Standing Orders, pharmaceuticals in our Drug Bags, or other critical issues. Council maintains two lists of emails:
 - i. The GMVEMSC Listserve
 - ii. A distribution list of Agency Contacts
- c. As such, to participate in the Drug Bag Program, each agency must provide a minimum of one functioning email contact for each of those lists (may be the same person or different). Council desires to communicate as freely and effectively as possible, and agencies may provide as many as they like for each list, but must have at least one person who can reliably receive messages. Since in rare cases, these messages may be urgent, we encourage use of the "three-deep" rule: provide Council with three (or more) emails for each list.
- d. Additional Requirements For Drug Bag Program
 - i. The protocol testing compliance letter (7008) must be signed by the Chief within two weeks after completion of the CBT cycle, then faxed to Council.
 - ii. The copy of the license needs to go to Council by March 31 of each calendar year that the agencies' drug license is renewed. This is required, as the Pharmacy at each hospital needs the license on file in order to exchange drug bags with your department.
 - iii. Complete drug bag updates when scheduled. This is essential. The Pharmacy Board has made it very clear that updates must be completed on time.
 - iv. Signed agreement to abide by the GMVEMS Council Operating Guidelines for the Drug Bag Exchange Program (see 7007 Drug Bag Exchange Program Agency Agreement Letter)
- e. No department which participates in the Drug Bag Exchange Program shall possess a DEA License.
- f. Area hospital participation according to Council guidelines. (See 7006 Hospital Participation Policy).
- g. Document medical advisor approval for the use of the GMVEMS Council Operating Protocols with a signed, notarized letter, which is attached to the drug license renewal application form with a copy submitted to Council. Notarized letter is not required for renewal unless medications are added or there is a change in Medical Director from previous year.
- h. Agreement to complete the GMVEMSC annual skills and annual written test between 1 March and 31 May unless otherwise scheduled by Council (see Non-Compliance Procedures).
- i. Maintain all drugs at all times in a clean, temperature-controlled environment per Rule 4729-33-03 of the OH State Pharmacy Board Administrative Code.
- j. The rules can be seen at: https://codes.ohio.gov/ohio-administrative-code/rule-4729:3-3-03
- k. The ideal temperature span is 59-86 degrees Fahrenheit.
- In order to utilize an ALS/BLS or BLS drug bag in the pre-hospital emergency setting, the following equipment must be available, unless otherwise noted:



7001

Subject: Drug Bag Exchange Program:

General Operating Guidelines

Effective:

June 1, 2021

Mar. 1, 2022

- i. BLS Provider:
 - 1. Oxygen
 - 2. Pulse Oximetry
 - 3. Extraglottic Airways
 - 4. CPAP administration and management
 - 5. Oral Glucose
 - 6. Glucometry
 - 7. Ice Packs
 - 8. Suction (manual is acceptable)
 - 9. AED (if approved by Medical Advisor)
- ii. ALS Provider:
 - Oxygen
 - 2. EtCO₂ detection, monitoring and waveform for intubated patients
 - 3. 12-Lead acquisition, transmission and interpretation
 - 4. Mucosal Atomizer Device (MAD)
 - 5. IO and device
 - 6. BAAM
 - 7. Digital intubation
 - 8. IV pressure infuser
 - 9. Suction (manual is acceptable)
 - 10. Monitor or defibrillator or AED & intubation equipment
- m. Departments are required to have a tracking system that tracks all drug bag exchanges.

7001.4 General Non-Compliance Procedures

- a. Each agency and their Medical Director(s) will be notified if the annual written test and skills check-off has not been completed within the prescribed time period.
- b. The Ohio State Board of Pharmacy will be notified that a department or individual members of a department have not completed the annual written test and skills check-off within the prescribed time period.
- c. Hospital EMS coordinators and pharmacy departments will receive a list of departments or individuals within a department that are not in compliance with the operating guidelines.
- d. At the end of the testing season, if a department does not have 100% of their personnel completing both skill and written tests (or explanations for individuals not in compliance) noted in the Standing Orders database, then appropriate action, up to and including the removal of department from the Drug Bag program, may be taken by the chair of the drug bag committee.
- e. If copy of drug license(s) is not received by due date, GMVEMS Council will notify the agencies' medical director. GMVEMS Council reserves the right to initiate the non-compliance action process for any Fire/EMS/Private Ambulance service that does not provide documentation for drug license(s) renewal.

7001.5 Levels of Participation

- a. Paramedic Level
 - i. Each drug bag consists of a navy, standard issue drug bag.



7001

Subject: Drug Bag Exchange Program:

General Operating Guidelines

Effective:

June 1, 2021

Mar. 1, 2022

- ii. Each standard issue bag is labeled with a metal tag reflecting the assigned bag number.
- iii. A Paramedic can access any of the compartments within the bag to obtain medications.

b. <u>AEMT Level</u>

- i. A side compartment will be labeled "Intermediate"
- ii. The AEMT can access compartments to obtain medications per their protocol.
- iii. They cannot access the Center inside Compartment

c. EMT Level

- i. The RED BLS Pouch on an ALS/BLS bag will carry the following medications ONLY:
 - 1. Nitrostat
 - 2. Baby Aspirin
- ii. The BLS fanny-pack style bag will carry:
 - 1. Albuterol
 - 2. Atrovent
 - 3. Baby Aspirin
 - 4. Nitrostat
- iii. The EMT can only access following to treat their patient per protocol:
 - 1. The Airway Pouch
 - 2. The BLS Pouch
 - 3. The Naloxone Pouch



7002

Subject: Drug Bag Exchange Program:

Wasted Drug Procedure

Effective:

June 1, 2021

Dec. 8, 2020

7002.1 Guideline

- a. Some hospitals also require the use of the GMVEMSC approved Controlled Drug Usage Form in addition to documentation on the run sheet.
- b. This GMVEMSC approved form must be filled out for any controlled drug use, even if there is no wastage.
- c. This information shall be on both the original EMS department form and the hospital copy for reference if needed.
- d. Every crew transporting a patient will provide a completed run sheet to the hospital within 3 hours.

7002.2 Procedure

- a. Fentanyl, Ketamine, Morphine, Versed and Valium are all controlled drugs.
 - i. If a controlled medication is only partially administered, the paramedic or AEMT must account for the all of the unused portion.
- b. To insure the medications are properly accounted for, all paramedics and AEMTs will document:
 - i. The drug name
 - ii. The amount used
 - iii. The amount wasted (if all the medication was administered, then list "none")
 - iv. The signature of a second witness if there is wastage.
 - 1. The second witness can be a member of the EMS crew.
 - 2. Many hospital employees are no longer permitted to witness or sign for drug wastage.

June 1, 2021

7003

Subject: Drug Bag Exchange Program:

Exchange Process

Effective:

Last Modified:

Mar. 1, 2022

7003.1 Exchange Process Guidelines

- a. Each department is assigned to a "home" hospital.
- b. The assigned hospital is the central resource for initial fulfillment of medications for the drug bags and wholesale exchanges, replacement, or additions as required by revisions to the protocols.
- c. Drug bags can be exchanged at any participating hospital or within the same department.
- d. ALS/BLS bags may be exchanged one-for-one with another ALS/BLS bag.
- e. BLS bags may be exchanged one-for-one with another BLS bag.
- f. It is **not** permissible to exchange drug bags between two different Fire/EMS Agencies.
- g. For discrepancies (missing meds, expired meds, wrong meds or dose, altered or tampered meds, drug bag number discrepancy, etc.) follow 7004 Drug Bag Program: Drug Bag Discrepancies
- h. The primary care provider is responsible for the inventory of the drug bag prior to sealing it.
- i. If two departments have accessed a drug bag, they should jointly seal the drug bag.
- j. Each hospital designates a specific location for the exchange of drug bags.
- k. EMS personnel are **required** to complete the Sign In and Out log when exchanging a drug bag.
- I. Each agency is responsible to track drug bag exchanges within their own organization (i.e. documentation, internal log, tracking software, etc.)
- m. Once sealed, any provider can exchange the drug bag.
- n. Unless the patient was removed to a non-participating drug bag exchange hospital or the patient was a non-removal, the drug bag must be exchanged at the time of patient delivery to the hospital.
- o. In the exceptions listed above, the drug bag will be exchanged at a participating hospital within 8 hours.

7003.2 Drug Bag Blue Seals

- a. Blue seals:
 - i. Blue seals are used by the pharmacy that inventories and restocks the ALS/BLS drug bags.
 - ii. The blue seals will have a hospital sticker attached to the seal that identifies the hospital and pharmacist that inventoried the bag and the expiration date of the next drug to expire.
 - iii. The inner compartment of the ALS bag and Intermediate will be sealed with a blue seal and will have the expiration date noted.
 - iv. The blue seal will be looped through the proximal portion of the zipper tab (not the outermost portion of the zipper tab).
 - v. EMS should verify the blue seal is intact and has an expiration date before accepting the bag.
 - vi. When a provider opens a drug bag compartment, they should keep the blue seal in their possession until they have verified the contents are accounted for.
 - vii. Once they have verified the contents, they should place the blue seal in the compartment, unless there is a discrepancy and then seal the compartment with RED tag.
 - viii. EMS MUST PLACE THE BLUE SEAL IN THE COMPARTMENT!

b. Red Seals:

- i. Red seals identify ALS/BLS bags as being used.
- ii. EMS providers are required to inventory each opened pouch, discard any used sharps and clean any contaminants from bag used and then take red seal from the inside compartment (supplied by pharmacy when restocking the ALS/BLS bag) and seal the used compartment.
- iii. The red seal will be looped through the proximal portion of the zipper tab (not the outermost portion of the zipper tab).



7004

Subject: Drug Bag Exchange Program:

Drug Bag Discrepancies

June 1, 2021

Last Modified:

Mar. 22, 2022

7004.1 General Guidelines

a. EMS providers are required to inventory each opened pouch prior to applying the red seal.

Effective:

- b. All discrepancies (missing meds, expired meds, wrong med or dose, altered or tampered meds, drug bag number discrepancy, etc.) that are identified shall be reported to GMVEMSC using the Drug Bag Discrepancy Report (Addendum E).
- c. If at any time, an EMS provider encounters a discrepancy they will:
 - i. Notify their EMS Officer of the discrepancy.
 - ii. If the discrepancy was discovered after opening the bag, retain the blue seal and the hospital sticker that was attached to the drug bag in question.
 - iii. If the EMS provider is at the hospital, he/she will log the bag in using the normal procedure at that hospital while retaining the blue seal.
 - iv. He/she will advise the pharmacist or EMS Coordinator of the discrepancy and that they will be initiating the Discrepancy form as described below (pharmacist may request a copy of the Discrepancy form).
 - v. The EMS Officer may contact the EMS Coordinator if assistance is needed.

7004.2 Discrepancies Involving Controlled Drugs or Potential Tampering:

- a. When an issue arises concerning any of the following, a collaborative effort between the EMS organization or provider and the Hospital EMS Coordinator or Pharmacist shall be made in an attempt to resolve the issue:
 - i. A controlled drug (Fentanyl, Ketamine, Valium, Versed, or Morphine)
 - ii. A stolen, missing or lost bag
 - iii. Any medication that appears to have been altered or tampered with.
- b. If the issue cannot be resolved, the following steps shall be taken:
 - If the discrepancy was discovered by the EMS organization/provider, the person designated by the organization/provider shall comply with the requirements of OAC 4729-9-15 and GMVEMSC requirements as indicated below.
 - ii. If the discrepancy was discovered by the hospital, the person designated by the hospital shall comply with the requirements of OAC 4729-9-15 and GMVEMSC requirements as indicated below.
- c. Required reporting for unresolved issues involving Controlled Drug or potential/suspected tampering or lost or stolen drug bags pursuant to Federal and State Laws and GMVEMSC Protocol include:
 - If you have knowledge of or suspect a discrepancy is due to a theft, contact your State of Ohio Board of Pharmacy agent immediately. Advise them you want to report a theft or drug discrepancy. They will connect you with the appropriate person. (OAC 4729-9-15)
 - ii. Notify the Drug Bag Exchange Committee Chairs immediately.
 - iii. File a report with the appropriate law enforcement authorities (ORC 2921.22).
 - iv. Notify the Drug Enforcement Agency within 24 hours of discovery using DEA Form 106
 - v. DEA Form 106: https://www.deadiversion.usdoj.gov/webforms/app106Login.jsp.
 - vi. A 30-day extension may be requested in writing from the DEA. (CFR 1301.76(b)).
 - vii. Submit a completed GMVEMSC Drug Bag Discrepancy Report located at Addendum #E, with appropriate supporting documentation, to the GMVEMSC.



7004

Subject: Drug Bag Exchange Program:

Drug Bag Discrepancies

Effective:

June 1, 2021

Mar. 22, 2022

- d. "Dangerous drug" means any of the following:
 - i. Any drug to which either of the following applies:
 - Under the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A.
 301, as amended, the drug is required to bear a label containing the legend "Caution:
 Federal law prohibits dispensing without prescription" or "Caution: Federal law restricts
 this drug to use by or on the order of a licensed veterinarian" or any similar restrictive
 statement, or the drug may be dispensed only upon a prescription;
 - 2. Under Chapter 3715 or 3719 of the Revised Code, the drug may be dispensed only upon a prescription.
 - ii. Any drug that contains a schedule V controlled substance and that is exempt from Chapter 3719. of the Revised Code or to which that chapter does not apply;
 - iii. Any drug intended for administration by injection into the human body other than through a natural orifice of the human body;
 - iv. Any drug that is a biological product, as defined in section 3715.01 of the Revised Code.

7004.3 Discrepancies Not involving Controlled Drugs or Potential Tampering:

- a. Examples may include:
 - i. Non-controlled drugs that were not in the bag
 - ii. Wrong number of medications or doses
 - iii. Wrong drug concentration
 - iv. Expired medications found
 - v. No expiration date on tag
 - vi. Medications improperly labeled
 - vii. Empty vials or packages left in bag. DO NOT PUT ANY USED VIALS BACK IN DRUG BAG
 - viii. Unsealed medications
 - ix. Wrong medication administered
 - x. Unsealed pouch discovered
 - xi. Bag logged out with red seal (used bag)
- b. If discovered by EMS, the EMS Officer will initiate the Discrepancy form. They shall provide a copy of the form and the Blue Seal to the Hospital EMS Coordinator and shall fax a copy of the report to the GMVEMSC.
- c. If the Hospital discovers the discrepancy, the EMS Coordinator will initiate the Discrepancy Form and submit to GMVEMSC. If the EMS Coordinator is able to determine which EMS agency/hospital is responsible for the discrepancy, the agency or hospital will be notified and will receive a copy of the Discrepancy Form and the Blue Seal if applicable.

7004.4 Follow Up Procedures

- a. The GMVEMSC will:
 - i. Maintain a record of all discrepancies that occur.
 - ii. Follow up with the agencies involved as needed.
 - iii. Advise the Drug Bag Chairperson of any and all discrepancies and action taken.



7004

Drug Bag Exchange Program:

Drug Bag Discrepancies

Effective:

Last Modified: June 1, 2021

Mar. 22, 2022

- b. The Drug Bag Committee Chairperson will:
 - i. Report at the bi-annual Drug Bag Committee meetings for discussion and resolutions to all discrepancies encountered.
 - ii. Assist the Council and or affected departments with any issues or questions that may result.



7005

Subject: Drug Bag Exchange Program:

Lost or Stolen Drug Bag Policy

Effective:

June 1, 2021

Last Modified:

Mar. 1, 2022

7005.1 Purpose

a. To provide a uniform mechanism for the investigation and reporting of lost or stolen drug bags.

7005.2 Notification

- a. Upon discovery of a missing GMVEMSC drug bag, agencies will notify or cause to be notified the GMVEMSC Drug Bag Committee Chair(s).
- b. A responsible party at the agency will initiate the Drug Bag Discrepancy Form and follow instructions for reporting lost or stolen drug bags. Completed paperwork and reports will be submitted to GMVEMSC.
- c. The agency representative or the GMVEMSC Drug Bag Committee Chair (s) will notify the State of Ohio Board of Pharmacy (SOBP) at 614-466-4143
 - i. The Drug Bag Chair(s) may elect to notify the SOBP for the agency or advise the agency to contact them individually.
 - ii. Either way contact with the SOBP must be coordinated and accomplished

7005.3 Investigation

- a. The EMS agency shall develop and implement an internal search mechanism for lost drug bags.
- b. The internal search mechanism should include:
 - i. Determine if drug bag was left at the scene.
 - ii. Determine if drug bag was not exchanged on last run.
 - iii. Determine if drug bag is in the wrong vehicle.
- c. The GMVEMSC will seek the assistance of the GMVEMSC Drug Bag Chair(s) to check with all hospitals to determine if the bag might be in inventory or be alerted if it shows up at one of the hospitals.
- d. The GMVEMSC will contact the hospital EMS Coordinator with whom the EMS Department is assigned to work out a drug bag replacement.
 - i. Drug bag replacement will only occur after all paperwork is submitted
 - ii. The GMVEMSC will assess a fee for replacement bag to be paid for by the receiving agency.



7006

Subject: Drug Bag Exchange Program:
Hospital Participation Policy

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

7006.1 Purpose

a. To assure uniformity of hospital pharmacy participation in the Drug Bag Exchange Program.

7006.2 The Hospital Shall:

- a. Purchase (at cost), fill, and maintain a supply of drug bags sufficient to meeting the needs of an average day, plus a few extra to meet peak demands for drug bag replacement.
- b. Accept responsibility for filling new drug bags for departments or vehicles as assigned by GMVEMS Council, at hospital expense.
- c. Assign one licensed pharmacist and an EMS coordinator to attend and participate in the Standing Orders and Drug Bag Exchange Program Committees.
- d. Agree to pay annual dues and any fees assessed by GMVEMS Council that are approved by the Drug Bag Exchange Program Committee and the GMVEMS Council that pertain to the Drug Bag Exchange Program.

7006.3 The Greater Miami Valley EMS Council shall:

- a. Maintain a current State Drug Licenses for all participants in the Drug Bag Exchange Program.
- b. Furnish hospital pharmacy with a current listing of all departmental personnel authorized to access the GMVEMSC drug bags and copy of the protocol.
- c. Assign departments to hospitals in both a geographic and otherwise equitable fashion.



7007

Subject: Drug Bag Exchange Program:

New Agency Member Policy

Effective:

June 1, 2021

Dec. 8, 2020

7007.1 Purpose

a. To establish the procedures required to provide new agency members with an ALS or BLS drug bag from the GMVESMC Drug Bag Exchange Program.

7007.2 Procedure:

- a. Those agencies who have applied for membership and require a GMVEMSC Drug Bag to license their units may request a GMVEMSC Drug Bag be available 24 hours prior to the Ohio Medical Transportation Board (OMTB) inspection date.
- b. In order to receive a drug bag, the EMS agency shall:
 - i. Have applied for a GMVEMSC membership.
 - 1. Have been given a provisional membership by the GMVEMSC Executive Committee if the inspection is before regularly scheduled Council meeting.
 - ii. Provide a copy of their State Pharmacy License.
 - iii. Check off all agency personnel on Standing Orders and data entered in the GMVEMSC data base.
 - iv. Have the Medical Director submit a notarized letter to the State Pharmacy Board with License application stating they approve their department to use the GMVEMSC protocols.
 - 1. Medical Directors have the right to limit their personnel from using certain medications or procedures within the scope of the GMVEMSC protocols.
 - 2. Medical Directors may elect to change or add medications or procedures to the protocol.
 - 3. The Medical Director must include those protocols in addendum to the GMVEMSC, be responsible for the training and documentation of training in of their protocol as well as purchasing and maintaining those drugs that are not included in the standard inventory of the GMVEMSC ALS or BLS drug bag.
- c. The agency has 72 hours to show proof of a temporary permit from the date of inspection to the GMVEMS Council office.
- d. If they cannot demonstrate an OMTB permit in that time the drug bag must be returned to either the hospital to which the agency is assigned or the hospital that provided the drug bag.

7007.3 Agreement Letter

- a. In order to participate in the GMVEMS Council Drug Bag Exchange program, the agency will provide the agreement letter that follows to the Greater Miami Valley EMS Council.
- b. A similar example of the agencies' choosing may also be used.



7007

Subject: Drug Bag Exchange Program:

New Agency Member Policy

Effective:

June 1, 2021

Last Modified:

Dec. 8, 2020

Greater Miami Valley EMS Council Drug Bag Exchange Program Agency Agreement Letter

Please type or print legibly
DEPARTMENT/SERVICE:
CONTACT PERSON:
TELEPHONE:
FAX:
This department/service agrees to abide by the GMVEMS Council Drug Bag Exchange Program and Standing Orders.
SIGNATURE:
Fire Chief, EMS Administrator, or Private Ambulance Administrator
DATE:
Deturn to
Return to: GMVEMSC
124 E. Third St.
Dayton OH 45402

7008

Subject: Drug Bag Exchange Program: Protocol Testing Compliance Letter

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

Protocol Testing Compliance

I,	(Chief's Name Printed), do hereby certify that all
members of	(Agency/ Department Name)
have completed the (Year) GMVEMSC Protocol	Testing as of(Date
of Completion) with the exception of the following persor	nnel:
(List anyone who has not completed testing)	
Chief's Signature	_



7009

Subject: Drug Bag Exchange Program:
GMVEMSC Drug Bag Discrepancy Report

June 1, 2021

Last Modified:

Dec. 8, 2020

7009.1 General Guideline

- a. If at any time an EMS provider encounters a discrepancy in the GMVEMS Council Drug Bag they are using, they will notify their agencies' EMS Officer (or their supervisor if an EMS Officer does not exist).
- b. If the EMS provider is at a hospital that participates in the GMVEMS Council Drug Bag Exchange Program, they will log the bag in using the normal procedure at that hospital.


Effective:

- c. If the discrepancy was discovered after opening the bag, retain the blue seal and the hospital sticker that was attached to the drug bag in question. The tags (or photo copies of the tags) should be attached to the **GMVEMSC Drug Bag Discrepancy Report.**
- d. They will advise the pharmacist or EMS Coordinator of the discrepancy and that they will be initiating the **GMVEMSC Drug Bag Discrepancy Report** provided on the opposite page.
- e. Examples of the **GMVEMSC Drug Bag Discrepancy Report** should be available at all hospitals. They will often be found in the EMS rooms.
- f. The **GMVEMSC Drug Bag Discrepancy Report** will be completed in triplicate with a copy going to the GMVEMS Council, the receiving pharmacy and the EMS agency reporting.
- g. The pharmacist may request a copy of the GMVEMSC Drug Bag Discrepancy Report.

GMVEMSC Drug Bag Discrepancy Report

If at any time an EMS provider encounters a discrepancy they will notify their EMS Officer of the discrepancy. If the discrepancy was discovered after opening the bag, retain the blue seal and the hospital sticker that was attached to the drug bag in question. If the EMS provider is at the hospital, they will log the bag in using the normal procedure at that hospital. They will advise the pharmacist or EMS Coordinator of the discrepancy and that they will be initiating the Discrepancy form as described below (pharmacist may request a copy of the Discrepancy form).

Date of report:	Bag Number:	Date Discrepancy discovered:	
Discovered by:	Hospital/EMS Dept making discovery:		_
Have blue Hospital seal? YES/NO If yes	s - Attach seal to repo	ort	
Tracking:			
	om (hospital)	To (EMS agency)	
Date Bag turned in: to (hosp	oital)		
Description of the discrepancy : (Attach	addendum if additio	nal space needed)	
Describe efforts to resolve the discrepa	ncy: (Attach addendi	um if additional space needed)	
Was the discrepancy satisfactorily resolv	ved?	If not, what steps are to be taken:	
Reporting requirements:			
Was a police report filed?	Date:	By whom?	
Was a DEA report filed?	Date:	By whom?	
Was the Stat Pharmacy Board notified?		By whom?	
Required documents submitted to GMV	/EMSC By:	Date:	
For Drug Bag committee use:			
Wrong medication stocked		Bag logged out with red seal	
Expired medication found		Empty vials/packages found	
Wrong dose packaged		Open pouch found	
Missing medications		Unsealed bottles found	
Wrong number packaged		Medication found in wrong compartment	
No expiration date on tag		Wrong medication administered	
Atrovent/Albuterol not labeled		Lost or stolen bag	
Damaged medications		Other:	
Other:		5	



7010.1 OAC 4729-9-15

- (A) Each prescriber, terminal distributor of dangerous drugs, or wholesale distributor of dangerous drugs shall notify the following upon discovery of the theft or significant loss of any dangerous drug or controlled substance, including drugs in transit that were either shipped from or to the prescriber, terminal distributor of dangerous drugs, or wholesale distributor of dangerous drugs:
 - (1) The state board of pharmacy, by telephone immediately upon discovery of the theft or significant loss;
 - (2) If a controlled substance, the drug enforcement administration (DEA) pursuant to section 1301.76(b), Code of Federal Regulations;
 - (3) Law enforcement authorities pursuant to section 2921.22 of the Revised Code.
- (B) Controlled substance thefts must also be reported by using the Federal DEA Report form whether or not the controlled substances are subsequently recovered and/or the responsible parties are identified and action taken against them. A copy of the federal form regarding such theft or loss shall be filed with the State Board of Pharmacy within thirty days following the discovery of such theft or loss.
 - (1) An exemption may be obtained upon sufficient cause if the federal form cannot be filed within thirty days.
 - (2) A request for a waiver of the thirty-day limit must be requested in writing.
- (C) Each prescriber, terminal distributor of dangerous drugs, or wholesale distributor of dangerous drugs immediately upon discovery of any theft or loss of:
 - (1) Uncompleted prescription blank(s) used for writing a prescription, written prescription order(s) not yet dispensed, and original prescription order(s) that have been dispensed, shall notify the state board of pharmacy and law enforcement authorities.
 - (2) Official written order form(s) as defined in division (Q) of section 3719.01 of the Revised Code shall notify the state board of pharmacy and law enforcement authorities, and the drug enforcement administration (DEA) pursuant to section 1305.12(b), Code of Federal Regulations.

Subject:

Ambulance Restocking Policy

Effective:

June 1, 2021

Last Modified:

Dec. 8, 2020

7011.1 History

- a. The member hospitals of Greater Dayton Hospital Association (GDAHA) have supported Emergency Medical Services agencies in the region for decades.
- b. In 1998, GDAHA received permission (Advisory Opinion No. 98.7) from the Department of Health & Human Services to continue to exchange drugs (GMVEMSC Drug Bag Exchange Program) and supplies with EMS agencies and avoid violating the anti-kickback (safe harbor) statute of the Social Security Act.
- c. The hospitals named in the advisory are in the eight (8) county West Central Region: Champaign, Clark, Darke, Greene, Miami, Montgomery, Preble and Shelby.
- d. In December 2001, the Centers for Medicare and Medicaid Services issued an Ambulance Final Rule on Ambulance Restocking Safe Harbor.
 - i. Elements of the Safe Harbor include:
 - 1. Billing and claim submission
 - 2. Documentation
 - 3. Not tied to referrals
 - 4. Compliance with other laws

7011.2 EMS Supply Exchange Program:

- a. EMS agencies and personnel should understand the benefits of the EMS Supply exchange program, as offered by GDAHA members participating in this program.
- b. Hospitals are not required to participate in this restocking program.
- c. EMS agencies and personnel must adhere to the agreement, particularly the areas highlighted below:
 - i. For all transports to member hospitals, the EMS agencies will provide the receiving hospital with copies of the written records describing each of the medical supplies and/or medications utilized by or for the patient during the transport. In most cases, this should be done immediately after patient transfer.
 - ii. Participating hospitals will restock EMS agency ambulances, at no charge to the EMS agency, with the medical supplies and/or medications which were **utilized by or for the patient during the transport to the receiving hospital.**
- d. Hospitals will not restock items used on patients delivered to another hospital.
 - i. Restocking an ambulance at a participating hospital for items used on a patient delivered to a hospital not participating in the agreement will jeopardize this program.
 - ii. It is the responsibility of the EMS agencies to restock items used on patients delivered to a hospital that is not a participant in the Agreement.
- e. Participating hospitals will restock drug bags.
- f. Hospitals will not provide medical supplies to a new ambulance, or an old ambulance being returned to service.
 - i. These ambulances must be stocked for the first time by the EMS agency.

7012

Subject:

Diversion of Emergency Patients

Effective: June 1, 2021

Last Modified:

Feb. 8, 2022

7012.1 Greater Dayton Area Hospital Association, Greater Miami Valley Emergency Medical Services Council, Greater Montgomery County Fire Chiefs' Association Policy Statement For Temporary Rerouting Of Emergency Patients

- a. When situations exist that prevent the timely treatment of additional emergency cases or certain types of emergency patients, the designated hospital or satellite emergency department (ED) Official will report that they are on "Diversion of Emergency Patients," formerly referred to as rerouting.
- b. For patients impacted by the type of diversion specified, EMS should utilize hospitals in normal status. Transport to a hospital in diversion status may jeopardize patient care more than the delay in treatment caused by longer transport times
- c. To avoid misunderstanding, all parties are cautioned to use the words "divert or diversion" not "closed."

7012.2 Diversion Procedures

- a. The hospital or satellite ED will:
 - i. Update the "GDAHA SurgeNet Web Page."
 - 1. Anyone with a SurgeNet account can set up email and/or email text alerts for when any hospital changes status.
 - 2. Notify appropriate dispatch centers. (Hospitals and satellite EDs located in the southern Miami Valley region may also need to contact northern Cincinnati area hospitals or dispatch centers).
 - **3.** Dispatch centers unable to continuously monitor the GDAHA SurgeNet Web Page may provide a phone number to GDAHA which will receive a text to voice notification.
 - ii. Communicate the following information:
 - **1.** Diversion of emergency patients is requested by (<u>name of hospital or satellite ED</u>) because of (<u>specify what situation exits from the options provided below</u>)

7012.3 Diversion Options

- a. LOCKDOWN
 - i. The hospital or satellite ED has activated its disaster plan because of an internal emergency or other situation rendering the hospital or satellite ED unable to accept any emergency patient.
 - ii. EMS will not transport any patient to a facility in lockdown.

b. DIVERSION OF CERTAIN TYPES OF PATIENTS

- i. On occasion, hospitals or satellite EDs will not be able to handle a certain type of patient.
- ii. EMS will not transport this type of patient to the diverting hospital or satellite ED.
- iii. Examples are but not limited to:
 - 1. Stroke or head trauma
 - 2. Hazardous materials exposures
 - 3. Mental health
 - 4. ICU
 - 5. Cardiac
 - 6. OB
 - 7. All but major trauma (trauma centers only)

7012

Subject:

Diversion of Emergency Patients

Effective: June 1, 2021

Last Modified:

Feb. 8, 2022

7012.4 Patient Requesting Transport to Hospital on Diversion

a. When a patient and/or the patient's physician requests emergency medical services to transport to a hospital which is on diversion, emergency medical services have the responsibility to advise the patient and/or the physician that "due to diversion resulting from (<u>nature of situation</u>), patient care may be ieopardized".

7012.5 Review and Cancellation of Diversion Status

- a. After two (2) hours the hospital or satellite ED will be notified by page and/or email to review diversion status.
- b. It is the responsibility of the diverting hospital or satellite ED to cancel the diversion status with dispatch centers and update the GDAHA SurgeNet Web page using the same notification protocols used to initiate the diversion procedure.

7012.6 Participating Hospitals (Additional hospitals added upon approval)

Atrium Medical Center (Middletown)

1 Medical Center Dr, Middletown, OH 45005

Austin Boulevard Emergency Center

300 Austin West Blvd., Miamisburg, OH 45342

Dayton Children's Hospital

1 Children's Plaza, Dayton, OH 45404

Dayton Children's Hospital - South Campus

South Campus 3333 W. Tech Blvd, Miamisburg, OH 45342

Dayton-Springfield Emergency Center

1840 Springfield Road, Fairborn, OH 45324

Grand Lake Health System

200 St. Clair Street, St Marys OH 45885

Jamestown Emergency Center

4940 Cottonville Rd, Jamestown, OH 45335

Joint Township District Memorial Hospital

200 St. Clair Ave, St. Marys, OH 45885

Kettering Health Dayton

405 W Grand Ave, Dayton, OH 45405

Kettering Health Network Franklin Emergency Center

100 Kettering Way, Franklin, OH 45005

Kettering Health Greene Memorial

1141 N Monroe Dr, Xenia, OH 45385

Kettering Health Hamilton

630 Eaton Ave, Hamilton, OH 45013

Kettering Health Network Huber Emergency Center

8701 Troy Pike, Huber Heights, OH 45424

Kettering Health Main Campus

3535 Southern Blvd, Kettering, OH 45429

Kettering Health Miamisburg

4000 Miamisburg Centerville Rd, Miamisburg, OH 45342

Kettering Health Middletown Emergency Center

6147 W. State Route 122 Middletown, OH, 45005

Kettering Health Piqua Emergency Center

1 Kettering Way, Piqua OH 45356-4109

Kettering Health Preble Emergency Center

450-B Washington-Jackson Rd, Eaton, OH 45320

Kettering Health Springfield

2300 N. Limestone St., Springfield OH 45503

Kettering Health Troy

600 W. Main St., Troy, OH 45373

Kettering Health Washington Township

1997 Miamisburg Centerville Rd, Dayton, OH 45459

Mercy Health – Springfield

100 Medical Center Drive, Springfield, OH 45504

Mercy Health Urbana Hospital

904 Scioto St, Urbana, OH 43078

7012

Subject:

Diversion of Emergency Patients

Effective: June 1, 2021

Last Modified:

Feb. 8, 2022

Miami Valley Hospital

1 Wyoming St, Dayton, OH 45409

Miami Valley Hospital North

9000 N Main St, Dayton, OH 45415

Miami Valley Hospital South

2400 Miami Valley Dr, Centerville, OH 45459

Soin Medical Center

3535 Pentagon Blvd, Beavercreek, OH 45431

Upper Valley Medical Center

3130 N Co Rd 25A, Troy, OH 45373

END OF SECTION

Dayton VA Medical Center

4100 West 3rd Street, Dayton, OH 45428

Wayne Healthcare

835 Sweitzer St, Greenville, OH 45331

Wilson Memorial Hospital

915 West Michigan Street, Sidney, OH 45365

WPAFB 88th Medical Center

4881 Sugar Maple Dr, Wright-Patterson AFB, OH 45433

7013

Subject: Hospital Capabilities Chart

June 1, 2021

Effective:

Last Modified:

Feb. 8, 2022

HOSPITAL	Trauma Center	Burn Center	Interventional Cardiac Cath	Stroke Telemedicine	Stroke Primary	Stroke Comprehensive	L&D
Atrium Medical Center (Middletown)	A 3		Cardiac	Y	Υ		Υ
Austin Blvd. Emergency Center				Υ			
Bethesda Arrow Springs				Υ			
Bethesda Butler Hospital				Υ			
Christ Hospital Liberty				Υ			Υ
Dayton Children's Hospital	P 1	Υ					
Dayton Children's - South Campus							
Dayton-Springfield Emergency Center				Υ			
Jamestown Emergency Center				Υ			
Joint Township District Memorial Hosp.				Υ			
Kettering Health Dayton	A 3		Cardiac	Y	Υ		
Kettering Health Franklin				Y			
Kettering Health Greene Memorial				Υ			
Kettering Health Hamilton	A 3		Cardiac	Υ	Υ		Υ
Kettering Health Huber				Y			
Kettering Health Main Campus	A 2		Cardiac	Y	Υ	Y	Υ
Kettering Health Miamisburg				Υ	Υ		
Kettering Health Middletown				Y			
Kettering Health Piqua				Y			
Kettering Health Preble				Y			
Kettering Health Springfield				Y			
Kettering Health Troy				Y			
Kettering Health Washington Twp.				Y	Υ		Υ
McCullough-Hyde Hospital				Y			Υ
Mercy Health - Springfield			Cardiac	Y	Υ		Υ
Mercy Health - Urbana Hospital				Y			
Miami Valley Hospital	A 1	Υ	Cardiac	Y	Υ	Y	Υ
Miami Valley Hospital North				Y			
Miami Valley Hospital South	A 3		Cardiac	Υ			Υ
Reid Health	A 3		Cardiac	Y			Υ
Soin Medical Center	A 3		Cardiac	Υ	Υ		Υ
Upper Valley Medical Center	А3		Cardiac	Υ	Υ		Υ
Dayton VA Medical Center							
Wayne Health Care				Υ			Υ
West Chester Hospital	A 3		Cardiac	Υ	Υ		Υ
Wilson Memorial Hospital			Cardiac	Υ			Υ
WPAFB 88 th Medical Center							Υ

Notes: Comprehensive stroke centers have the capability of endovascular intervention 24/7. Primary stroke centers have CT and tPA capabilities and focus on evaluating patients for intravenous tPA. Telemedicine with tPA ready offers immediate access to a Neurologist.

This Page Intentionally Left Blank



Subject: Llocuite

Hospital Contact Information

Effective: June 1, 2021

Last Modified:

Feb. 8, 2022

Hospitals in **bold type** ask to be called for every patient.

HOSPITAL	PHONE	FAX
Atrium Medical Center, Middletown	513-424-3924	513-420-5133
Austin Boulevard Emergency Center	937-865-9663	937-223-9175
Bethesda Arrow Springs	513-282-7222	513-867-2581
Bethesda Butler Hospital	513-893-8222	513-893-8321
Christ Hospital Liberty	513-648-7874	513-648-7962
Cincinnati Children's Stat Line	513-636-8008	513-636-4050
Dayton Children's Hospital	937-641-4444	937-641-5301
Dayton Children's Hospital South	937-641-5642	937-641-4880
Dayton-Springfield Emergency Center	937-523-8792	937-523-8788
Jamestown Emergency Center	937-374-5274	937-374-5275
Joint Township District Memorial Hospital	419-394-7333	419-394-1902
Kettering Health Dayton	937-723-3419	937-723-4609
Kettering Health Franklin Emergency Center	937-458-4728	937-458-4737
Kettering Health Greene Memorial	937-372-2297	937-352-3501
Kettering Health Hamilton	513-867-2144	513-867-2581
Kettering Health Huber	937-558-3301	937-558-3349
Kettering Health Main Campus	937-395-8080	937-395-8347
Kettering Health Miamisburg	937-384-8766	937-384-8729
Kettering Health Middletown	513-261-3415	513-261-3419
Kettering Health Piqua	937-916-2627	937-916-2624
Kettering Health Preble	937-456-8328	937-456-8377
Kettering Health Springfield	937-504-8306	937-504-8309
Kettering Health Troy	937-980-7015	937-980-7019
Kettering Health Washington Township	937-435-1832	937-401-6447
Maternity	937-401-6850	937-401-6861
McCullough-Hyde Hospital	513-524-5353	513-523-0144
Mercy Health - Springfield	937-523-1902	937-523-1950
Mercy Health Urbana Hospital	937-484-6160	937-484-6183
Miami Valley Hospital	937-208-2440	937-208-8030
Maternity	937-208-2408	937-208-2651
Miami Valley North Hospital	937-540-1067	937-734-5977
Miami Valley South Hospital	937-438-2662	937-438-2262
Maternity	937-438-5817	
Regional Hospital Notification System	937-333-8727	
Reid Memorial Hospital	765-983-3161	765-983-3038
Soin Medical Center	937-702-4525	937-702-4509
Upper Valley Medical Center	937-440-9444	937-440-4346
Maternity	937-440-4181	937-440-4340
Dayton VA Medical Center	937-262-2172	937-267-5364
Wayne Health Care	937-547-5777	937-569-6291
West Chester Hospital	513-298-7777	513-298-8978
Maternity	513-298-7777	
Wilson Memorial Hospital	937-498-5300	
WPAFB Medical Center	937-257-3295	937-656-1673

Hospitals in **bold type** ask to be called for every patient.

This Page Intentionally Left Blank

7015

Subject: Infectious Disease Exposure

Reporting Policy

Effective: June 1, 2021

Last Modified:

Jan. 31, 2021

7015.1 General Guideline

- a. The purpose of this policy is to provide public safety personnel (including fire, EMS, and law enforcement) and hospitals with a set of standard guidelines and expectations for defining, responding to, and following up on an infection control exposure incident involving an emergency response provider.
- b. This guideline is a cooperative effort between the Greater Miami Valley EMS Council (GMVEMSC) and the Greater Dayton Area Hospital Association (GDAHA).

7015.2 Bloodborne Exposure

a. <u>Definition Of A Bloodborne Exposure</u>

- i. An exposure incident that may place a public safety worker at risk for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV) infections or other blood borne pathogens that includes:
 - 1. A percutaneous injury (e.g., a needle stick or cut), or
 - 2. Contact of mucous membrane or non-intact skin (e.g., exposed skin that is chapped, abraded, or afflicted with dermatitis) with blood, tissue, or other body fluids that are potentially infectious.
- ii. What is NOT an exposure?
 - 1. A percutaneous injury with a clean or sterile needle or instrument.
 - 2. Intact skin splashed with potentially infectious blood, body fluid, or tissue.

b. Post Exposure Procedure

- i. An exposed public safety worker should take the following immediate "first aid" action steps:
 - 1. Immediately irrigate the involved area.
 - 2. Flush eyes with copious amounts of IV fluids, if indicated.
 - 3. Wash skin vigorously with soap and water.
 - 4. If soap and water is not available, rinse area with another available solution such as IV fluids or a water-based liquid.
 - 5. Waterless hand cleaners are not recommended for post-exposure gross decontamination, but can be used when other options are not available.
- ii. The Employee shall report the exposure incident to the receiving hospital and to their immediate supervisor.
- iii. Exposed employees are required to register as a patient at the same hospital as the source.
- iv. Once at the receiving hospital, the exposed employee should locate and complete the "Request for Information by Emergency Care Workers (RIECW)" form (see Appendix A).
- v. When completed, the form should be submitted to the nurse handling the exposed employee's care in the Emergency Department (ED).
- vi. The EMS Coordinator for the receiving hospital can serve as a liaison between the organization and the hospital.
- vii. The department's infection control officer (ICO) or designated supervisor should, upon receiving notification that there has been an exposure incident, notify the receiving hospital's EMS Coordinator.



7015

Subject: Infectious Disease Exposure

Reporting Policy

Effective: June 1, 2021

Last Modified:

Jan. 31, 2021

- viii. For the purpose of this policy the "department's Infection Control Officer (ICO), designated supervisor, or designee" refers to the person responsible for reporting and coordinating an exposed employee's incident within that Public Safety entity.
- ix. Follow-up care/exam(s) will be provided to each employee involved when indicated. All follow-up care/exam(s) will be coordinated through your employer.

c. <u>Testing The Source Patient</u>

- i. A blood sample is required to determine whether a patient has HIV, HBV or HCV. Blood/Body Fluid (B/BF) testing of a source patient includes the following (MMWR, June 29, 2001):
 - 1. HIV antibody
 - 2. HBV surface antigen (HBsAg)
 - 3. HCV antibody
- ii. If the source patient is <u>transported</u> to a hospital:
 - 1. The ED obtains patient consent and the blood specimen for testing.
 - 2. In the event that the patient refuses to or cannot give consent (e.g., due to an altered level of conscious) a hospital's "infection control committee... or other body of a health care facility performing a similar function" has the authority to obtain the HIV screening when there has been a significant exposure (Ohio Revised Code §3701.242).
- iii. If the source patient refuses transport to a hospital:
 - 1. If the patient refuses to give consent for blood sampling and refuses transport, the public safety worker must follow up with their ICO or designee.
 - 2. At this point it is a legal matter to obtain the source patient's blood for testing (Ohio Revised Code §3701.247).
 - 3. Following a significant exposure in which the source patient refuses to provide a blood sample and refuses transport, the employee should seek immediate medical evaluation and counseling for their selves (MMWR, Sept. 30, 2013).
 - 4. In cases where the patient refuses transport, or in exposure incidents where the source patient is unknown, an exposed employee should follow the steps outlined in **7018.2e Patients Not Transported to a Hospital**.
 - 5. EDs or hospitals will not run source patient blood samples if the source patient is not a patient at their hospital.

d. Source Patient (Transported To Hospital) Results

- i. Hospital-run HIV test results should be available within an hour (may be longer for "stand alone" or smaller EDs); HBV and HCV results may not be available for several days.
- ii. The exposed employee is expected to remain a patient in the ED until they have received the results of the rapid HIV test and any additional counseling from the attending physician.
- iii. The employee is expected to communicate his/her follow-up needs to your department's ICO or designated supervisor.
- iv. Written notification of positive test results shall be provided directly to the affected employee by the hospitals designated infection control point of contact within three (3) days after oral notification (Ohio Revised Code §3701.248).



7015

Subject: Infectious Disease Exposure

Reporting Policy

Effective:

June 1, 2021

Last Modified:

Jan. 31, 2021

- v. Confidentiality of the source patient and public safety worker information shall be maintained
- vi. Only information pertaining to source patient results will be released to the organization's ICO or designee and/or an employee who is still present in the ED as described above.
- vii. The department ICO or designee and the public safety worker shall not disclose any medical information publicly about the source patient.

e. Patients Not Transported To A Hospital By EMS

- i. Employees should notify their immediate supervisor, and their immediate supervisor should notify the organization's ICO or designee. Federal regulations dictate that, "following report of an exposure, the employer shall make immediately available to the exposed employee a confidential medical evaluation and follow-up" (OSHA 29 CFR, 1910.1030(f) (3)).
- ii. Exposed employee should be directed to any ED for treatment.
- iii. Employee shall locate, complete, and sign the Request for Information by Emergency Care Workers (RIECW) Form (Appendix A), which should be available, completed, and submitted to the nurse handling care in the ED.
- iv. If the public safety worker is aware that the patient went to an ED by other means, the employee's supervisor may call the ED charge nurse of the patient's destination and notify them of the exposure, with a request to obtain baseline testing of the source patient.
- v. The written Request for Notification of Test Results shall be faxed to the ED charge nurse as soon as possible by the employee or the department's ICO.

f. Prophylaxis For Blood/Body Fluid Exposed Public Safety Worker

- i. Post-exposure prophylaxis (PEP) treatment may be offered to the public safety worker by the ED or workplace health provider in accordance with current clinical guidelines and local PEP protocols. Additionally, the employee may wish to consult their personal physician.
 - 1. The decision to take PEP includes a risk-based assessment based on known or unknown source patient and type of exposure.
 - 2. Employees receiving PEP treatment should be followed up within 72 hours of starting treatment.
 - 3. The PEP treatment decision should consider laboratory results when available.

ii. HIV prophylaxis:

- 1. Decisions about chemoprophylaxis can be modified if additional information becomes
- 2. Public safety workers must register as ED patients to receive HIV prophylaxis from the hospital.
- 3. HIV PEP should be started as soon as possible.
- 4. Consideration should be given by the ED for expert consultation and guidance on HIV PEP (e.g., infectious disease physician, MMWR, 2011) or the National Clinicians' Post Exposure Prophylaxis Hotline @ #888-448-4911).
- 5. Counseling should be made available through the agency's employee assistance program (EAP) or by contractual agreements.

7015

Subject: Infectious Disease Exposure

Reporting Policy

June 1, 2021

Last Modified:

Jan. 31, 2021

iii. Hepatitis Prophylaxis

1. Hepatitis Prophylaxis is dependent on the public safety worker's vaccine status.

Effective:

- 2. A small percentage of immunized individual's protection from the vaccine declines over time, which may require Hepatitis B Immunoglobulin (HBIG) and additional doses of the Hepatitis B vaccine to protect against both the current exposure and future exposures.
- 3. The results of the HBV Surface Antibody test will demonstrate the employee's immunity to HBV, but are not typically given in the ED as the results of the HBV Surface Antibody test are usually not available immediately.
- 4. Employees must follow up with his/her organization's workplace health provider for related prophylaxis as soon as possible.
- 5. There is no prophylaxis for HCV at this time. In cases of positive source HCV results, the employee should follow up with their workplace health provider for evaluation and care.

g. Public Safety Worker Baseline Testing

- i. Baseline testing of the exposed public safety worker is the employee's choice.
- ii. Agencies should maintain signed statements of employees who decline baseline testing/evaluation at the time of an exposure.
- iii. Baseline testing is the term given to the set of initial laboratory tests that should be drawn on an exposed employee.
- iv. This data may be used to compare future assessments in determining if an infectious disease was contracted.
- v. Baseline testing is not emergent; however, evaluation for PEP as discussed above should be considered urgent and care sought immediately.
- vi. In cases where PEP was determined not an appropriate emergency treatment, the public safety worker should seek follow up care as instructed.
- vii. This follow up should be by the organization's workplace health provider. This follow up should optimally occur the next day and no later than seven days post exposure (MMWR, 2001).
- viii. In cases where the source patient testing is negative but the public safety worker still wants further testing, the employee is encouraged to follow up with their private physician or your department's workplace health provider.
- ix. Public safety worker baseline testing includes at minimum:
 - 1. HIV antibody
 - 2. Hepatitis B surface antibody
 - 3. Hepatitis C virus antibody
- x. A positive Hepatitis and/or HIV test of the source patient should trigger viral load testing of the source patient.

7015.3 Respiratory Exposure

a. <u>Definition Of A Respiratory Exposure</u>

- i. Respiratory exposure is defined as contamination with an infectious agent through the respiratory tract.
- ii. This occurs via one of two routes (CDC, Rationale for Isolation Precautions in Hospitals, 1996):



7015

Subject: Infectious Disease Exposure
Reporting Policy

June 1, 2021

Last Modified:

Jan. 31, 2021

iii. Via airborne infectious agents with small-particle residue [5 μ m or smaller] of evaporated droplets containing microorganisms that remain suspended in the air for long periods of time

Effective:

- iv. Via droplet infectious agents which are propelled a short distance (less than three feet) through the air by coughing or sneezing: these droplets are acted upon rapidly by gravity (examples are meningitis, pertussis and influenza).
- v. Respiratory exposures may not be immediately known by the public safety worker, especially if the patient is not overtly symptomatic.

b. Immediate actions of the airborne-exposed public safety worker

(example is tuberculosis, rubella, and varicella virus).

- i. Don PPE as soon as possible at the scene or during transport if the patient is known to have a respiratory infection or is coughing or spraying secretions.
- ii. If secretions are splashed or coughed into the eyes or other mucous membranes, flush with copious amounts of IV fluids as soon as possible.
- iii. The public safety worker who suspects or is notified of respiratory exposure:
 - 1. Notify the department ICO that an exposure occurred
 - 2. Notify the ED charge nurse of the exposure upon delivery of the patient
 - 3. Complete the Request for Notification of Test.
 - 4. In these cases being checked in as an ED patient may or may not be necessary.
- iv. Upon receipt of the source patient's diagnosis, follow-up care and prophylaxis may be necessary for those exposed.
 - 1. At this point exposed employees may have to return to the receiving hospital and be checked in as a patient to receive care.
 - 2. In other situations follow-up care and prophylaxis may come from your department's workplace health provider.

c. Prophylaxis For The Airborne-Exposed Public Safety Worker

 If an exposed employee needs prophylaxis, prophylaxis should be coordinated thru the receiving (or notifying) hospital or when immediately available at the department's workplace health provider's clinic.

d. Testing The Source Patient

i. Source testing for respiratory exposures is done by the hospital based on patient symptoms.

e. Source Patient Results

- i. The hospital ICO or designee will notify the department ICO or designee of the infectious agent as soon as possible after symptoms of clinical presentation, or within 48 hours of a positive infectious agent determination.
- ii. Your organization's ICO, possibly after consulting with your department physician, will assess the potential exposure of the employee based on the interaction history with the source patient and the agent involved.
- iii. Confidentiality of source patient and the employee's information shall be maintained.



7015

Subject: Infectious Disease Exposure

Reporting Policy

June 1, 2021

Last Modified:

Jan. 31, 2021

iv. Only information pertaining to source patient results will be released to the department's ICO.

7015.4 Blood or Body Fluid & Airborne Exposures By Coroner's Cases

a. Exposure during resuscitation

- i. In cases where there is a public safety worker exposure during resuscitation efforts, it is recommended that crews transport the patient to the hospital where source testing can be performed, rather than follow field termination procedures.
- ii. However, in some incidents, exposure of a public safety worker may occur from a deceased victim who must remain at a scene for a period of time pending a coroner's investigation.

b. <u>Immediate actions of the exposed provider:</u>

- i. Decontaminate self as described in previous sections.
- ii. Notify the department ICO or designee that the exposure occurred.
- iii. At the direction of the department ICO or designee, seek treatment at an ED or at your organization's workplace health provider.
- iv. Consider prophylaxis based on the index of suspicion.

c. Actions of the ICO or designee:

- i. The Coroner or Coroner's Investigator shall be notified as soon as possible by the department's ICO or designee that an exposure has occurred.
- ii. A *Request for Information by Emergency Care Workers* form (Appendix A) shall be forward to the Coroner's Office as soon as possible after notification.

d. Testing the source patient:

- i. The Coroner shall make every effort to test a source patient by the next business day of being notified of the exposure.
- ii. In some cases, the Coroner may elect to send a specimen to an outside lab for testing. The public safety worker shall not wait for testing results from the Coroner to seek medical evaluation.

e. Source patients test results:

- i. The Coroner or Deputy Coroner shall notify the department ICO or designee of source patient test results as soon as possible.
- ii. Oral notification of source HIV status (positive or negative) shall be provided to the department ICO or designee within two days of test results, and written notification of positive test results shall be provided within three days after oral notification (ORC §3701.248).

Administrative

June 1, 2021

Infectious Disease Exposure Subject:

Effective:

Last Modified:

Reporting Policy

Jan. 31, 2021

Appendix A

REQUEST NO.

10349

REQUEST FOR INFORMATION BY EMERGENCY CARE WORKERS

PLEASE PRINT - Use Blue or Black Ink - PRESS HARD

This form is for use by emergency care workers to request information on the presence of a contagious or infectious disease (if known) of a person, alive or dead, who has been treated, handled, or transported for medical care by an emergency

Before you can be provided with this information, you must believe that you have suffered significant exposure through contact with the person about whom you are requesting the information. A significant exposure means:

(1) A percutaneous (break in skin or needle stick) or mucous membrane exposure (eyes, nose, mouth) to the blood,

- semen, vaginal secretions, or spinal, synovial (joint, bone, tendon), pleural (lung), peritoneal (abdomen), pericardial (heart), or amniotic fluid of another person; or

(2) Exposure to a contagious or infectious disease.
You may expect to receive a reply to this request within 2 days after contagious or infectious disease testing results are known. This may be longer than 2 days after you submit your request. A written notification will follow. Your supervisor will also

Deposit top (white) copy in designated area or with charge nurse. Submit yellow copy to your agency or employer. Retain pink

The requestor should follow his/her agency's or employer's exposure control plan for post-exposure follow up.

1. Your Name:		ń)	
2. Your Home Address:			
City/State/Zip:			
3. Your telephone number: Home:	Work:	Pager:	
4. Have you completed more than two	o (2) injections in Hepatitis B series. Yes	No	
5. Employer or volunteer agency for w	Employer or volunteer agency for whom you were administering health care when exposure occurred:		
Employer or Agency:			
Name of your supervisor at above	isted place of employment or volunteer age	oncy:	
7. Regarding the exposure, what was			
Name of Source Patient:			
Date:			
Place:			
Manner of exposure:		0	
Dirty Needle Stick Splash - Eye, Nose, Mouth		ken Skin Exposure protected Mouth to Mouth	
	specific)	T.	
his is to attest that the above statements	s are true and correct to the best of my kno	wledge and belief.	
four Signature:		Date:	
	ACKNOWLEDGEMENT		
Signature of Person Receiving Request:			
Received: Date	Time		
Vhite: Hospital/Coroner	Yellow: Agency/Employer	Pink: Requestor's	

Yellow: Agency/Employer

Pink: Requestor's Copy

Administrative

7015

Subject: Infectious Disease Exposure

Reporting Policy

Effective:

June 1, 2021

Last Modified:

Jan. 31, 2021

Appendix B

REQU	JEST NO					
THIS I LAW. RELEA FOR T	INFORMATION HAS BEEN DISCLOSED TO YOU FROM YOU SHALL MAKE NO FURTHER DISCLOSURE OF ASE OF THE INDIVIDUAL TO WHOM IT PERTAINS,	OM CONFIDENTIAL RECORDS PROTECTED FROM DISCLOSURE BY STATE THIS INFORMATION WITHOUT THE SPECIFIC, WRITTEN, AND INFORMED OR AS OTHERWISE PERMITTED BY STATE LAW. A GENERAL AUTHORIZATION ON IS NOT SUFFICIENT FOR THE PURPOSE OF THE RELEASE OF HIV TEST				
1.	Date of oral report:	Person giving report:				
	Report given to worker Supervisor Supervisor	pervisor's nameervisor within 3 working days following oral notification of final results.				
2.	Date of written report:	Person sending report:				
		ervisor's name				
3.	Your request for information has been received	d.				
		use:				
	Presence of a contagious or infections disease					
	b No tests were performed.	c The source person in question has refused HIV testing.				
	d Source patient discharged home.	e No blood available				
		f Source patient discharged to health care facility/coroner's office/funeral home.				
	Address of facility/coroner's office/funeral hor	Address of facility/coroner's office/funeral home (if known):				
	g. The following tests were performed on source patient with negative results:					
	h. Testing on source person in question was p	positive for:				
Comn	h. Testing on source person in question was p					
	ments:					
	ments: Written and oral report included:					
	ments:	☐ (Medical) precautions necessary to prevent transmission				
	Written and oral report included: Name of disease Signs & symptoms of disease	☐ (Medical) precautions necessary to prevent transmission☐ Recommended prophylaxis (if any)				
	Written and oral report included: Name of disease Signs & symptoms of disease Date of Exposure	☐ (Medical) precautions necessary to prevent transmission ☐ Recommended prophylaxis (if any) ☐ Suggested treatment				
4.	Written and oral report included: Name of disease Signs & symptoms of disease Date of Exposure Incubation period of disease Mode of transmission	☐ (Medical) precautions necessary to prevent transmission ☐ Recommended prophylaxis (if any) ☐ Suggested treatment				
4.	Written and oral report included: Name of disease Signs & symptoms of disease Date of Exposure Incubation period of disease Mode of transmission Sources of materials provided regarding disease	☐ (Medical) precautions necessary to prevent transmission ☐ Recommended prophylaxis (if any) ☐ Suggested treatment ☐ Appropriate Counseling				
4.	Written and oral report included: Name of disease Signs & symptoms of disease Date of Exposure Incubation period of disease Mode of transmission Sources of materials provided regarding disease It is expected that the emergency care worker provider of report and recipients that decisions that physician. THIS RESPONSE PROVIDES ALL INFORMATION ANY ADDITIONAL REQUEST WILL NEED TO BE	☐ (Medical) precautions necessary to prevent transmission ☐ Recommended prophylaxis (if any) ☐ Suggested treatment ☐ Appropriate Counseling e: will consult a physician in cases of true disease exposure. It is understood by				
4.	Written and oral report included: Name of disease Signs & symptoms of disease Date of Exposure Incubation period of disease Mode of transmission Sources of materials provided regarding disease It is expected that the emergency care worker provider of report and recipients that decisions that physician. THIS RESPONSE PROVIDES ALL INFORMATION	(Medical) precautions necessary to prevent transmission Recommended prophylaxis (if any) Suggested treatment Appropriate Counseling e: will consult a physician in cases of true disease exposure. It is understood by a related to prophylaxis, treatment, and counseling will be at the discretion of				
4. 55.	Written and oral report included: Name of disease Signs & symptoms of disease Date of Exposure Incubation period of disease Mode of transmission Sources of materials provided regarding disease It is expected that the emergency care worker provider of report and recipients that decisions that physician. THIS RESPONSE PROVIDES ALL INFORMATION ANY ADDITIONAL REQUEST WILL NEED TO BE	(Medical) precautions necessary to prevent transmission Recommended prophylaxis (if any) Suggested treatment Appropriate Counseling e: will consult a physician in cases of true disease exposure. It is understood by a related to prophylaxis, treatment, and counseling will be at the discretion of AVAILABLE AS OF THE DATE OF THIS WRITTEN RESPONSE. SUBMITTED FOR ANY FUTURE INFORMATION REGARDING				

Administrative

7015

Subject: Infectious Disease Exposure


Reporting Policy

Effective: June 1, 2021

Last Modified:

Jan. 31, 2021

Exposure Incident Flowchart



END OF SECTION

8000 Series

EMS Drug Formulary

8001

Subject:

Adenosine (Adenocard)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	6 mg (1 in drug bag) and 12 mg (2 in drug bag) prefilled syringes			
Indications	Stable Paroxysmal Supraventricular Tachycardia (PSVT)			
Adult Dosing	A 6 mg rapid IV as quickly as possible A If not successful, may repeat 12 mg rapid IV. A If not successful, may repeat 12 mg rapid IV. A All doses of Adenosine are followed by 20 ml bolus of IV fluid. A Go directly to 12 mg if patient with history of PSVT advises it takes 12 mg. May repeat once.			
Pediatric Dosing	 P 0.1 mg/kg rapid IV followed by 10 ml rapid saline flush. Max single dose 6 mg. P If unsuccessful, 0.2 mg/kg rapid IV followed by 10 ml rapid saline flush. P Max single dose 12 mg. May repeat x one. 			
Therapeutic Action	 Decreases electrical conduction through the AV node without causing negative inotropic effects Acts directly on SA node to decrease chronotropic activity 			
Contraindications	 Second or third degree AV block or sick sinus syndrome Hypersensitivity to Adenosine 			
Precautions And Side Effects	Ventricular ectopyNauseaMetallic taste.	f sinus bradycardia, sinus pause, or a	nsystole ma and in patients with bronchopulmonary	
Medical Control	 Adult patient: No Pediatric Patient: No 			
Protocols	Cardiac Protocol 2011 – Tachycardia			
END OF SECTION				

8001 - Adenosine Page 1 of 1

8002

Subject: Albuterol (Proventil)

Effective: June 1, 2021

Last Modified:

Oct. 29, 2021

EMR	EMT	AEMT	Paramedic
Packaging	2.5 mg in 3 ml plastic ampule (4 in drug bag)		
Indications	 For the EMT, AEMT and Paramedic: Exacerbation of Asthma, Emphysema, or COPD Bronchospasm in Asthma, COPD Allergic reaction with wheezing For the Paramedic only: Hyperkalemia in the presence of Crush Syndrome Trauma 		
Adult Dosing	 A 2.5 mg (3 ml), nebulized with O₂ at 8-10 LPM. A Combine Ipratropium with first dose of Albuterol. A May repeat Albuterol up to 2 times for a total of 3 doses A Give all 4 doses for hyperkalemia A In Crush syndrome: administer 10 mg nebulized 		
Pediatric Dosing	P 2.5 mg (3 ml), nebulized with O ₂ at 8-10 LPM. P Combine Ipratropium with first dose of Albuterol. P May repeat Albuterol up to 2 times for a total of 3 doses P In Crush syndrome: administer 10 mg nebulized		
Therapeutic Action	Bronchodilator		
Contraindications	Prior hypersensitiveCardiac dysrhythmias	reaction to Albuterol s associated with tachycardia.	
Precautions And Side Effects	 Side Effects Restlessness Apprehension Dizziness Palpitations Tachycardia Dysrhythmia 	on	
Medical Control	 Adults: For the EMT: Yes For the AEMT or Paramedic: No Pediatrics: For the EMT: Yes For the AEMT or Paramedic: No 		
Protocols	 General Protocol 1008 – Advanced Airway Management Trauma Protocol 3007 – Crush Syndrome Trauma (Paramedic only) Medical Protocol 4002 – Allergic Reaction/Anaphylaxis Medical Protocol 4003 – Asthma/Emphysema/COPD 		
END OF SECTION			

8002 - Albuterol Page 1 of 1

8003

Subject:

Amiodarone (Cordarone)

Effective: June 1, 2021

Last Modified:

Jan. 6, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 150 mg in 3 ml vial, 50 mg/ml 3 vials in drug bag 		
Indications	 Ventricular Fibrillation or Pulseless Ventricular Tachycardia Stable Wide-Complex Tachycardia 		
	 Ventricular Fibrillation or Pulseless Ventricular Tachycardia A 300 mg IV or IO. A May repeat with half the initial dose (150 mg IV or IO) no sooner than 10 minutes after first dose. 		
Adult Dosing	If patient converts with ROSC from a ventricular arrhythmia and no anti-arrhythmic has been given: A 150 mg in 250 ml NS, IV wide open over 10 minutes using 60 gtt/ml tubing & 18 g angiocath		
	Stable Wide-Complex A 150 mg in 29		utes using 60 gtt/ml tubing & 18 g angiocath
Pediatric Dosing	P 5 mg/kg IV o P May repeat	n or Pulseless Ventricular Tachycard or IO (max first dose 300 mg). 5 mg/kg IV or IO no sooner than 10 x repeat dose is 150 mg	
	Not indicated for stal	ole wide complex tachycardia	
Therapeutic Action	Antidysrhythmic agent with multiple mechanisms of action		
Contraindications	 Pulmonary congestion Cardiogenic shock Hypotension (SBP less than 100) Sensitivity to Amiodarone 		
Precautions And Side Effects	 Continuous EKG monitoring is required. Side Effects Hypotension Headache Dizziness Bradycardia AV conduction abnormalities Flushed skin Abnormal salivation 		
Medical Control	 Adult patient: No Pediatric Patient: No 		
Protocols	 <u>Cardiac Protocol 2005 – Cardiac Arrest: Ventricular Fib or Pulseless V-Tach</u> <u>Cardiac Protocol 2011 – Tachycardia</u> 		
END OF SECTION			

8003 - Amiodarone Page 1 of 1

8004

Subject:

Aspirin (Abbreviated as ASA)

Effective:

June 1, 2021

Last Modified:

Jan. 6, 2022

EMR	EMT	AEMT	Paramedic	
Packaging	81mg tablets in a blister pack (4 tablets total)			
Indications	Given as soon as possible to the patient with AMI.			
Adult Dosing	324 mg chewed (Four 81 mg tablets)			
Pediatric Dosing	Not applicable to pediatric patients			
Therapeutic Action	Anti-platelet			
Contraindications	 Hypersensitivity to salicylates Active ulcer disease Bleeding disorders Third trimester pregnancy 			
Precautions And Side Effects	 Suspected cardiac chest pain must be at least 25 years old. Patient must chew the tablets Side Effects Stomach irritation Heartburn or indigestion Nausea or vomiting Allergic reactions 			
Medical Control	 Adult patient: For AEMT and Paramedic: No, unless patient is 25 y/o or younger with AMI symptoms. For EMTs: Yes Pediatric Patient: Not applicable 			
Protocol	 Cardiac Protocol 2008 – Suspected Cardiac Chest Pain Medical Protocol 4011 – Obstetrical Emergencies 			
END OF SECTION				

8004 - Aspirin Page 1 of 1

8005

Subject: Atropine

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

Packaging In It at Mal/WMD Socurity Bag: Duodote: 2 mg auto-injector (along with 2-Pam 600 mg autoinjector) In WMD Drug Caches and Chempack: Duodote: 2 mg auto-injector (along with 2-Pam 600 mg autoinjector) In WMD Drug Caches and Chempack: Duodote: 2 mg auto-injector (along with 2-Pam 600 mg autoinjector) Multidose vial 8 mg in 20 ml, 0.4 mg/ml Symptomatic bradycardia Symptomatic bradycardia A gradycardia: 1 mg IV up to 3 mg Organophosphate or Nerve Gas poisoning: A For EMR, EMT, AEMT or Paramedic: 2 mg Duodote auto-injector. Paramedic only: 2 mg IV, IO or in A no max dose, given every 5 min or until lungs are clear to auscultation. P Minimum single dose of 0.1 mg, max single dose 0.5 mg P Machine total dose 1 mg P Machine total dose 1 mg P For EMR, EMT and Paramedic: P Los 4 dogs; 2.0 mg AtroPen auto-injector P P Paramedic only: 4 mg yea auto-injector P P P P active Control only: 4 mg yea auto-injector P P P Active Control only: 4 mg yea auto-injector P P P P Active Control only: 4 mg yea auto-injector P P P P Active Control only: 4 mg yea auto-injector P P P P P P P P P P P P P P P P P P P	EMR	EMT	AEMT	Paramedic	
- Organophosphate or Nerve Agent poisoning (regardless of cardiac rate) A Bradycardia: 1 mg IV up to 3 mg Organophosphate or Nerve Gas poisoning: A ↑ For EMR, EMT, AEMT or Paramedic: 2 mg Duodote auto-injector. Paramedic only: 2 mg IV, IO or io A No max dose, given every 5 min or until lungs are clear to auscultation. P Bradycardia: 0.02 mg/kg IV or IO every 5 min. P Minimum single dose of 0.1 mg, max single dose 0.5 mg P Maximum tord dose 1 mg P ↑ Serve Han 20 kgs: 0.5 mg AtroPen auto-injector P ↑ 6 For EMR, EMT, AEMT or Paramedic: P P + Greater than 40 kgs: 2.0 mg AtroPen auto-injector P ↑ Greater than 40 kgs: 2.0 mg AtroPen auto-injector P ↑ For EMR, EMT, akmT or Paramedic: P P Paramedic only: ↑ May give atropine doses listed IV or IM P No max dose, given every 5 minutes or until lungs are clear to auscultation. Therapeutic Action Therapeutic Action Anticholinergic None for severe organophosphate exposure. Tachycardia Hypersensitivity to atropine Obstructive disease of Gl tract Obstructive leuropathy Unstable cardiovascular status in acute hemorrhage with myocardial ischemia Narrow angle glaucoma Thyrotoxicosis E EMR, EMT and AEMT can only administer the Duodote auto-injector to Organophosphate or Nerve Agent patients Pupillary dilation rendering the pupils nonreactive. Pupil response may not be useful in monitoring CNS status attains and venting Paradoxical bradycardia when pushed too slowly or when used at doses less than 0.5 mg Headache or dizziness O pysrhythmias, tachycardia, palpitations Paradoxical bradycardia when pushed too slowly or when used at doses less than 0.5 mg Headache or dizziness Anticholinergic effects (dryness, photophobia, blurred vision, urinary retention, constipation) Nausea and vomiting Flushed, hot, dry skin Aldult patient: Bradycardia — No, Organophosphate Nerve Agent Poisoning—Yes Pediatric Patient: Bradycardia — No, Organophosphate Nerve Agent Poisoning—Yes Protocol Cardiac Protocol 2010 — Bradycardia Cardiac Protocol 2010 — Bradycardia	Packaging	 1mg in 10 ml prefilled syringe; (3 in drug bag) In Haz Mat/WMD Security Bag: Duodote: 2 mg auto-injector (along with 2-Pam 600 mg autoinjector) In WMD Drug Caches and Chempacks: 2 mg, 1mg and 0.5 mg AtroPen auto-injectors; 			
Adult Dosing A → For EMR, EMT, AEMT or Paramedic: 2 mg Duodote auto-injector. Paramedic only: 2 mg IV, IO or I A No max dose, given every 5 min or until lungs are clear to auscultation. P Bradycardia: 0.02 mg/kg IV or IO every 5 min. P Minimum single dose of 0.1 mg, max single dose 0.5 mg P Maximum total dose 1 mg P Organophosphate or Nerve Gas polsoning: P For EMR, EMT, AEMT or Paramedic: P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P P aramedic only: * May give atropine doses listed IV or IM P No max dose, given every 5 minutes or until lungs are clear to auscultation. Therapeutic Action • Anticholinergic Contraindications Obstructive disease of Git tract Obstructive neuropathy Unstable cardiovascular status in acute hemorrhage with myocardial ischemia Narrow angle glaucoma Thyrotoxicosis • EMR, EMT, AEMT on only administer the Duodote auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + 40 - 40 kgs: 1.0 mg AtroPen auto-injector P + 40 - 40 kgs: 1.0 mg AtroPen auto-injector P + 40 - 40 kgs: 1.0 mg AtroPen auto-injector P + 40 - 40 kgs: 1.0 mg AtroPen auto-injector P + 40 - 40 kgs: 1.0 mg AtroPen auto-injector P + 40 - 40 kgs: 1.0 mg AtroPen auto-injector P + 40 - 40 kgs: 1.0 mg AtroPen auto-injector P + 40 - 40 kgs: 1.0 mg A	Indications			rdiac rate)	
Pediatric Dosing P Minimum single dose of 0.1 mg, max single dose 0.5 mg P Maximum rotal dose 1 mg P Organophosphate or Nerve Gas poisoning: P For EMR, EMT, AEMT or Paramedic: P Less than 20 kgs: 0.5 mg AtroPen auto-injector P + 20 - 40 kgs: 1.0 mg AtroPen auto-injector P + Greater than 40 kgs: 2.0 mg AtroPen auto-injector P Paramedic only: • May give atropine doses listed IV or IM P No max dose, given every 5 minutes or until lungs are clear to auscultation. Therapeutic Action Anticholinergic None for severe organophosphate exposure. 1 Tachycardia Hypersensitivity to atropine Obstructive disease of Gi tract Obstructive disease of Gi tract Obstructive neuropathy Unstable cardiovascular status in acute hemorrhage with myocardial ischemia Narrow angle glaucoma Thyrotoxicosis EMR, EMT and AEMT can only administer the Duodote auto-injector to Organophosphate or Nerve Agent patients Pupillary dilation rendering the pupils nonreactive. Pupil response may not be useful in monitoring CNS status Side Effects Paradoxical bradycardia, palpitations Paradoxical bradycardia when pushed too slowly or when used at doses less than 0.5 mg Headache or dizziness Anticholinergic effects (dryness, photophobia, blurred vision, urinary retention, constipation) Nausea and vomiting Flushed, hot, dry skin Allergic reactions. Medical Control P Medical Control P Minimum single dose of sex positions and provided and control organophosphate Nerve Agent Poisoning—Yes Pediatric Patient: Bradycardia — No, Organophosphate Nerve Agent Poisoning—Yes Cardiac Protocol 2009 — Cardiac Alert Program	Adult Dosing	A <u>Organophosphate or Nei</u> A ◆ For EMR, EM	A Organophosphate or Nerve Gas poisoning: A ◆ For EMR, EMT, AEMT or Paramedic: 2 mg Duodote auto-injector. Paramedic only: 2 mg IV, IO or IM		
Therapeutic Action Anticholinergic None for severe organophosphate exposure. Tachycardia Hypersensitivity to atropine Obstructive disease of GI tract Obstructive neuropathy Unstable cardiovascular status in acute hemorrhage with myocardial ischemia Narrow angle glaucoma Thyrotoxicosis EMR, EMT and AEMT can only administer the Duodote auto-injector to Organophosphate or Nerve Agent patients Pupillary dilation rendering the pupils nonreactive. Pupil response may not be useful in monitoring CNS status Side Effects Precautions And Side Effects Dysrhythmias, tachycardia, palpitations Dysrhythmias, tachycardia when pushed too slowly or when used at doses less than 0.5 mg Headache or dizziness Anticholinergic effects (dryness, photophobia, blurred vision, urinary retention, constipation) Nausea and vomiting Flushed, hot, dry skin Allergic reactions. Medical Control Adult patient: Bradycardia—No, Organophosphate Nerve Agent Poisoning—Yes Pediatric Patient: Bradycardia—No, Organophosphate Nerve Agent Poisoning—Yes Cardiac Protocol 2009—Cardiac Alert Program Cardiac Protocol 2010—Bradycardia Cardiac Protocol 2010—Bradycardia	Pediatric Dosing	P Minimum single dose of 0.1 mg, max single dose 0.5 mg P Maximum total dose 1 mg P Organophosphate or Nerve Gas poisoning: P For EMR, EMT, AEMT or Paramedic: P ↓ Less than 20 kgs: 0.5 mg AtroPen auto-injector P ↓ 20 - 40 kgs: 1.0 mg AtroPen auto-injector P ↓ Greater than 40 kgs: 2.0 mg AtroPen auto-injector P Paramedic only: ♦ May give atropine doses listed IV or IM			
Contraindications Precautions And Side Effects Precautions And Side Effects Medical Control Adult patient: Bradycardia — No, Organophosphate Nerve Agent Poisoning—Yes Protocol Acardiac Protocol 2009 — Cardiac Alert Program Constructive disease of GI tract Obstructive disease of GI tract Phyrotoxicosis EMR, EMT and AEMT can only administer the Duodote auto-injector to Organophosphate or Nerve Agent patients Preventions And Side Effects Dysrhythmias, tachycardia, palpitations Paradoxical bradycardia when pushed too slowly or when used at doses less than 0.5 mg Headache or dizziness Anticholinergic effects (dryness, photophobia, blurred vision, urinary retention, constipation) Nausea and vomiting Flushed, hot, dry skin Allergic reactions. Adult patient: Bradycardia — No, Organophosphate Nerve Agent Poisoning—Yes Pediatric Patient: Bradycardia — No, Organophosphate Nerve Agent Poisoning—Yes Cardiac Protocol 2009 — Cardiac Alert Program Cardiac Protocol 2010 — Bradycardia	Therapeutic Action		,		
patients Pupillary dilation rendering the pupils nonreactive. Pupil response may not be useful in monitoring CNS status Side Effects Dysrhythmias, tachycardia, palpitations Paradoxical bradycardia when pushed too slowly or when used at doses less than 0.5 mg Headache or dizziness Anticholinergic effects (dryness, photophobia, blurred vision, urinary retention, constipation) Nausea and vomiting Flushed, hot, dry skin Allergic reactions. Adult patient: Bradycardia—No, Organophosphate Nerve Agent Poisoning—Yes Pediatric Patient: Bradycardia—No, Organophosphate Nerve Agent Poisoning—Yes Cardiac Protocol 2009 — Cardiac Alert Program Cardiac Protocol 2010 — Bradycardia		None for severe organophosphate exposure. Tachycardia Hypersensitivity to atropine Obstructive disease of GI tract Obstructive neuropathy Unstable cardiovascular status in acute hemorrhage with myocardial ischemia Narrow angle glaucoma			
Adult patient: Bradycardia —No, Organophosphate Nerve Agent Poisoning—Yes Pediatric Patient: Bradycardia—No, Organophosphate Nerve Agent Poisoning—Yes Cardiac Protocol 2009 — Cardiac Alert Program Cardiac Protocol 2010 — Bradycardia		patients Pupillary dilation renderi Side Effects Dysrhythmias, Paradoxical bra Headache or d Anticholinergic Nausea and vo	ing the pupils nonreactive. Pupil resp tachycardia, palpitations adycardia when pushed too slowly or izziness ceffects (dryness, photophobia, blurr miting iry skin	onse may not be useful in monitoring CNS status. when used at doses less than 0.5 mg	
Cardiac Protocol 2009 – Cardiac Alert Program Cardiac Protocol 2010 – Bradycardia	Medical Control	Adult patient: Bradycardia —No, Organophosphate Nerve Agent Poisoning—Yes			
 Special Operations Protocol 6005 – Organophosphate or Nerve agent Exposure 	Protocol	 <u>Cardiac Protocol 2009 – Cardiac Alert Program</u> <u>Cardiac Protocol 2010 – Bradycardia</u> <u>Special Operations Protocol 6002 – Antidote Resources</u> 			

8005 - Atropine Page 1 of 1

8006

Subject:

Calcium Chloride 10%

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	1 gram in 10 ml vial.			
		t in cardiac arrest or with ♦ bradycare	dia	
	 Calcium Channel Blo 			
		exposure with tetany <u>or</u> cardiac arres	st.	
Indications			eflexes, spasms of the hands and feet,	
	cramps, and	laryngospasm.		
			high concentration (> 40%) Hydrofluoric Acid	
		Syndrome presenting with abnormal	ECG or hemodynamic instability	
	A 1 gm (10 ml) IV for:			
		est in renal dialysis patients		
Adult Daring		hannel Blocker OD		
Adult Dosing	-	oric Acid exposure with tetany or car		
		high concentration Hydrofluoric Acid ent with bradycardia: 1 gm (10 ml) IV		
	A ◆ Renal dialysis patie A ◆ Crush syndrome: 1			
	P 20 mg/kg IV (max do			
		est in renal dialysis patients		
Pediatric Dosing		Channel Blocker OD		
			c acid exposures in pediatric patients	
Therapeutic		toxicity in hyperkalemia associated w		
Action	_	of Calcium Channel Blocker	, , , , , , , , , , , , , , , , , , , ,	
Contraindications	None in the emerger			
		ith Sodium Bicarbonate because if m	ixed, a precipitate develops.	
	 Flush tubing betwee 		, , , ,	
	Side Effects:	4.453.		
		(may cause asystole)		
Precautions And				
Side Effects				
			- Cile - Ai	
		necrosis and sloughing following IV in		
	• •	e vasospasm in coronary and cerebra		
	o Hypertension	n and bradycardia may occur with rap	oid administration.	
	Adults:			
	Cardiac Arres			
	· ·	s patient in bradycardia- Yes nnel Blocker OD—Yes		
		Acid Exposure—Yes		
Medical Control	O TrydrondoneO Crush syndro	•		
Wicarda Control	Pediatrics	Tes		
	o Arrest—No			
	 Calcium Char 	nnel Blocker OD— Yes		
	 Hydrofluoric 	Acid Exposure—Yes		
	 Crush syndro 	ome- Yes		
	Cardiac Protocol 200	04 – Cardiac Arrest - Renal Failure/Dia	alysis	
	 Cardiac Protocol 201 			
Protocol		07 – Crush Syndrome Trauma		
		12 – Overdose or Poisoning		
	 Special Operations P 	rotocol 6004 – Hydrofluoric Acid Exp	<u>osure</u>	

END OF SECTION

8006 – Calcium Chloride 10% Page 1 of 1

8007

Subject:

END OF SECTION

Calcium Gluconate

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT AEMT	Paramedic	
Packaging	1 gram in 10 ml vial, 100 mg/ml. Only in the drug bag in the event of Calcium Chloride 10% sh		
<u> </u>	Renal dialysis patient in cardiac arrest or with ◆ bradycardia		
	Calcium Channel Blocker OD		
	 Hydrofluoric Acid exposure with tetany or cardiac arrest. 		
Indications	 Tetany may present as: overactive neurological reflexes, spas 	ms of the hands and feet	
	cramps, and laryngospasm.	ms or the hands and rect,	
	 May be given prophylactically, after exposure to high concent 	tration (> 40%) Hydrofluoric Acid	
		· · · ·	
	 Adults with Crush Syndrome presenting with abnormal ECG or hem A 1 gm (10 ml) IV for: 	odynamic instability	
	Cardiac arrest in renal dialysis patients		
Adult Dosing	 ♦ Hydrofluoric Acid exposure with tetany or cardiac arrest 		
	A ◆ For prophylaxis in high concentration Hydrofluoric Acid exposure: 4	00 mg (4 ml) IV	
	A ◆ Renal dialysis patient with bradycardia: 1 gm (10 ml) IV	3 . ,	
	A ◆ Crush syndrome: 1 gm (10 ml) IV		
	P 20 mg/kg IV (max dose 500 mg) for:		
Pediatric Dosing	 Cardiac arrest in renal dialysis patients 		
rediatife Dosing	 Calcium Channel Blocker OD 		
	P • Call in advance to treat crush syndrome or hydrofluoric acid exposu	ures in pediatric patients	
Therapeutic	 Antagonizes cardiac toxicity in hyperkalemia associated with dialysis 	patients.	
Action	Reverses symptoms of Calcium Channel Blocker		
Contraindications	None in the emergency setting		
	Do not administer with Sodium Bicarbonate because if mixed, a precipita	te develops.	
	Flush tubing between drugs.		
	Side Effects:		
Precautions And	 Bradycardia (may cause asystole) 		
Side Effects	 Hypotension 		
Side Lifetts	o Metallic taste		
	 Severe local necrosis and sloughing following IV infiltration 		
	 May produce vasospasm in coronary and cerebral arteries 		
	 Hypertension and bradycardia may occur with rapid administrati 	on.	
	Adults:		
	 Cardiac Arrest—No 		
	Renal dialysis patient in bradycardia- Yes		
	Calcium Channel Blocker OD—Yes		
Medical Control	Hydrofluoric Acid Exposure—Yes Grush sundrame Yes		
	Crush syndrome—YesPediatrics		
	• Pediatrics • Arrest—No		
	Calcium Channel Blocker OD—Yes		
	Hydrofluoric Acid Exposure—Yes		
	 Crush syndrome- Yes 		
	Cardiac Protocol 2004 – Cardiovascular Emergencies: Renal Failure/Di	ialysis	
	Cardiac Protocol 2010 – Bradycardia		
Protocol	Trauma Protocol 3007 – Crush Syndrome Trauma		
	 Medical Protocol 4012 – Overdose or Poisoning 		
	 Special Operations Protocol 6004 – Hydrofluoric Acid Exposure 		

8007 – Calcium Gluconate Page 1 of 1

8008

Subject: Ciprofloxacin (Cipro)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	Tablets		
Indications	 As prophylaxis again 	inst Anthrax, Cholera or Plague	
Adult Dosing	A ◆ 500 mg tablet by	y mouth, twice a day	
Pediatric Dosing	P ◆ Dosage will be sp	pecified at time of incident.	
Therapeutic Action	 Antibiotic 		
Contraindications	Allergy to quinoloneTendon pain or inflatePediatricsPregnancy		
Precautions And Side Effects	 Side Effects Atrial flutter Hypotension Premature Vent QT prolongation Torsade De Poin Tendon pain/inf 	ntes,	
Medical Control	Adult: YesPediatric: Yes		
Protocol		ations 5002 – Newborn Care and Res Protocol 6006 – Other Hazardous M	

8008 - Ciprofloxacin Page 1 of 1

8009

Subject:

Dextrose 10% (D10)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 500 ml of D10W, contains 50 g Dextrose 1 bag of solution in drug bag 		
Indications	 Diabetic with mental status changes Evidence of hypoglycemia in cardiac arrest Generalized hypothermia with or without arrest Altered level of consciousness of unknown cause Seizures with BGL of less than 60 mg/dl No blood sugar monitor is available or suspicion of hypoglycemia despite glucometer readings. 		
Adult Dosing	A 250 ml IV at wide opA May repeat in 10 minA Maximum dose is 50	nutes if patient fails to respond o	r BGL remains less than 60 mg/dl.
Pediatric Dosing	P Pediatric patients: P 5 ml/kg P Maximum dose is 250 ml P Newborn patients: P 2 ml/kg if BGL is less than 40 mg/dl		
Therapeutic Action	Principal form of carbohydrate utilized by the body		
Contraindications	Known or suspected	CVA in the absence of hypoglyce	mia
Precautions And Side Effects	 Side Effects: Warmth Pain Hyperglycer 	m medication infusion	ine deficient patients
Medical Control	Adults: NoPediatrics: No		
Protocol		08 – Diabetic Emergencies - Hypo ions 5002 – Newborn Care and Re	

8009 – Dextrose 10% Page **1** of **1**

This Page Intentionally Left Blank

8010

Subject:

Diazepam (Valium) (JITSO) & CANA Pen

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	 Vial for AEMT and Paramedic only 10 mg in 2 ml vial (5 mg/1ml) One vial present in the drug bag in the event of Midazolam shortage WMD Drug Cache & CHEMPACK resource for all certification levels Convulsive Antidote, Nerve Agent (CANA) 10 mg auto-injector 			
Indications	 Vial for AEMT and Paramedic on Seizures A Chest pain associated w CANA Auto-injector for all certific Seizures associated with 	vith stimulant overdose (ad		
Adult Dosing	A Vial for AEMT and Paramedic on A Seizures: 5 mg slow IV; A Cocaine or crack use: 5 A CANA Auto-injector for all certific A 10 mg IM by auto-inject	ly may repeat dose once. mg slow IV , may repeat do cations	-	
Pediatric Dosing	 Vial for AEMT and Paramedic P Seizures: P 0.2 mg/kg slow IV over 2 min. (maximum dose 5 mg IV) or P 0.5 mg/kg rectally, (maximum dose 10 mg rectally) P May repeat 0.2 mg/kg slow IV over 2 min (maximum 5 mg) CANA Auto-injector for all certifications 			
Therapeutic Action	 P 10 mg IM by auto-injector Treats alcohol withdrawal and grand mal seizure activity Used to treat anxiety and stress. 			
Contraindications	None in the emergency setting			
Precautions And Side Effects	Side Effects: Hypotension Reflex tachycardia (rare) Respiratory depression Ataxia Psychomotor impairment Confusion Nausea May cause local venous irritation			
Medical Control	 Vial for AEMT and Paramedic only Adults: No Pediatrics: No CANA Auto-injector for all certifications Adults: Yes Pediatrics: Yes 			
Protocol	 Trauma Protocol 3008 – Cyanide Poisoning Medical Protocol 4012 – Overdose/Poisoning Special Operations Protocol 6002 – Antidote Resources Special Operations Protocol 6005 – Organophosphate or Nerve Agent Exposure 			

END OF SECTION

8010 - Diazepam Page 1 of 1

8011

Subject:

Diphenhydramine (Benadryl)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	ı	EMT	AEMT	Paramedic
Packaging	• 50 mg in 1ml vial			
Indications	 Allergic reaction or Anaphylaxis In anaphylaxis, for the patient who goes into cardiac arrest if not previously given Extrapyramidal reaction 			
Adult Dosing	A 50 mg IM or slow IV			
Pediatric Dosing	P :	1 mg/kg (max dose 5	0 mg) IM or slow IV	
Therapeutic Action	Prevents the physiologic actions of histamine by blocking histamine receptors			
Contraindications	None in the emergency setting			
Precautions And Side Effects		Side Effects: O Dose related O Sedation O Disturbed co O Hypotension O Palpitations,	d drowsiness pordination n tachycardia or bradycardia of bronchial secretions	er respiratory diseases such as asthma.
Medical Control	 Adults: No, for the Paramedic. YYes, for the AEMT when treating Extrapyramidal Reactions Pediatrics: No, for the Paramedic. YYes, for the AEMT when treating Extrapyramidal Reactions 			
Protocol	 Medical Protocol 4002 – Allergic Reactions/Anaphylaxis Medical Protocol 4010 – Extrapyramidal (Dystonic) Reactions 			
END OF SECTION				

8011 - Diphenhydramine Page **1** of **1**

This Page Intentionally Left Blank

8012

Subject: Dopamine (JITSO)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 Premixed 250 ml bag (400 mg/250 ml) Concentration: 1600 mcg/ml Only present in the drug bag in the event of Norepinephrine shortage 		
Indications	Shock with or without Pulmonary Edema		
Adult Dosing	A IV drip rate, 5 to 20 mcg/kg/min of 400 mg/250 ml; increase by increments of 5 mcg/kg/min.		
Pediatric Dosing	 P IV drip rate, 5 to 20 mcg/kg/min of 400 mg/250 ml; start at 5 mcg/kg/min. P Titrate to maintain adequate perfusion 		
Therapeutic Action	 Acts on alpha, beta and dopaminergic receptors in dose dependent fashion Increases cardiac output in higher doses 		
Contraindications	None in the emergency setting		
Precautions And Side Effects	 Correct hypovolemia prior to using Dopamine. Infuse through large stable vein to avoid possibility of extravasation injury. Side Effects: Dose related tachydysrhythmias Hypertension Increased myocardial oxygen demand (ischemia) 		
Medical Control	 Adults: No Pediatrics: No 		
Protocol	 As a replacement for Norepinephrine: Cardiac Protocol 2009 – Cardiac Alert Program Medical Protocol 4015 – Sepsis Medical Protocol 4016 – Shock 		
END OF SECTION			

8012 - Dopamine Page **1** of **1**

This Page Intentionally Left Blank

8013

Subject:

Doxycycline

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 Tablets 		
Indications	 As prophylaxis a 	gainst Anthrax, Cholera or Plague	
Adult Dosing	A ◆ 100 mg tablet	t by mouth, twice a day	
Pediatric Dosing	P → Dosage will be	e specified at time of incident.	
Therapeutic Action	 Antibiotic 		
Contraindications	PregnancyAllergies to Tetra	acycline antibiotics	
Precautions And Side Effects	 Use with cau 	irth control pills less effective Ition in patients with liver disease, kidney Padache, blurred vision and flu-like sympt	
Medical Control	Adult: YesPediatric: Yes		
Protocol	Special Operatio	ons Protocol 6006 – Other Hazardous Mat	terials
END OF SECTION			

8013 - Doxycycline Page 1 of 1

This Page Intentionally Left Blank

8014

Subject: Duodote

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	 Auto-injector Atropine 2 mg and Pralidoxime Chloride (2-Pam) 600 mg In WMD Drug Caches and CHEMPACKS 			
Indications	Organophosphate or Nerve Agent poisoning			
Adult Dosing	A ◆ Single auto-injector containing Atropine 2 mg and 2-Pam 600 mg			
Pediatric Dosing	P ◆ Single auto-injector containing Atropine 2 mg and 2-Pam 600 mg			
Therapeutic Action	Anticholinergic as a result of WMD MCI; also reactivates cholinesterase.			
Contraindications	None in the emergency s	setting		
Precautions And Side Effects	 Use with caution in myasthenia gravis, renal impairment, pregnancy, lactation or children. Atropine causes pupillary dilation rendering the pupils nonreactive. Pupil response may not be useful in monitoring CNS status. Side Effects: Tachycardia Paradoxical bradycardia when pushed too slowly or when used at doses less than 0.5 mg Palpitations or dysrhythmias Headache Dizziness Anticholinergic effects (dry mouth, nose, skin, photophobia. blurred vision, urinary retention, constipation) Nausea & vomiting Flushed, hot, dry skin Allergic reactions 			
Medical Control	Adults: YesPediatrics: Yes			
Protocol	Special Operations Protocol 6005 – Organophosphate or Nerve Agent Exposure			
END OF SECTION				

8014 - Duodote Page 1 of 1

This Page Intentionally Left Blank

8015

Subject: Epinephrine

Effective: June 1, 2021

Last Modified:

Sept. 1, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 EpiPen auto-injector: 0.3 mg (one in drug bag) EpiPen Jr. auto-injector: 0.15 mg (one in drug bag) 1:10,000 – 1 mg/10ml prefilled syringes (six in drug bag) 1:1,000 – 1mg/ml 30 ml vial (one in drug bag) 		
Indications	 For the EMR, EMT, AEMT and Paramedic: Anaphylaxis or allergic reaction For the AEMT and Paramedic: Asthma in severe distress The EMR and the EMT cannot treat Asthma with Epinephrine For the Paramedic Ventricular Fibrillation, Pulseless Ventricular Tachycardia, Asystole, and PEA 		
Adult Dosing	A If 30 kg or gr A May repeat A Asthma or anaphylax A Epinephrine A May repeat A If hypotensiv A Ventricular Fibrillatio	kis (Paramedic) e (1:1,000) 0.5 mg IM in 5 minutes	slow IV, every 3 minutes, up to 0.5 mg.
Pediatric Dosing	P If less than 1 P If 15 kg or gr P May repeat P Asthma or Anaphylax P If less than 1 P If 15 kg or gr P May repeat P Ventricular Fibrillatio	15 kg, Epi (1:1,000) 0.01 mg/kg IM (ma reater and less than 30 kg, Epi (1:1,00)	ax 0.15 mg). O) 0.01 mg/kg IM (max 0.3 mg) se should equal initial dose) after 5 minutes Asystole, and PEA (Paramedic)
Therapeutic Action	 Directly stimulates alpha and beta adrenergic receptors in dose-related fashion Causes bronchodilation, vasoconstriction, and increased cardiac output. 		
Contraindications	None in the emergen	ncy setting	
Precautions And Side Effects	HypertensionTachycardiaMay increase myocar	ing ventricular tachycardia and ventric rdial oxygen demand or precipitation of d following epinephrine administratio	of angina pectoris

8015 – Epinephrine Page **1** of **2**

8015

Subject: Epinephrine

Effective: June 1, 2021

Last Modified:

Sept. 1, 2021

Medical Control	 Adults: Initial dose administration at all levels and follow-up dosing for AEMT and Paramedics – No In allergies/anaphylaxis, repeat doses by EMR/EMTs - YYes Pediatrics: No
Protocol	 Cardiac Protocol 2003 – Cardiac Arrest: Asystole or PEA Cardiac Protocol 2005 – Cardiac Arrest: V-Fib or Pulseless V-Tach Cardiac Protocol 2009 – Cardiac Alert Program Cardiac Protocol 2010 – Bradycardia Medical Protocol 4002 – Allergic Reactions/Anaphylaxis Medical Protocol 4003 – Asthma/Emphysema/COPD Pediatric Considerations 5002 – Newborn Care and Resuscitation Special Operations Protocol 6004 – Hydrofluoric Acid Exposure
END OF SECTION	

8015 – Epinephrine Page **2** of **2**

8016

Subject: Etomi

Etomidate

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	Г	AEMT	Param	edic
Packaging	• 40 mg i	in 20 ml vial (2 mg/	'ml)		
Indications	• To prov	vide sedation prior	to Sedate to Intubate proc	edure	
Adult Dosing	 A 0.3 mg/kg IV A May repeat within 2 minutes if patient resistant to intubation. A Average dose is 15 mg - 25 mg 				
Pediatric Dosing	P Not ap	plicable			
Therapeutic Action	 Short-acting, potent sedative Hypnotic 				
Contraindications	 Hypersensitivity Not to be administered to pediatric patients 				
Precautions And Side Effects	 Must be authorized for use by the agencies' Medical Director Side Effects: Bradycardia Respiratory depression or tachypnea Sinus tachycardia Hypotension Nausea and vomiting 				
Medical Control	Adults: Pediate	: No rics: Not applicable			
Protocol	General Protocol 1010 – {Sedate to Intubate and Rapid Sequence Intubation}				
END OF SECTION					

8016 – Etomidate Page **1** of **1**

8017

Subject:

Fentanyl (Sublimaze)

Effective: June 1, 2021

Last Modified:

Dec. 15, 2021

EMR	EMT	AEMT	Paramedic	
Dockosins	• 100 mcg/2 mL (50 mc	cg/ml) vial	·	
Packaging	 One in drug bag 			
Indications	 Suspected Cardiac Ch Pain associated with Extremity Fractures Dislocations Sprains Frostbite Abdominal Pain Hydrofluoric Acid (Hf 	traumatic events) exposure		
Adult Dosing	 A 50-100 mcg slow IV, provided SBP is greater than 100. A If no response, or inadequate response to IV Fentanyl and a second drug bag is available: A May repeat 50-100 mcg slow IV, after 15 minutes provided SBP greater than 100. 			
Pediatric Dosing	 P Fentanyl is not to be administered to anyone less than 2 years of age. P ◆ Contact MCP prior to treatment of abdominal pain P First choice treatment for pain: P 1 mcg/kg IN, max dose 100 mcg. P Repeat 1 mcg/kg IN after 15 minutes, if an additional drug bag is available. P Second choice treatment for pain: P 1 mcg/kg, slow IV, max dose 100 mcg, provided age appropriate normal SBP (80 + 2x age in years). P Repeat 1 mcg/kg, slow IV after 15 minutes, max dose 100 mcg P Maintain age appropriate blood pressure P I mcg/kg IM, max dose 100 mcg P 1 mcg/kg IM, max dose 100 mcg P 2 mcg/kg IM, max dose 100 mcg P 3 mcg/kg IM, max dose 100 mcg <l< td=""></l<>			
Therapeutic	P Repeat 1 moProvides analgesia	.g/ kg IIVI, max dose 100 mcg, n	o sooner than 15 minutes after first dose.	
Action	 Reduces cardiac prelo 			
Contraindications	Prevents addTypically occReversible w	vith naloxone.	d ventilation. kg) or with rapid administration.	
Precautions And Side Effects	 Geriatric & debilitate Apnea CNS depression Bradycardia which makes Ensure adeq Atropine onl 	d patients require lower doses ay be transient. Juate ventilation and oxygenat	c and hemodynamically significant.	
Medical Control	Adults: NoPediatrics: Yes, for all	odominal pain		
Protocol	 General Protocol 1014 - Pain Management Cardiac Protocol 2006 - AICD Activations Cardiac Protocol 2008 - Suspected Cardiac Chest Pain Cardiac Protocol 2009 - Cardiac Alert Program 			

8017 - Fentanyl Page 1 of 1

8018

Subject: Glucagon

Effective: June 1, 2021

Last Modified:

Aug. 28, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	1 mg dose (CombineOne in drug bag	liquid and powder vials, then admir	nister)	
Indications	 Hypoglycemia if no IV No blood sugar monit IV access. Seizures with blood g Generalized hypother Calcium Channel Bloom 	tor is available or a strong suspicior :lucose levels less than 60 mg/dl	n of hypoglycemia despite BGL reading and no	
Adult Dosing	_	aphylaxis unresponsive to Epinephri locker overdose: 1 mg IV or IM	ine: 1 mg IV or IM	
Pediatric Dosing	P Less than 8 years old – 0.5 mg P 8 years old or older – 1.0 mg			
Therapeutic Action	Increases breakdown	of glycogen to glucose and stimula	ites glucose synthesis, raising blood sugar	
Contraindications	None in the emergen	cy setting		
Precautions And Side Effects	 Should not be considered a first line choice Side Effects: Tachycardia Hypotension Nausea and vomiting Urticaria 			
Medical Control	Calcium ChaPediatrics:Hypoglycem	ia, Allergic Reaction/Anaphylaxis— nnel Blocker or Beta Blocker OD—Y ia, Allergic Reaction/Anaphylaxis— nnel Blocker or Beta Blocker OD—Y	/es No	
Protocol	 General Protocol 1005 – General Patient Management General Protocol 1012 – Intraosseous Infusion General Protocol 1013 – Alternate Vascular Access Medical Protocol 4002 – Allergic Reactions/Anaphylaxis Medical Protocol 4008 – Diabetic Emergencies - Hypoglycemia Medical Protocol 4012 – Overdose/Poisonings 			

END OF SECTION

8018 - Glucagon Page 1 of 1

8019

Subject:

Hydroxocobalamin (Cyanokit)

Effective:

June 1, 2021 Last N

Last Modified:

Dec. 23, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	 1 vial, containing 5 g lyophilized Hydroxocobalamin dark red crystalline powder for injection. After reconstitution with 200 ml fluid, the vial contains Hydroxocobalamin for injection, 25 mg/mL. Available in caches located in each county in Homeland Security Region 3. 			
Indications	 Known or strongly suspected cyanide intoxication Smoke inhalation with suspected cyanide component. Victim exposed to fire or smoke who presents with altered mental status, seizures, shock, or difficulty breathing. 			
	A ◆ May repeat s response		an be given IO as a last resort) minutes to 2 hours depending on clinical	
Adult Dosing	A Add 20 A Mix: T infusio	stitute: Place the vial in an upright posit 00 mL of NS or LR to the vial using the t he vial should be repeatedly inverted o	ransfer spike. Fill to the line. r rocked, not shaken, for at least 1 min. before	
Pediatric Dosing	P ◆ 70 mg/kg slow IV over 15 minutes; max dose of 5 grams (Can be given IO as a last resort) P → May repeat a dose of 35 mg/kg IV; max dose 2.5 g, depending on severity of poisoning and clinical response.			
Therapeutic Action	Binds to cyanide molecules and is eliminated as waste			
Contraindications	None in the emergency setting			
Precautions And Side Effects	 Must not be used in conjunction with other Cyanide antidotes May cause hypertension 			
Medical Control	 Adults: In cardiac arrest—No In patients not in arrest—Yes Pediatrics: In cardiac arrest—No In patients not in arrest—Yes 			
Protocol	Trauma Protocol 3008 – Cyanide Poisoning & Antidotes			
END OF SECTION				

8019 - Hydroxocobalamin Page 1 of 1

8020

Subject:

Ipratropium (Atrovent)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

Packaging	0.5 mg in 2.5 ml plastic1 in drug bag	ampule	
Indications	Bronchospasm in AsthmAllergic reaction/Anaph		
Adult Dosing	A 0.5 mg (2.5 ml), nebulizeA Combined with first dos		
Pediatric Dosing	P 0.5 mg (2.5 ml), nebuliz P Combined with first dos	zed with O ₂ at 8-10 LPM se of Albuterol	
Therapeutic Action	Causes bronchodilation	n by anticholinergic effect	
Contraindications	 None in the emergency 	r setting	
Precautions And Side Effects		ent should be removed by EMS. cients with narrow-angle glaucoma and l	lactating mothers.
Medical Control	• Pediatrics: For the EMT	or Paramedic: No	
Protocols	 Medical Protocol 4003 - 	– Advanced Airway Management– Asthma/Emphysema/COPD– Allergic Reactions/Anaphylaxis	

8020 - Ipratropium Page **1** of **1**

8021

Subject: Ketamine (Ketalar)

Effective: June 1, 2021

Last Modified:

Dec. 15, 2021

EMR	EMT	AEMT	Paramedic
Packaging	500 mg/10 mL vial (50 mg/ml)One in drug bag		
Indications	Pain control (For the Paramedic	traint for combative patient, includin	g excited delirium nedication for the management of pain)
Adult Dosing	A If unable to 0 A 25 m A For combative patient. A 250 mg IM ar or A 100 mg slow A If no change i A 250 cor A 100 cor	ng IN <u>or</u> 50 mg IM , may repeat 25 mg :s: nterolateral thigh.	oid Sequence Intubation}:
Pediatric Dosing	P Emergency sedation for P Limited to use P 1 mg/kg slow or P 5 mg/kg IM (d for pain to any patient less than 16 or combative patient, including excite e in patients age 8 or greater. IV (max dose 100 mg). maximum dose is two doses of no mor repeat doses	ed delirium:
Therapeutic Action	 Ketamine is a Schedule III Phencyclidine (PCP) derivative that is rapid acting and produces a "dissociative" anesthesia in which the patient's consciousness is detached from their nervous system. Due to its "dissociative" properties, Ketamine is a potent analgesic. May be given as an adjunct to narcotic pain medication, particularly in patients at risk for hypotension or respiratory depression. 		
Contraindications	_	ations in BP might prove harmful: rdial Infarction ris	

8021 - Ketamine Page 1 of 2

8021

Subject: Ketamine (Ketalar)

Effective: June 1, 2021

Last Modified:

Dec. 15, 2021

Precautions And Side Effects	 Emergence reaction may occur, when patient is awakening (hallucinations, delirium, confusion, etc.) Provide continuous cardiac monitoring, EtCO₂ and pulse oximetry with sedated patients. Management should include use of a nasopharyngeal airway, proper positioning and persistent suctioning to maintain a clear airway. Geriatric & debilitated patients require lower doses & are more prone to side effects. Catecholamine release (hypertension, tachycardia) Hypersalivation (the ketamine drool) Nausea, vomiting, particularly prevalent in pediatrics. Minimal cardiac depression occasionally reported with high doses administered rapidly IV. May transiently increase heart rate and blood pressure by central sympathetic stimulation. May require administration of midazolam prior to wearing off.
Medical Control	Pediatrics:
Protocol	 General Protocol 1008 – Advanced Airway Management General Protocol 1010 – {Sedate to Intubate and Rapid Sequence Intubation} General Protocol 1014 – Pain Management Trauma Protocol 3007 – Crush Syndrome Trauma Medical Protocol 4007 – Combative Patients/Emergency Sedation
END OF SECTION	

8021 - Ketamine Page 2 of 2

8022

Subject: Lactated Ringers

Effective: June 1, 2021

Last Modified:

Jan. 6, 2022

EMR	EMT	AEMT	Paramedic
Packaging	 Usually a 1000 ml flexible, non-latex plastic bag Generally with a pH of 6.5. Not in drug bags or caches 		
Indications	 Solution for fluid and electrolyte replenishment Hypovolemia Flushing of wounds Shock Pulmonary edema with systolic BP over 100 mmHg Sepsis 		
Adult Dosing	A Non traumatic shock without pulmonary edema: A 500 ml IV A May repeat 500 ml IV up to two times if needed A Non traumatic shock with pulmonary edema: 250 ml IV A Sepsis: A 1 L IV A ◆ Additional IV fluid if indicated A Penetrating trauma to chest or abdomen: enough fluid to obtain a radial pulse A Crush syndrome: A Initial treatment: 1 L IV then 500 ml/hour IV A If hypotensive and the patient has been trapped more than 1 hour, then additional 1 L IV A Heat exposure: A 500 ml IV, may repeat one time A ◆ Additional IV fluid, if indicated		
Pediatric Dosing	P 20 ml/kg IV bolus P ◆ In shock, call for orders to administer additional fluid		
Therapeutic Action	Used for hydration and management of hypotension		
Contraindications	None in the emergency setting		
Precautions And Side Effects	• None		
Medical Control	 Adults: Yes, for additional fluid administrations in some circumstances Pediatrics: Yes, for additional fluid administrations in some circumstances 		
Protocol	General Protocol 1005 – General Patient Management		

8022 – Lactated Ringers Page 1 of 1

8023

Subject: Lidocaine 2%

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic	
Dockoging	• 100 mg in 5 ml syri	nge (20 mg/ml)		
Packaging	 Two in drug bag 			
	For AEMT and Para	amedic:		
	o For pain c	aused by pressure of intraosseous flu	id administration	
Indications	 For Paramedic: 			
	 Intubation 	n on conscious patient		
	○ JITSO – Ca	ardiac arrest: V-Fib/Pulseless V-Tach a	nd Tachycardia, in the absence of Amiodarone	
	A Pain associated wi	th IO infusion (AEMT, Paramedic):		
		g IO (maximum dose 100 mg)		
		cious patient (Paramedic):		
	A 100 mg (5	ml) nebulized		
	<u>or</u>			
Adult Dosing		5 ml) IN with 50 mg (2.5 ml) in each no		
		rrest: V-Fib or Pulseless V-Tach (Para	medic):	
	A 150 mg (7	-		
	f A Repeat do $f A$ JITSO for Tachycard	ose of 75 mg (3.75 ml) IV or IO		
	A 1130 for racinycan	·		
		th IO infusion (AEMT, Paramedic):		
		g IO (maximum dose 100 mg)		
	P Intubation on conscious patient (Paramedic):			
		g nebulized (maximum dose 100 mg)		
Pediatric Dosing	or	s nebunzeu (maximum dose 100 mg)		
		ml) IN with 50 mg (2.5 ml) in each no	ostril	
		rrest: V-Fib or Pulseless V-Tach (Para		
		P 1 mg/kg IV or IO (maximum dose 100 mg)		
		P Repeat dose of 1 mg/kg IV or IO (maximum dose 75 mg)		
Therapeutic Action	Decreases automa			
-	Hypersensitivity	,		
Contraindications		hird degree heart block, in absence o	f an artificial nacemaker	
		on in patients with hepatic disease, he	·	
			ete heart block or bradycardia and atrial fib.	
	• Side Effects:	sion, nypovolenia or shock, meomple	the fredit block of brudyed and and attraction.	
B 12 A1	Altered level of consciousness, confusion or lightheadedness			
Precautions And	Cardiovascular collapse and/or hypotension			
Side Effects	o Bradycardia			
	 Blurred vi 			
	 irritability 	o irritability		
	 Muscle tw 	vitching and seizures with high doses		
Medical Control	 Adults: No 			
ivicalcal collinor	Pediatrics: No			
		008 – Advanced Airway Management		
		012 – Intraosseous Infusion		
		003 – Cardiac Arrest: Asystole or PEA		
Protocol		 Cardiac Protocol 2005 – Cardiac Arrest: V-Fib or Pulseless V-Tach 		
	Cardiac Protocol 2011 – Tachycardia			
	· · · · · · · · · · · · · · · · · · ·	002 – Allergic Reactions/Anaphylaxis		
	 Medical Protocol 4 	003 – Asthma/Emphysema/COPD		

END OF SECTION

8024

Subject:

Lidocaine 2% Gel

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

EMR	EMT	AEMT	Paramedic
Packaging	 2% gel in a tube Not carried in drug ba	g	
Indications	Lubrication of airway adjunct on conscious patient		
Adult Dosing	${f A}$ Apply to airway adjund	ct.	
Pediatric Dosing	P Apply to airway adjund	ct.	
Therapeutic Action		n of the upper airway activity such astimulation and elevation in intracrar	s, swallowing, gagging or coughing that can nial pressure
Contraindications	• None		
Precautions And Side Effects	• None		
Medical Control	Adults: NoPediatrics: No		
Guidelines	General Protocol 1008	3 – Advanced Airway Management	
END OF SECTION			

8024 – Lidocaine 2% Gel Page 1 of 1

8025

Subject:

Magnesium-Containing Antacid

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 Varies by manufacturer or vendor Not carried in drug bag Examples include Maalox and Mylanta 		
Indications	 Ingestion of Hydrofluoric Acid Hydrofluoric Acid on skin 		
Adult Dosing	 A For Ingestion: A Following dilution with water or milk, have patient drink 3-4 oz. Maalox or Mylanta. A For exposure: A Following irrigation, apply topically to burned area unless industry has already applied topical agents. 		
Pediatric Dosing	P Apply to airway adjunct.		
Therapeutic Action	Neutralize acid and increases the pH		
Contraindications	None in the emerger	ncy setting.	
Precautions And Side Effects	Use with caution in: Neonates Geriatric patients Patients with renal impairment Side Effects: Hypercalcemia Hypermagnesemia Hypotension Nausea & vomiting		
Medical Control	 Adults: No Pediatrics: No 		
Protocol	• Special Operations P	rotocol 6004 – Hydrofluoric Acid Expe	osure
END OF SECTION			

8026

Subject:

Methylprednisolone (Solu-medrol)

Effective:

June 1, 2021

Last Modified: Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 125 mg in 2 ml One in drug bag 		
Indications	 Severe allergic reaction Anaphylaxis Asthma COPD Emphysema Intended to augment steedema and inflammatic 	tandard therapy for anaphylaxis,	allergic reaction, and to address airway
Adult Dosing	 A Solu-Medrol 125 mg IV A Given to patients in the Allergic reaction or Anaphylaxis protocol only after all other applicable first-line medications have been delivered. 		
Pediatric Dosing	 P Solu-Medrol 2 mg/kg IV, max dose 125 mg P Given to patients in the Allergic reaction or Anaphylaxis protocol only after all other applicable first-line medications have been delivered. 		
Therapeutic Action	 Potent anti-inflammatory steroid Accelerates detoxification of cyanide 		
Contraindications	None in emergency set	ting	
Precautions And Side Effects	 Intended for cases that are of a more urgent nature. No significant change in patient condition in the field should be expected after administration. Do not to initiate an IV only to administer this medication. Side Effects: Cardiac arrhythmias Syncope 		
Medical Control	 Adults: No Pediatrics: No 		
Guidelines	 Medical Protocol 4002 – Allergic Reactions/Anaphylaxis Medical Protocol 4003 – Asthma/Emphysema/COPD 		

8026 - Methylprednisolone Page 1 of 1

8027

Subject:

Midazolam (Versed)

Effective: June 1, 2021

Last Modified:

Dec. 15, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	 10 mg in 2 ml vial, (5 mg/ml) Two in drug bag 			
Indications	 For the AEMT and Paramedic Seizures As chemical restraint for combative patient Chest pain associated with stimulant overdose (adults only) Paramedic Conscious patient requiring cardioversion Conscious patient requiring pacing After intubation, if patient is resisting and SBP is normal for age. 			
Adult Dosing	 A If seizures, or chemical Paramedic): A 10 mg IN (5 r) A Repeat 5 mg 	Il restraint for combative patients mg in each nostril) or 2 mg slow IV IN (after 5 min.) or 2 mg slow IV equiring cardioversion/pacing or	s, or chest pain in stimulant overdose (AEMT,	
Pediatric Dosing	P If seizures, or chemical restraint for combative patients (AEMT, Paramedic): P 0.2 mg/kg IN (maximum dose 10 mg) or P 0.1 mg/kg slow IV (maximum dose 2 mg) or P 0.2 mg/kg IM (maximum dose 4 mg) P In seizures, repeat at same doses (maximum IN 5mg, maximum IV 2 mg, maximum IM 4 mg) P In chemical restraint, call MCP for repeat doses P If conscious patients requiring cardioversion/pacing or patient resisting ETT (Paramedic) P 0.1 mg/kg slow IV (maximum dose 2 mg)			
Therapeutic Action	Provides sedation			
Contraindications	Respiratory distress			
Precautions And Side Effects	 Use with caution with lactating mothers. Geriatric & debilitated patients require lower doses & are more prone to side effects. Can cause respiratory depression Monitor respirations and ventilate if necessary. The Paramedic should intubate as indicated, the AEMT should intubate if apneic. Provide continuous cardiac monitoring, EtCO₂ and pulse oximetry with sedated patients. 			
Medical Control	 Adults: No Pediatrics: No Yes, for repeat doses in Combative Patient/Emergency Sedation Protocol 			
Protocol	 Yes, for repeat doses in Combative Patient/Emergency Sedation Protocol General Protocol 1008 – Advanced Airway Management General Protocol 1010 – {Sedate to Intubate and Rapid Sequence Intubation} Cardiac Protocol 2006 – AICD Activations Cardiac Protocol 2009 – Cardiac Alert Program Cardiac Protocol 2010 – Bradycardia Cardiac Protocol 2011 – Tachycardia Medical Protocol 4007 – Combative Patients/Emergency Sedation Medical Protocol 4014 – Seizures Medical Protocol 4012 – Overdose/Poisoning Special Operations Protocol 6005 – Organophosphate or Nerve Agent Exposure 			

8027 - Midazolam Page **1** of **1**

8028

Subject:

END OF SECTION

Morphine (JITSO)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 5 mg in 1ml vial Two in drug bag in the absence of fentanyl 		
Indications	 Pain relief in suspected cardiac chest pain, trauma emergencies, extremity fractures, dislocations, sprains, frostbite, abdominal pain, Hydrofluoric Acid (HF) exposure 		
Adult Dosing	 A Up to 5 mg slow IV based on patient's weight, provided SBP greater than 100. A May repeat up to 5 mg slow IV A If unable to establish IV, Morphine 5 mg IM 		
Pediatric Dosing	P Pain relief in pediatric patients greater 2 years old P 0.1 mg/kg slow IV (maximum dose 5 mg) provided appropriate SBP. P ◆ May repeat 0.1 mg/kg, (maximum dose 5 mg) P If unable to establish IV, 0.1 mg/kg IM (maximum dose 5 mg)		
Therapeutic Action	 Provides analgesia, reduces cardiac preload by increasing venous capacitance and decreasing afterload 		
Contraindications	 Hypersensitivity to narcotics Hypotension Head injury, increased intracranial pressure Severe respiratory depression Patients who have taken MAO inhibitors within 14 days 		
Precautions And Side Effects	Use with caution in the elderly, those with asthma, and in those susceptible to CNS depression. Side Effects: Hypotension Tachycardia, or bradycardia May worsen bradycardia or heart block in inferior MI (vagotonic effect) Palpitations Syncope Euphoria Facial flushing Respiratory depression Bronchospasm Dry mouth Allergic reaction		
Medical Control	 Adults: No Pediatrics: No Yes, for repeat doses 		
Guidelines	 General Protocol 1014 – Pain Management Cardiac Protocol 2006 – AICD Activations Cardiac Protocol 2008 – Suspected Cardiac Chest Pain Cardiac Protocol 2009 – Cardiac Alert Program 		

8028 - Morphine Page 1 of 1

8029

Subject: Naloxone (Narcan)

Effective: June 1, 2021

Last Modified:

Dec. 8, 2021

EMR	EMT	AEMT	Paramedic	
Packaging	2 mg in 2 ml vial (1 mg/mlSix in drug bag	- ···· · · · · · · · · · · · · · · · ·		
Indications	High index of suspicion ofRespiratory depression	Respiratory depression		
Adult Dosing	A (EMR or EMT) Up to 4 mg IN (half dose per nostril) A (AEMT or Paramedic) A Up to 4 mg IN (half dose per nostril) or 2 mg IV A If no IV, up to 4 mg IM A Titrate dosing to adequate respirations, repeat as needed			
Pediatric Dosing	P (EMR or EMT) P If 20 kg or less, then 0.1 mg/kg IN (maximum dose 2 mg) (half dose per nostril) P If greater than 20 kg, then 2 mg IN, may repeat as needed P (AEMT or Paramedic) P For neonates, consider 0.1 mg/kg IV, every 3 minutes until respirations improve) P If 20 kg or less, then 0.1 mg/kg IN (half dose per nostril), IV or IM (maximum dose 2 mg) P If greater than 20 kg, then 2 mg IN (half dose per nostril) P If using IN route and respirations don't improve after 2 mins., establish and administer via IV P Titrate dosing to adequate respirations, repeat as needed.			
Therapeutic Action	A competitive narcotic and			
Contraindications	 Hypersensitivity 	• Hypersensitivity		
Precautions And Side Effects	 Any intranasal administration should be given at a half dose in each nostril Onset of action is two minutes, if no response two minutes after dosing, then give additional doses For the Paramedic: if the patient has a pulse, Naloxone should be given before intubation. After administration, patient transport by EMS is encouraged, even if patient becomes responsive. Use with caution in narcotic-dependent patients who may experience withdrawal syndrome (including neonates of narcotic-dependent mothers). Caution should be exercised when administering to narcotic addicts (may precipitate withdrawal symptoms) Side Effects: Tachycardia Hypertension Dysrhythmias Diaphoresis Blurred vision Nausea and vomiting May not reverse hypotension 			
Medical Control	 Adult: No Pediatric: No General Protocol 1005 – General Patient Management General Protocol 1012 – Intraosseous Infusion Cardiac Protocol 2003 – Cardiac Arrest: Asystole or PEA Cardiac Protocol 2009 – Cardiac Alert Program Medical Protocol 4012 – Overdose/Poisoning Pediatric Considerations 5002 – Newborn Care and Resuscitation 			
Guidelines				

8029 - Naloxone Page 1 of 1

8030

Subject:

Nitroglycerin (Nitrostat)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

Packaging	 Dark brown glass bottle, 0.4 mg SL tablets One bottle in drug bag 		
Indications	 For the EMT, AEMT and Paramedic: Cardiac related chest pain For the EMT, the patient must be prescribed Nitroglycerin For the AEMT and Paramedic: Pulmonary edema with systolic BP over 100 mmHg Stimulant overdose with chest pain 		
Adult Dosing	A 0.4 mg SL every 5 min for continued chest pain up to a total of 3 tablets		
Pediatric Dosing	P Not applicable		
Therapeutic Action	Vasodilator which decreased preload and to a lesser extent, afterload		
Contraindications	 Hypersensitivity Hypotension Use of sexual enhancement drugs (Viagra, Cialis, Levitra) in last 24 hours Taking Revatio (a pulmonary hypertension medication) Head injury 		
Precautions And Side Effects	 Use only on patients who are at least 25 years old or have been prescribed Nitroglycerin Side Effects: Transient headache Reflex tachycardia Hypotension Diaphoresis Postural syncope Nausea & vomiting 		
Medical Control	 Adult: For the EMT: To assist the patient with their initial dose of Nitroglycerin: No To access the drug bag to administer Nitroglycerin: Yes For the AEMT and Paramedic: No Pediatric: Not applicable 		
Protocol	 Cardiac Protocol 2008 – Suspected Cardiac Chest Pain Medical Protocol 4012 – Overdose/Poisoning Medical Protocol 4013 – Respiratory Distress/Pulmonary Edema 		

8030 - Nitroglycerine Page 1 of 1

8031

Subject:

Norepinephrine (Levophed)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramed	ic	
Packaging	4 mg in 4ml (1mg/mOne in drug bag	l) vial for dilution in 250 ml of IV fluid	ds		
Indications	 For blood pressure c 	ontrol in acute hypotensive states ir	n the non-trauma patient	:	
	 A Add 4 mg to 250 ml of IV fluids. A Infuse starting at 30 drops per minute (max. 45 drops) with 60 drop tubing and titrate to effect. A Increase by 5 drops every 5 minutes. 				
Adult Dosing			gtts/min	mcg/min	
7100016			30	= 8	
			35 40	= 9.35 = 10.7	
			45	= 12	
Therapeutic Action	Peripheral vasoconstPositive inotrope (included)	trictor. creases cardiac contractility) and chi	ronotrope (increases hea	rt rate).	
Contraindications	 Should not be given to patients who are hypotensive from acute hemorrhage. Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains particles. 				
Precautions And Side Effects	 Protect the vial from light This drug must be diluted before administration. Administer in free-flowing IV and watch for infiltration. Avoid hypertension. If extravasation occurs, stop the infusion immediately as necrosis may occur. Leave the catheter in place so that a reversal agent can be given through the infiltrated catheter. 				
Medical Control	 Adult: Yes, during the management of septic patients. For all others, No. Pediatric: Yes 				
Protocol	 Cardiac Protocol 2009 – Cardiac Alert Program Medical Protocol 4015 – Sepsis Medical Protocol 4016 – Shock 				
END OF SECTION					

8031 - Norepinephrine Page 1 of 1

8032

Subject:

Normal Saline (Sodium Chloride Solution)

Effective:

June 1, 2021

Last Modified:

Jan. 6, 2022

EMR	EMT	AEMT	Paramedic
Packaging	 Usually a 1000 ml flexible, non-latex plastic bag Generally with a pH of 6.5. Not in drug bags or caches 		
Indications	 Solution for fluid and electrolyte replenishment Hypovolemia Flushing of wounds Shock Pulmonary edema with systolic BP over 100 mmHg Sepsis 		
Adult Dosing	A Non traumatic shock without pulmonary edema: A 500 ml IV A May repeat 500 ml IV up to two times if needed A Non traumatic shock with pulmonary edema: 250 ml IV Sepsis: A 1 L IV A ◆ Additional IV fluid if indicated A Penetrating trauma to chest or abdomen: enough fluid to obtain a radial pulse A Crush syndrome: A Initial treatment: 1 L IV then 500 ml/hour IV A If hypotensive and the patient has been trapped more than 1 hour, then additional 1 L IV A Heat exposure: A 500 ml IV, may repeat one time A ◆ Additional IV fluid, if indicated		
Pediatric Dosing	P 20 ml/kg IV bolus P ◆ In shock, call for orders to administer additional fluid		
Therapeutic Action	Used for hydration and management of hypotension		
Contraindications	None in the emergency setting		
Precautions And Side Effects	• None		
Medical Control	 Adults: Yes, for additional fluid administrations in some circumstances Pediatrics: Yes, for additional fluid administrations in some circumstances 		
	General Protocol 1005 – General Patient Management		

8032 – Normal Saline Page **1** of **1**

8033

Subject: Normosol-R

Effective: June 1, 2021

Last Modified:

Dec. 8, 2020

EMR	EMT	AEMT	Paramedic
Packaging	 Usually a 1000 ml flexible, non-latex plastic bag Generally with a pH of 6.5. Not in drug bags or caches 		
Indications	 Solution for fluid and electrolyte replenishment Hypovolemia Flushing of wounds Shock Pulmonary edema with systolic BP over 100 mmHg Sepsis 		
Adult Dosing	A Non traumatic shock without pulmonary edema: A 500 ml IV A ◆ May repeat 500 ml IV if needed A Non traumatic shock with pulmonary edema: 250 ml IV A Sepsis: A 1 L IV A ◆ Additional IV fluid if indicated A Penetrating trauma to chest or abdomen: enough fluid to obtain a radial pulse Crush syndrome: A Initial treatment: 1 L IV then 500 ml/hour IV A If hypotensive then additional 1 L IV Heat exposure: A 500 ml IV, may repeat x1 A ◆ Additional IV fluid, if indicated		
Pediatric Dosing	P 20 ml/kg IV bolus P ◆ In shock, call for orders to administer additional fluid		
Therapeutic Action	Used for hydration and management of hypotension		
Contraindications	None in the emergency setting		
Precautions And Side Effects	• None		
Medical Control	 Adults: Yes, for additional fluid administrations Pediatrics: Yes, for additional fluid administrations 		
Protocol	General Protocol 1005 – General Patient Management		
END OF SECTION			

8033 – Normasol-R Page 1 of 1

8034

Subject: Ondor

Ondansetron (Zofran)

Effective: June 1, 2021

Last Modified:

Jan. 6, 2022

EMR	EMT	AEMT	Paramedic
Packaging	 4 mg in 2 ml vial, (2 mg/ml) 1 vial in drug bag 4 mg tablet 1 tablet in drug bag 		
Indications	For nausea or active vomiting		
Adult Dosing	A For the AEMT and Paramedic: A 4 mg tablet PO A For the Paramedic: A 4 mg slow IV, preferred route for active vomiting as patient may need hydration. A If no IV, may use 4 mg tablet PO A Consider administering 4 mg/2 ml of the IV form by discharging into the patient's mouth.		
Pediatric Dosing	P For the AEMT and the Paramedic: P 4 mg tablet PO if patient 12 y/o or older and weight is 40 kg or more. P Transport time should be considered prior to administration. P For the Paramedic P 0.1 mg/kg IV (max 4 mg)		
Therapeutic Action	 Stimulation of 5-HT 3 receptors causes transmission of sensory signals to the vomiting center via vaga afferent fibers to induce vomiting. By binding to 5-HT 3 receptors, Ondansetron blocks vomiting mediated by serotonin release. 		
Contraindications	Known hypersensitivity to Ondansetron		
Precautions And Side Effects	 During pregnancy it should only be used where clearly needed. Side effects: Constipation or diarrhea Fever Headache. Sudden blindness of 2-3 minutes duration. (the speed of delivery may contribute to the blindness) 		
Medical Control	 Adults: No Pediatrics: No 		
	Medical Protocol 4001 – Abdominal Pain		

8034 - Ondansetron Page 1 of 1

8035

Subject: Oral Glucose

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 Tube; concentration varies, check label Not carried in drug bag 		
Indications	 Hypoglycemia Generalized hypothermia without arrest Altered level of consciousness of unknown cause Seizures with BGL of less than 60 mg/dl, no BGL monitor; or suspicion of hypoglycemia despite BGL reading For the AEMT and Paramedic, no IV access or available Glucagon 		
Adult Dosing	A 1 tube A May be repeated in 10 minutes if BGL remains less than 60 mg/dl		
Pediatric Dosing	P 1 tube P May be repeated in 10 minutes if BGL remains less than 60 mg/dl		
Therapeutic Action	Raise blood glucose concentration		
Contraindications	Inability to control the airway		
Precautions And Side Effects	 Use caution when giving to unresponsive patients. Hyperglycemia 		
Medical Control	 Adults: No Pediatrics: No 		
Protocol	Medical Protocol 4008 – Diabetic Emergencies - Hypoglycemia		
END OF SECTION			

8035 – Oral Glucose Page 1 of 1

8036

Subject: Plasmalyte-A

Effective: June 1, 2021

Last Modified:

Jan. 6, 2022

EMR	EMT	AEMT	Paramedic
Packaging	 Usually a 1000 ml flexible, non-latex plastic bag Generally with a pH of 6.5. Not in drug bags or caches 		
Indications	 Solution for fluid and electrolyte replenishment Hypovolemia Flushing of wounds Shock Pulmonary edema with systolic BP over 100 mmHg Sepsis 		
Adult Dosing	 Sepsis A Non traumatic shock without pulmonary edema: A 500 ml IV A May repeat 500 ml IV up to two times if needed A Non traumatic shock with pulmonary edema: 250 ml IV A Sepsis: A 1 L IV A • Additional IV fluid if indicated A Penetrating trauma to chest or abdomen: enough fluid to obtain a radial pulse A Crush syndrome: A Initial treatment: 1 L IV then 500 ml/hour IV A If hypotensive and the patient has been trapped more than 1 hour, then additional 1 L IV A Heat exposure: A 500 ml IV, may repeat one time A Additional IV fluid, if indicated 		
Pediatric Dosing	P 20 ml/kg IV bolus P ◆ In shock, call for orders to administer additional fluid		
Therapeutic Action	Used for hydration and management of hypotension		
Contraindications	None in the emergency setting		
Precautions And Side Effects	• None		
Medical Control	 Adults: Yes, for additional fluid administrations in some circumstances Pediatrics: Yes, for additional fluid administrations in some circumstances 		
	General Protocol 1005 – General Patient Management		

8036 – Plasmalyte-A Page **1** of **1**

8037

Subject:

Pralidoxime (2-PAM)

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	600 mg auto-injector		
Indications	 To be used following Atropine in organophosphate, or nerve agent poisoning. Both for treatment of civilian patients at the scene, as well as for protection of public safety personnel who walk into scene & become unexpectedly contaminated. 		
Adult Dosing	A ◆ 600 mg IM auto-injector		
Pediatric Dosing	P ◆ Patients greater than 20 kg: 600 mg IM auto-injector		
Therapeutic Action	 Reactivates cholinesterase after poisoning with anticholinesterase agents, (Organophosphate or Nerve Gas) Reverses muscle paralysis after organophosphate poisoning 		
Contraindications	 Hypersensitivity 		
Precautions And Side Effects	 Use with caution in myasthenia gravis, renal impairment, pregnancy, children. Can spread to child through breast feeding 		
Medical Control	 Adults: Yes Pediatrics: Yes 		
Protocol	 Special Operations Protocol 6002 – Antidote Resources Special Operations Protocol 6005 – Organophosphate or Nerve Agent Exposure 		
END OF SECTION			

8037 - Pralidoxime Page 1 of 1

8038

Subject: Sodium Bicarbonate

Effective: June 1, 2021

Last Modified:

Aug. 1, 2021

EMR	EMT	AEMT	Paramedic	
Dealacina	50 mEq in 50 ml syringe (1 mEq/ml)			
Packaging	• Two in drug bag			
	 Not for routine arres 	sts. Studies indicate no proven effica	acy.	
	Renal dialysis patient in asystole or PEA cardiac arrest			
Indications	 Excited delirium pat 	ients that go into cardiac arrest		
	 Known tricyclic over 	dose		
	 Crush Syndrome 			
	A Cardiac Arrest:			
		lysis patient: 100 mEq IV		
	A ◆ Consider	for the excited delirium patient who	o goes into arrest: 100 mEq IV	
Adult Dosing	A Tricyclic antidepress	ant OD:		
Addit Dosilig	A ♦ 100 mEq	IV		
	A ◆ May repe	eat dose of 50 mEq IV for persistent	or prolonged QRS	
	A Crush syndrome:			
	A 100 mEq IV			
	P Cardiac Arrest:			
	P In renal dia	lysis patient: 1 mEq/kg IV		
	P Tricyclic antidepress	ant OD:		
Pediatric Dosing	P ◆ 1 mEq/kg IV			
	P → May repeat dose of 0.5 mEq/kg IV for persistent or prolonged QRS			
	P Crush syndrome:			
	P 1 mEq/kg I	V		
Therapeutic Action	Buffers metabolic ac			
Contraindications	None in the emerge	None in the emergency setting		
		·		
	Metabolic alkalosis			
Precautions And	Hypoxia Rise in intracellular I	OCO, and increased tissue acidesis		
Side Effects	 Rise in intracellular PCO₂ and increased tissue acidosis Electrolyte imbalance (hypernatremia) 			
Side Lifects	Seizures			
	Tissue sloughing at injection site			
	Adults:	injection site		
		sis Arrest – No		
	 Tricyclic OE 			
	=	lirium Arrest - Yes		
Medical Control	Pediatrics:			
	o Arrest – No)		
	 Tricyclic OE 			
	o Crush Synd			
		04 – Cardiac Arrest - Renal Failure/Di	<u>ialysis</u>	
	 Cardiac Protocol 202 			
Protocol	· · · · · · · · · · · · · · · · · · ·	07 – Crush Syndrome Trauma		
	· · · · · · · · · · · · · · · · · · ·	07 – Combative Patients/Emergency	<u> Sedation</u>	
	 Medical Protocol 40 	12 – Overdose/Poisoning		

END OF SECTION

8038 – Sodium Bicarbonate Page 1 of 1

8039

Subject: Sodium Nitrito

Sodium Nitrite (JITSO)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 300 mg in 10 ml vial (30 mg/ml) Available in caches located in each county in Homeland Security Region 3. 		
Indications	Patients with known or suspected cyanide poisoning		
Adult Dosing	A ◆ 300 mg (10 ml) 3% solution slow IV		
Pediatric Dosing	P Not applicable		
Therapeutic Action	 Oxidizes hemoglobin w 	hich then combines with cyanide to form	an inactive compound
Contraindications	Nitrite/nitrate allergy		
Precautions And Side Effects	Methemoglobinemia if given in excessive amounts		
Medical Control	 Adults: Yes Pediatrics: Not applicable 		
Guidelines	Trauma Protocol 3008 – Cyanide Poisoning & Antidotes		
END OF SECTION			

8039 – Sodium Nitrite Page 1 of 1

8040

Subject:

Sodium Thiosulfate

Effective:

June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT		AEMT	Paramedic
Packaging	_	50 ml vial (250 mg/n n caches located in ea	·	eland Security Region 3.
Indications	 Smoke inh 	patient with known c alation with suspecte est from known or su	ed cyanide componer	
Adult Dosing	A ◆ 12.5 gm	(50 ml) 25% solution	n slow IV	
Pediatric Dosing		than 25 kg: 12.5 gm (n 25 kg: 412.5 mg/kg		n slow IV % solution (max dose 12.5 g (50 ml))
Therapeutic Action	 Accelerate 	s detoxification of cy	anide	
Contraindications	• None			
Precautions And Side Effects	• Possible hy	/potension		
Medical Control	Pediatrics:In	cardiac arrest—No patients not in arres cardiac arrest—No patients not in arres		
Protocol	• <u>Trauma Pr</u>	otocol 3008 – Cyanid	e Poisoning & Antido	dotes
END OF SECTION				

8040 – Sodium Thiosulfate Page **1** of **1**

8041

Subject: Tetracaine

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	0.5%/ml eye drop botOne in drug bag	ttle (10 ml)	
Indications		in cases of chemical injury to the exty of penetrating trauma to eye.	ye and in other situations with significant eye
Adult Dosing	A 2 drops in each affect	ted eye	
Pediatric Dosing	P 2 drops in each affect	ted eye	
Therapeutic Action	 Provides rapid, brief, s nerves 	superficial anesthesia by inhibiting	conduction of nerve impulses from sensory
Contraindications	Hypersensitivity to TeOpen injury to eye	etracaine	
Precautions And Side Effects	Can cause epithelial d	r stinging sensation or irritation lamage and systemic toxicity ercury or silver salts often found in o	ophthalmic products
Medical Control	Adults: NoPediatrics: No		
Protocol	• <u>Trauma Protocol 3011</u>	1 – Eye Injuries	
END OF SECTION			

8041 - Tetracaine Page 1 of 1

8042

Subject: Vasopressin (JITSO)

Effective: June 1, 2021

Last Modified:

Oct. 10, 2021

EMR	EMT	AEMT	Paramedic
Packaging	 20 units in 1 ml vial, 2 Usually 2 vials (20 ml) Not routinely present) present	
Indications	Adult patients in cardi	liac arrest	
Adult Dosing	A 40 units IVA Once IV is established	d, Vasopressin is permitted after ei	ther first or second dose of Epinephrine.
Pediatric Dosing	P Not applicable		
Therapeutic Action	Potent peripheral vaseMay be used as an altrand PEA		the treatment of adult shock-refractory VF
Contraindications	None in the adult card	diac arrest	
Precautions And Side Effects	May produce cardiac i	ischemia and angina	
Medical Control	Adults: NoPediatrics: Not application	cable	
Protocol	• <u>Cardiac Protocol 2005</u>	5 – Cardiac Arrest: V-Fib or Pulseles	ss V-Tach
END OF SECTION			

8042 – Vasopressin Page 1 of 1

Appendix A

Protocol Changes

A

Subject: 2022 Protocol Changes

Effective: Jan. 1, 2022

Last Modified:

Feb. 8, 2022

Appendix A.1 General Guidelines

- a. All important changes made to the 2022 GMVEMSC protocol are listed in this section.
- b. Grammatical changes, formatting or clerical corrections are not mentioned.
- c. The different tabs are:
 - i. <u>General Protocol Changes</u> includes any changes that effect the protocol as a whole or all of the different disciplines
 - ii. EMR changes affecting the patient care from an EMR
 - iii. EMT changes affecting the patient care from an EMT, including from EMR tabs
 - iv. AEMT changes affecting the patient care from an EMT, including from EMR & EMT tabs
 - v. Paramedic changes affecting the patient care from a Paramedic, including from all other tabs
 - vi. <u>Drug Formulary</u> changes made to the 8000 series drug listings, affecting all levels
- d. It is recommended that each discipline review the changes to all the other levels as well as their own as some changes could affect their practice.

Appendix A.2 2022 GMVEMSC Protocol Changes

General Protocol Changes			
Tab	Section	Change/Edit/Addition	
All	Complete protocol	Added title pages to each section	
All	All	Added hyperlinks from drug names to specific formularies	
Various	Various	Re-ordered the tabs in areas where it made the most sense, some sections are now alphabetical	
1003	1003.1.a	Removed the EMR from those who can determine that non-initiaton of care is indicated	
1004	1004	Re-worked the tab for clarification and simplification	
1005	1005.3 Pediatrics	Added line "the maximum dose for pediatric medication administration is the adult dose"	
1011	1011.1.d	Added bullet to consider how long ago a tracheostomy had been placed	
3004	Clinical Pearls	Removed guideline to change hand placement for CPR on a pregnant patient	
3005	3005.1.b	Added recommendation to estimate total BSA involved in burn with "universally accepted methods"	
3005	3005.1.b.i	Clarified that BSA should be isolated to partial and full thickness burns	
3008	3008.1	Changed number of Sodium Thiosulfate doses from 5 to 3	
3017	3017	Edited entire section, changed "Triage Tag" to "Treatment Tag" and added 3017.5 Special Considerations	
3018	3018.6	Section changed from "Sporting Injuries" to "Equipment Issues"	
3018	3018.6.b	Added a bullet to address removal of helmets for SMR or airway management	
3018	3018.7	Added statement addressing patients over 69 y/o as "High Risk" patients and use of a cervical collar	
3018	3018.7	Added reference to placing a Cervical Collar to patients who are "Trauma Alerts"	
4005	4005.1.a.ii	Added bullet to define gestation age in weeks	
4007	Subject	Changed title from "Combative Patients/Patient Restraint" to "Combative Patients/Emergency Sedation"	
4009	4009.2.b	Added stipulation that a parent or guardian may refuse transport of a diabetic patient after treatment	
4010	4010.1.b	Added reminder that extrapyramidal reactions can occur after ingestion of recreational drugs	
4011	4011	Cleaned up redundancies. Also removed reference to change hand placement for CPR on a pregnant patient	
4011	4011.2	Modified and clarified the transport decisions and positioning for pregnant patients	
4012	4012.1.c	Added request to bring substance information to the ED where safe and practical	
4017	4017.3 Assessment	Added signs of Large Vessel Occlusions (LVO) and migraine as a differential diagnosis	
4017	4017.3 Clinical Pearls	Added possible indicators of Large Vessel Occlusion (LVO)	
7001	7001.2.a	Added that all agencies with GMVEMSC Drug Bags must be able to contact MCP at a participating facility	
7012	7012.6	Edited hospital names to reflect most current versions	
7013	7013.2	Edited hospital names to reflect most current versions	
7013	Chart	Added Interventional Cardiac Cath to Miami Valley Hospital (South)	
7013	Chart	Added Level 3 Adult Trauma and Primary Stroke Capable to Upper Valley Medical Center	
7014	7014	Edited hospital names and phone numbers to reflect most current versions	

Α

Subject: 2022 Protocol Changes

Effective: Jan. 1, 2022

Last Modified:

Feb. 8, 2022

Emerge	Emergency Medical Responder			
Tab	Section	Change/Edit/Addition		
Various	Complete protocol	Where mentioned, moved CO-oximetry and capnography to the EMR level		
1005	1005.4 EMR	Added criteria that EMR are only allowed to obtain manual blood pressures		
2002	2002.2 EMR	Added the use of mechanical CPR to comply with Ohio EMS Scope of Practice		
3005	3005.1 EMR	Removed warmed and humidified oxygen to comply with Ohio EMS Scope of Practice		
3015	3015.1 EMR	Added (Wound Packing) for all disciplines, provided they have received the specialized training		
3016	3016.1 EMR	Removed warmed and humidified oxygen to comply with Ohio EMS Scope of Practice		
4005	4005.2 EMR	Changed the EMR role to assist with emergency childbirth		
4012	4012.1 EMR	Added a reminder that Naloxone is to be administered at a half dose per nostril		

Emerg	Emergency Medical Technician			
Tab	Section	Change/Edit/Addition		
1005	1005.3 EMT	Added a section that defines what skills an EMT may assist an advanced provider with		
1005	1005.4 EMT	Defined that an EMT may only acquire a 12 Lead EKG for the purpose of transmission		
1005	1005.4 EMT	Defined that an EMT may assist a Paramedic with applying a 12 Lead EKG		
1005	1005.4 EMT	Defined that an EMT may assist an advanced provider with setting up an IV administration kit		
1009	1009.2 EMT	Changed EtCO ₂ detection from "recommended" to "mandatory for advanced airway confirmation"		
2008	2008.2 EMT	Clarified that the EMT must contact MCP for <u>any</u> aspirin administration		
2008	2008.2 EMT	Added language to remind the EMT that they must transit 12-Lead EKGs		
2009	2009.4 EMT	Added recommendation to apply defibrillation pads to confirmed MI patients		
3004	3004.3 Consult	Removed Blood Glucose as requirement for Field Termination		
3005	3005.1 EMT	Moved warmed and humidified oxygen from EMR to EMT level		
3005	3005.1 EMT	Moved CO-oximetry to EMR level		
3015	3015.1 EMR	Added {Wound Packing} for all disciplines, provided they have received the specialized training		
3016	3016.1 EMT	Moved warmed and humidified oxygen from EMR to EMT level		
4012	4012.1 EMR	Added a reminder that Naloxone is to be administered at a half dose per nostril		
4014	4014.1 EMT	Added bullet to place patient in the recovery position during assessment and transport		

Advanced Emergency Medical Technician			
Tab	Section	Change/Edit/Addition	
1005	1005.4 AEMT	Defined that an AEMT may only acquire a 12 Lead EKG for the purpose of transmission	
1005	1005.4 AEMT	Defined that an AEMT may assist a Paramedic with applying a 12 Lead EKG	
1005	1005.4 AEMT	Added requirement for advanced monitoring for all patients given sedation, opiates, or benzodiazepines	
1008	1008.1 AEMT	Clarified that there should only be two ETT attempts per patient prior to moving to a rescue airway	
1008	1008.1 AEMT	Identified the three different needle decompression site choices	
1009	1009.2 EMT	Changed EtCO₂ detection from "recommended" to "mandatory for advanced airway confirmation"	
1012	1012.1 & 1012.2	Clarified some of the intent and direction for selecting a site and size for IO insertion	
1012	1012.1 iii	Added statement that the proximal tibia is not to be used in adult cardiac arrest	
1014	1014.3 AEMT	Clarified that Ketamine is the second line medication for pain management (to Fentanyl)	
2001	2001.2 Consult	Removed Blood Glucose as requirement for Field Termination	
2002	2002.2 AEMT	Removed consideration of the Impedance Threshold Device	
2008	2008.2 AEMT	Added language that an AEMT or higher doesn't need orders to administer aspirin	
2008	2008.2 AEMT	Added language to remind the AEMT to transmit the 12-Lead EKG	
2009	2009.4 EMT	Added recommendation to apply defibrillation pads to confirmed MI patients	
3002	3002.1 AEMT	Identified the approved site for needle decompression in patients less than 8 y/o as the mid-clavicular line only	
3004	3004.3 AEMT	Identified the approved site for needle decompression in patients less than 8 y/o as the mid-clavicular line only	
3004	3004.3 Consult	Removed Blood Glucose as requirement for Field Termination	
3015	3015.1 EMR	Added (Wound Packing) for all disciplines, provided they have received the specialized training	
4002	4006.2 AEMT	Added pediatric glucagon by age criteria	
4003	4003.1 AEMT	Changed decompression criteria to only the affected sides in patients who are not in cardiac arrest	
4003	4003.1 AEMT	Identified the approved site for needle decompression in patients less than 8 y/o as the mid-clavicular line only	
4003	4003.1 AEMT	Added COPD to "(NOT for emphysema)"	

Subject: 2022 F

2022 Protocol Changes

Jan. 1, 2022

Last Modified: Feb. 8, 2022

4007	4007.3 AEMT	Added the caution "DO NOT ADMINISTER KETAMINE AND MIDAZOLAM SIMULTANEOUSLY"
4007	4007.3 AEMT	Added the caution "Give the administered sedative time to work before moving on"
4007	4007.3 Clinical Pearls	Added reminder that NPA, positioning and suctioning will facilitate airway management after Ketamine
4008	4008.2 AEMT	Added pediatric glucagon by age criteria
4012	4012.1 EMR	Added a reminder that Naloxone is to be administered at a half dose per nostril
4012	4012.2 AEMT	Added "for unrelieved chest pain" to repeat Midazolam in Stimulant Overdose
4012	4012.2 AEMT	Added pediatric glucagon by age criteria
4014	4014.1 EMT	Added bullet to place patient in the recovery position during assessment and transport

Effective:

Parame	Paramedic				
Tab	Section	Change/Edit/Addition			
1005	1005.4 AEMT	Added requirement for advanced monitoring for all patients given sedation, opiates, or benzodiazepines			
1008	1008.1 AEMT	Clarified that there should only be two ETT attempts per patient prior to moving to a rescue airway			
1008	1008.1 AEMT	Identified the three different needle decompression site choices			
1009	1009.2 EMT	Changed EtCO ₂ detection from "recommended" to "mandatory for advanced airway confirmation"			
1010	1010.1.f	Added an option for Medical Directors to choose different paralytics for STI within their agencies			
1010	1010.1.g.ii	Defined that the paralyzing injury exclusion is specific to Succinylcholine			
1012	1012.1 & 1012.2	Clarified some of the intent and direction for selecting a site and size for IO insertion			
1012	1012.1 iii	Added statement that the proximal tibia is not to be used in adult cardiac arrest			
1014	1014.3 AEMT	Clarified that Ketamine is the second line medication for pain management (to Fentanyl)			
2001	2001.2 Consult	Removed Blood Glucose as requirement for Field Termination			
2002	2002.2 AEMT	Removed consideration of the Impedance Threshold Device			
2005	2005.2 Paramedic	Changed blood pressure to 100 systolic as indicator to use Amiodarone drip			
2008	2008.2 Paramedic	Clarified that a Paramedic should only transmit Cardiac Alert criteria, or questionable 12 Lead EKGs			
2009	2009.4 EMT	Added recommendation to apply defibrillation pads to confirmed MI patients			
2009	2009.4 Paramedic	Reworked the entire Paramedic section. Notably, removed checking V4R as requirement in Inferior MI			
3002	3002.1 AEMT	Identified the approved site for needle decompression in patients less than 8 y/o as the mid-clavicular line only			
3004	3004.3 AEMT	Identified the approved site for needle decompression in patients less than 8 y/o as the mid-clavicular line only			
3004	3004.3 Consult	Removed Blood Glucose as requirement for Field Termination			
3008	3008.4 Clinical Pearls	Added option to administer cyanide antidotes via IO in extreme cases, study guide will address how			
3015	3015.1 EMR	Added (Wound Packing) for all disciplines, provided they have received the specialized training			
4001	4001.2 Paramedic	Removed IV as the "preferred" route for Ondansetron in adult patients who just complain of nausea			
4002	4002.2 AEMT	Added pediatric glucagon by age criteria			
4002	4002.2 Paramedic	Added the line "If a patient deteriorating or unresponsive, consider early intubation"			
4003	4003.1 AEMT	Changed decompression criteria to only the affected sides in patients who are not in cardiac arrest			
4003	4003.1 AEMT	Identified the approved site for needle decompression in patients less than 8 y/o as the mid-clavicular line only			
4003	4003.1 AEMT	Added COPD to "(NOT for emphysema)"			
4004	4004.3 Paramedic	Removed "aggressively with medication" from the line concerning Paramedic treatment			
4007	4007.3 AEMT	Added the caution "DO NOT ADMINISTER KETAMINE AND MIDAZOLAM SIMULTANEOUSLY"			
4007	4007.3 AEMT	Added the caution "Give the administered sedative time to work before moving on"			
4007	4007.3 Clinical Pearls	Added reminder that NPA, positioning and suctioning will facilitate airway management after Ketamine			
4008	4008.2 AEMT	Added pediatric glucagon by age criteria			
4012	4012.2 AEMT	Added "for unrelieved chest pain" to repeat Midazolam in Stimulant Overdose			
4012	4012.2 Paramedic	Added qualifier "for persistent QRS prolongation" to repeat pediatric Sodium Bicarbonate in Tricyclic OD			
4012	4012.1 EMR	Added a reminder that Naloxone is to be administered at a half dose per nostril			
4012	4012.2 AEMT	Added pediatric glucagon by age criteria			
4014	4014.1 EMT	Added bullet to place patient in the recovery position during assessment and transport			

Drug Formulary				
Tab	Section	Change/Edit/Addition		
8002	Indications	Clarified that only a Paramedic may administer Albuterol to Crush Syndrome Trauma patients		
8003	Contraindications	Added "less than 100 SBP"		
8004	Medical Control	Clarified that the EMT must contact MCP for <u>any</u> aspirin administration		
8015	Medical Control	Clarified that the EMR and EMT must call for orders for repeat Epinephrine in Allergies/Anaphylaxis		



Δ

Subject: 2022 Protocol Changes

Jan. 1, 2022

Last Modified:

Feb. 8, 2022

8016	Precautions	Added "Provide continuous cardiac monitoring, EtCO ₂ and pulse oximetry with sedated patients"
8017	Precautions	Added "Provide continuous cardiac monitoring, EtCO ₂ and pulse oximetry with sedated patients"
8018	Pediatric Dosing	Added pediatric glucagon by age criteria
8021	Precautions	Added NPA, positioning and suctioning will facilitate airway management
8021	Precautions	Added "Provide continuous cardiac monitoring, EtCO ₂ and pulse oximetry with sedated patients"
8027	Precautions	Added "Provide continuous cardiac monitoring, EtCO ₂ and pulse oximetry with sedated patients"
8028	Precautions	Added "Provide continuous cardiac monitoring, EtCO ₂ and pulse oximetry with sedated patients"
8029	Precautions	Added a reminder that Naloxone is to be administered at a half dose per nostril

Effective:

END OF SECTION